Measuring NMDA receptors using $[^{18}\text{F}]\text{GE-179}$ PET in health and disease.

University College London
UCL Queen Square Institute of Neurology
Department of Clinical and Experimental Epilepsy Queen Square

A thesis presented in consideration for the degree of

Doctor of Philosophy

Marian Galovic
2021
I, Marian Galovic, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm this has been indicated in the thesis.

The scientific studies presented here reflect collaborations with a team of researchers including other colleagues from the UCL Department of Clinical and Experimental Epilepsy and UCL Institute of Nuclear Medicine. However, this thesis presents only studies in which I conducted most steps of data analysis. All results and data interpretation were presented by myself and were developed based on discussions at meetings with my colleagues and my scientific supervisors. My individual contributions to the scientific studies included in this thesis are outlined below.

The first project, development and validation of a kinetic modelling pipeline independent of arterial sampling, uses data acquired at Addenbrooke’s Hospital in Cambridge by our collaborators Jonathan Coles, Tim Fryer, and Young Hong. It builds on previous work of my colleague Hasan Sari in a joint project with the UCL Institute of Nuclear Medicine. I completely redeveloped the analysis pipeline with support from Kjell Erlandsson, Kris Thielemans, Benjamin A. Thomas, and Anna Barnes from the UCL Institute of Nuclear Medicine. I processed the data, performed statistical analysis, and wrote the manuscript.
For the remaining three projects (NMDA receptor activation in aging, epilepsy, and anti-NMDA-receptor encephalitis), I used PET and MR data acquired by myself at UCL Institute of Nuclear Medicine. I also used multicentre healthy volunteer data acquired using [18F]GE-179 PET and MRI at Hammersmith Hospital, Imperial College London, by Colm McGinnity (n=9) and Addenbrooke’s Hospital, Cambridge University, by Jonathan Coles, Tim Fryer, and Young Hong (n=10), with the permission of the collaborators. I processed all internal and external data using the same standardised methods, applied modelling software developed by Kjell Erlandsson at UCL Institute of Nuclear Medicine, performed statistical analysis, interpreted the data and wrote the manuscript.

Marian Galovic
**Abstract**

**Background:** N-methyl-D-aspartate receptors (NMDAR) are important glutamatergic ion channels in the brain. Studying the functional activation of NMDAR in vivo in humans has not been possible until recently.

**Methods:** We used positron emission tomography (PET) with $[^{18}F]$GE-179, a novel radioligand binding inside the open NMDAR channel, to assess the in vivo activation of NMDAR. We developed methodology for quantification of ligand binding (Project 1) that did not require arterial sampling and was then applied to study NMDAR activation in aging (n=29, Project 2), epilepsy (n=26, Project 3), and Anti-NMDAR encephalitis (n=5, Project 4).

**Results:** In Project 1, we validated a method for kinetic modelling using an image-derived input function and serial venous samples. This approach provided unbiased estimates of ligand volume of distribution ($V_t$) that were highly correlated ($r=0.95$, $p<0.001$) with the gold standard, an arterial input function.

In Project 2, we observed increased tracer uptake related to aging in healthy individuals ($V_t$ increase of 0.6 per 10 years, $p=0.04$), particularly in bilateral hippocampi, temporo-parieto-occipital junctions, dorsolateral prefrontal cortex, and striata. In people with epilepsy, the age-related increase in $V_t$ (1.4 per 10 years, $p=0.006$) was most pronounced in the striatum and thalamus.

In Project 3, we found reduced interictal ligand uptake in epilepsy that was related to longer disease duration ($V_t$ decrease of 1.6 per 10 years, $p=0.004$), spatially...
widespread and bihemispheric. Regional uptake was increased in those taking lacosamide and after anterior temporal lobe resection.

In *Project 4*, we observed decreased ligand uptake in Anti-NMDAR encephalitis with persisting Anti-GluN1-antibodies (mean $V_t$ 6.2 in cases vs. 8.8 in healthy volunteers, $p=0.02$), particularly in bilateral anterior temporal and superior parietal lobes.

**Conclusions:** $[^{[18}F]GE-179$ PET is useful to detect altered NMDAR function. We observed increased NMDAR activation in aging and decreased activation in interictal epilepsy and antibody-positive Anti-NMDAR encephalitis.
Impact statement

N-methyl-D-aspartate (NMDA) receptors are glutamatergic ion channels that are involved in a number of physiologic and pathologic processes. They play a role in synaptic plasticity, memory, excitotoxicity, and in several neurologic and psychiatric disorders. Studying NMDA receptors in humans in vivo has not been possible until recently.

Here, we used positron emission tomography (PET) with the novel radioligand $^{18}$F]GE-179 that binds specifically to the open, i.e. activated, NMDA receptor. A wider use of this ligand has been limited by the need for arterial blood sampling to correctly quantify radiotracer binding. In Project 1 we simplified this methodology by developing and validating a kinetic modelling approach using serial venous samples and an image-derived input function. This approach is less invasive than traditional methods relying on arterial blood sampling. It may allow the wider use of the tracer in research and, if proven useful, in clinical care.

In Project 2 we observed increased activation of NMDA receptors related to aging in healthy volunteers and patients with focal epilepsy. These findings are particularly relevant due to the unprecedented aging of the population in high income countries. They support the hypothesis of increased neuronal network hyperexcitability during aging that may contribute to cognitive decline and neurodegeneration. If these findings are reproduced in people with mild cognitive impairment and dementia, they may open avenues for novel treatments. The NMDA receptor antagonist memantine is
currently being used as a routine treatment of Alzheimer’s disease and the glutamatergic modulator riluzole is used in amyotrophic lateral sclerosis. These and other medications could be studied using $^{18}$FGE-179 to determine their effect on NMDA receptors during healthy aging and in people with neurodegenerative disorders.

In Project 3 we found decreased interictal NMDA receptor activation in people with refractory focal epilepsy. This observation contrasts with traditional models of neuronal hyperexcitability due to NMDA receptor overactivation in people with epilepsy. Our findings highlight the need to restore a balanced NMDA receptor activity in people with epilepsy and argue against overt blocking of NMDA receptors. We also observed the impact of anti-seizure medications on NMDA receptors that was most pronounced for lacosamide, which was not recognised previously. These results could contribute to the development of novel treatment strategies for epilepsy. $^{18}$FGE-179 PET could be useful to assess the influence of medication on the NMDA receptor.

In Project 4 we observed decreased activation of NMDA receptors in females recovering from Anti-NMDA-receptor encephalitis. These findings confirm for the first time in vivo the proposed disease mechanism of this autoimmune disorder. They also highlight persisting NMDA receptor abnormalities in individuals with only mild or minimal symptoms several months after discharge from hospital. If confirmed in larger studies, $^{18}$FGE-179 PET could be used to monitor disease activity and guide treatment decisions in the subacute and chronic phases of Anti-NMDA-receptor encephalitis.

In conclusion, $^{18}$FGE-179 PET is a valuable tool to study the molecular underpinnings of healthy aging and neurological disorders and the impact of medications.
Table of contents

DECLARATION ...................................................................................................................... 2
ABSTRACT .......................................................................................................................... 4
IMPACT STATEMENT ......................................................................................................... 6
TABLE OF CONTENTS ....................................................................................................... 8
LIST OF FIGURES ............................................................................................................... 12
LIST OF TABLES ................................................................................................................ 14
LIST OF ABBREVIATIONS ................................................................................................. 15
LIST OF PUBLICATIONS ................................................................................................... 18
ACKNOWLEDGEMENTS .................................................................................................... 23

1 INTRODUCTION ............................................................................................................... 25

1.1 NMDA RECEPTOR STRUCTURE AND FUNCTION ...................................................... 25
  1.1.1 Glutamatergic receptors ......................................................................................... 25
  1.1.2 Subunit composition .............................................................................................. 26
  1.1.3 Synaptic and extrasynaptic sites .............................................................................. 28
1.2 NMDA RECEPTOR INVOLVEMENT IN NEURONAL PROCESSES .......................... 29
  1.2.1 Long-term potentiation and depression ................................................................. 29
  1.2.2 Working memory .................................................................................................. 30
  1.2.3 Excitotoxicity ....................................................................................................... 31
  1.2.4 Excitatory and inhibitory roles on neuronal networks ........................................... 32
1.3 NMDA RECEPTORS IN HEALTH IN DISEASE ......................................................... 34
  1.3.1 Aging ..................................................................................................................... 34
  1.3.2 Epilepsy ................................................................................................................ 35
1.3.3 Epilepsy-aphasia syndromes ................................................................. 40
1.3.4 Brain tumours.......................................................................................... 40
1.3.5 Anti-NMDA-receptor encephalitis .......................................................... 41
1.3.6 Alzheimer’s disease .............................................................................. 43
1.3.7 Other disorders associated with NMDA receptor dysfunction ................. 46
1.4 IMAGING NMDA RECEPTORS IN VIVO .................................................... 46
   1.4.1 Positron emission tomography of NMDA receptors ............................. 46
   1.4.2 Information about [18F]GE-179 ........................................................... 48
2 COMMON METHODS .................................................................................... 51
   2.1 PARTICIPANTS ......................................................................................... 51
      2.1.1 Healthy volunteers ............................................................................ 52
      2.1.2 Patients with epilepsy ....................................................................... 52
      2.1.3 Patients with Anti-NMDA-receptor encephalitis ................................. 54
   2.2 REGULATORY APPROVAL ...................................................................... 54
   2.3 IMAGE ACQUISITION AND RECONSTRUCTION ...................................... 55
      2.3.1 Image acquisition in the UCL study ................................................ 55
      2.3.2 Image acquisition in the Cambridge study ....................................... 56
      2.3.3 Image acquisition in the Hammersmith study .................................... 57
   2.4 FITTING OF BLOOD DATA ...................................................................... 58
   2.5 ESTIMATION OF AN IMAGE-DERIVED INPUT FUNCTION ....................... 59
      2.5.1 Theoretical background and rationale ............................................. 59
      2.5.2 Carotid artery segmentation ............................................................ 61
      2.5.3 Coregistration of intra-modal images ............................................. 61
      2.5.4 Measuring and processing radioactivity concentration in the carotid arteries .......................................................... 62
   2.6 IMAGE PREPROCESSING AND MODELLING ........................................... 63
      2.6.1 Smoothing ......................................................................................... 63
      2.6.2 Flipping ............................................................................................ 63
      2.6.3 Rigid motion correction .................................................................... 63
      2.6.4 Inter-modal coregistration ............................................................... 64
      2.6.5 Structural parcellation ...................................................................... 64
      2.6.6 Partial volume correction .................................................................. 65
      2.6.7 Modelling ........................................................................................ 65
      2.6.8 Spatial normalization ........................................................................ 66
   2.7 STATISTICAL ANALYSIS ......................................................................... 66
      2.7.1 Numerical data .................................................................................. 66
Table of contents

5.3.4  $[^{18}F]$GE-179 uptake before and after temporal lobe surgery ........................................ 110  
5.4  DISCUSSION ......................................................................................................................... 112  
  5.4.1  NMDA receptor hypofunction and neuronal hyperexcitability ........................................ 112  
  5.4.2  Focal changes of NMDA receptor activation in epilepsy .................................................. 115  
  5.4.3  Effects of antiepileptic drugs .......................................................................................... 116  
  5.4.4  Effects of age .................................................................................................................. 117  
  5.4.5  Methodical considerations .............................................................................................. 118  
  5.4.6  Conclusions .................................................................................................................... 119  
6  PROJECT 4: NMDA RECEPTOR ACTIVATION IN ANTI-NMDA-RECEPTOR ENCEPHALITIS .......... 120  
  6.1  INTRODUCTION .................................................................................................................. 120  
  6.2  METHODS ........................................................................................................................... 122  
  6.3  RESULTS .............................................................................................................................. 126  
  6.4  DISCUSSION ......................................................................................................................... 128  
  6.4.1  NMDA receptor hypofunction as a disease mechanism in Anti-NMDA-receptor encephalitis 128  
  6.4.2  NMDA receptor hypofunction and clinical correlates ....................................................... 131  
  6.4.3  Limitations ...................................................................................................................... 133  
  6.4.4  Conclusions .................................................................................................................... 134  
7  CONCLUSIONS AND OUTLOOK ............................................................................................. 135  
  7.1  METHODOLOGICAL CONSIDERATIONS .............................................................................. 136  
  7.2  NMDA RECEPTOR ACTIVATION IN AGING ....................................................................... 138  
  7.3  NMDA RECEPTOR ACTIVATION IN EPILEPSY ................................................................. 139  
  7.4  NMDA RECEPTOR ACTIVATION IN ANTI-NMDA-RECEPTOR ENCEPHALITIS ..................... 141  
  7.5  OVERALL CONCLUSION .................................................................................................... 142  
8  REFERENCES .............................................................................................................................. 143
List of figures

Chapter 1
Figure 1.1  Scheme of NMDA receptor structure

Chapter 3
Figure 3.1  Comparison of arterial and IDIF + venous measurements
Figure 3.2  Comparison of arterial and venous radioactivity concentrations
Figure 3.3  Comparison of total volume of distribution estimates modelled with arterial or IDIF + venous input functions
Figure 3.4  Comparison of arterial and IDIF + single venous sample measurements
Figure 3.5  Comparison of total volume of distribution estimates modelled with arterial or IDIF + single venous sample input functions

Chapter 4
Figure 4.1  Association of GE-179 uptake in grey matter with age in healthy volunteers
Figure 4.2  Association of GE-179 uptake in white matter and nonbrain tissue with age in healthy volunteers
Figure 4.3  Association of grey matter volume with age in healthy volunteers
Figure 4.4  Association of GE-179 uptake in grey matter with age in individual cohorts
Chapter 5

Figure 5.1  Test-retest measurements of $[^{18}F]$GE-179 PET.
Figure 5.2  Association of GE-179 uptake with age, disease duration, and lacosamide intake in patients with epilepsy.
Figure 5.3  Abnormal GE-179 uptake and epilepsy localisation.
Figure 5.4  Relative changes in GE-179 uptake after epilepsy surgery.
Figure 5.5  Areas structurally connected with the hippocampus

Chapter 6

Figure 6.1  GE-179 uptake in “active” or “inactive” Anti-NMDA-receptor encephalitis and healthy volunteers.
Figure 6.2  Comparison of GE-179 uptake in antibody-positive Anti-NMDA-receptor encephalitis cases and healthy volunteers.
Figure 6.3  Association of GE-179 uptake in Anti-NMDA-receptor encephalitis cases with clinical variables.
List of tables

Chapter 1
Table 1.1 Selected mechanisms of epileptogenesis

Chapter 2
Table 2.1 Characteristics of healthy volunteers

Chapter 3
Table 3.1 Regional \( V_r \) estimates obtained with an arterial and venous/image-derived input function.
Table 3.2 Regional \( V_r \) estimates obtained with an arterial input function or an input function using a single venous and image-derived measurements.

Chapter 5
Table 5.1 Clinical characteristics and their association with \( [^{18}\text{F}]\text{GE-179} \) uptake in epilepsy patients.
Table 5.2 Multivariable model of \( [^{18}\text{F}]\text{GE-179} \) uptake in epilepsy patients.

Chapter 6
Table 6.1 Characteristics of patients with Anti-NMDA-receptor encephalitis
List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>2c4k</td>
<td>2-brain-compartment 4-rate-constant</td>
</tr>
<tr>
<td>Aβ</td>
<td>Amyloid beta-peptide</td>
</tr>
<tr>
<td>AD</td>
<td>Alzheimer’s disease</td>
</tr>
<tr>
<td>ADHD</td>
<td>Attention-deficit hyperactivity disorder</td>
</tr>
<tr>
<td>AED</td>
<td>Antiepileptic drug</td>
</tr>
<tr>
<td>AIF</td>
<td>Arterial input function</td>
</tr>
<tr>
<td>AMPA</td>
<td>Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid</td>
</tr>
<tr>
<td>ANCOVA</td>
<td>Analysis of covariance</td>
</tr>
<tr>
<td>APOE</td>
<td>Apolipoprotein E</td>
</tr>
<tr>
<td>APP</td>
<td>Amyloid precursor protein</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the curve</td>
</tr>
<tr>
<td>CAM</td>
<td>Cambridge</td>
</tr>
<tr>
<td>CAT12</td>
<td>Computational anatomy 12 toolbox</td>
</tr>
<tr>
<td>CoV</td>
<td>Coefficient of variation</td>
</tr>
<tr>
<td>CSF</td>
<td>Cerebrospinal fluid</td>
</tr>
<tr>
<td>CSWSS</td>
<td>Continuous spike and waves during slow-wave sleep syndrome</td>
</tr>
</tbody>
</table>
## List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>D2HG</td>
<td>D-2-hydroxyglutarate</td>
</tr>
<tr>
<td>DAPI</td>
<td>4’,6-diamidino-2-phenylindole</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s Modified Eagle Medium</td>
</tr>
<tr>
<td>DMN</td>
<td>Default mode network</td>
</tr>
<tr>
<td>FDG</td>
<td>Fluorodeoxyglucose</td>
</tr>
<tr>
<td>FLE</td>
<td>Frontal lobe epilepsy</td>
</tr>
<tr>
<td>FWHM</td>
<td>Full width at half maximum</td>
</tr>
<tr>
<td>GABA</td>
<td>Gamma-aminobutyric acid</td>
</tr>
<tr>
<td>GIF</td>
<td>Geodesic Information Flows</td>
</tr>
<tr>
<td>HAM</td>
<td>Hammersmith</td>
</tr>
<tr>
<td>HEPES</td>
<td>4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</td>
</tr>
<tr>
<td>HS</td>
<td>Hippocampal sclerosis</td>
</tr>
<tr>
<td>IDH1\text{mut}</td>
<td>Mutant isocitrate dehydrogenase 1</td>
</tr>
<tr>
<td>IDIF</td>
<td>Image-derived input function</td>
</tr>
<tr>
<td>LTD</td>
<td>Long-term depression</td>
</tr>
<tr>
<td>LTP</td>
<td>Long-term potentiation</td>
</tr>
<tr>
<td>mGluR</td>
<td>Metabotropic glutamate receptors</td>
</tr>
<tr>
<td>mRNA</td>
<td>Messenger ribonucleic acid</td>
</tr>
<tr>
<td>MR</td>
<td>magnetic resonance</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>MRS</td>
<td>Magnetic resonance spectroscopy</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>MTLE</td>
<td>Mesial temporal lobe epilepsy</td>
</tr>
<tr>
<td>NHNN</td>
<td>National Hospital for Neurology and Neurosurgery</td>
</tr>
<tr>
<td>NMDA</td>
<td>N-methyl-D-aspartate</td>
</tr>
<tr>
<td>NMDAR</td>
<td>N-methyl-D-aspartate receptor</td>
</tr>
<tr>
<td>PCP</td>
<td>Phencyclidine</td>
</tr>
<tr>
<td>PDS</td>
<td>Paroxysmal depolarization shifts</td>
</tr>
<tr>
<td>PET</td>
<td>Positron emission tomography</td>
</tr>
<tr>
<td>POB</td>
<td>Plasma-over-whole-blood</td>
</tr>
<tr>
<td>PVC</td>
<td>Partial volume correction</td>
</tr>
<tr>
<td>SPET</td>
<td>Single photon emission tomography</td>
</tr>
<tr>
<td>SPM12</td>
<td>Statistical parametric mapping 12</td>
</tr>
<tr>
<td>SUV</td>
<td>Standardized uptake value</td>
</tr>
<tr>
<td>TBI</td>
<td>Traumatic brain injury</td>
</tr>
<tr>
<td>TLE</td>
<td>Temporal lobe epilepsy</td>
</tr>
<tr>
<td>TOF</td>
<td>Time-of-flight</td>
</tr>
<tr>
<td>UCL</td>
<td>University College London</td>
</tr>
<tr>
<td>VBM</td>
<td>Voxel-based morphometry</td>
</tr>
<tr>
<td>$V_T$</td>
<td>Volume of distribution</td>
</tr>
</tbody>
</table>
List of publications

Original articles


* authors share first or senior authorship

**Reviews or commentaries**


**Book chapters**


Acknowledgements

This PhD and my years of research associated with it would not have been possible and as enjoyable without the great support of a number of people to whom I would like to express my deepest gratitude.

I am very grateful to my principal supervisor, Matthias Koepp, who was always available for discussion and guidance and who I admire for his creative research approach and his ability to think translationally and beyond boundaries of different research topics and disciplines.

I would also like to thank my co-supervisor, John Duncan, for his continuous support and highly valuable advice. I admire his diligent and thorough scientific method and his ability to combine excellence in research and clinical care with a patient-centred and sociable approach.

I thank my collaborators at the UCL Institute of Nuclear Medicine, in particular Kjell Erlandsson, Kris Thielemans, Ben Thomas, Hasan Sari, and Ana Barnes, for their support with data acquisition and data modelling. It was always a huge pleasure and fun to work with the team of radiographers at the Macmillan Cancer Centre PET-MR.

I am grateful to our collaborators at Addenbrooke’s Hospital in Cambridge, particularly Jonathan Coles, Tim Fryer, and Young Hong, and at Hammersmith Hospital in London, particularly Colm McGinnity and Alexander Hammers, who acquired and
shared parts of the data and without whom this project would not have been possible. My thanks also goes to our collaborators at GE Healthcare.

I would also like to thank all my fellow research colleagues for all the hours of support and discussions and for sharing challenges, worries, success and friendship.

I am extremely grateful to all the patients and healthy volunteers who participated in our research. This work would not have been possible without them.

I am enormously grateful to my parents, my wife, and friends for their support, encouragement and understanding for long working hours and sparse visits back home.
1 Introduction

1.1 NMDA receptor structure and function

1.1.1 Glutamatergic receptors

Glutamate is the main excitatory neurotransmitter of the central nervous system accounting for one third of all rapid excitatory synapses (Cotman and Berchtold, 2002; Watkins and Evans, 1981). The N-methyl-D-aspartate (NMDA) receptor is one of three ionotropic receptor types that bind glutamate (Palmada and Centelles, 1998). Other ionotropic glutamate channels are the kainate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Eight subtypes of metabotropic glutamate receptors (mGluR) that indirectly modulate synaptic transmission have also been described (Niswender and Conn, 2010).

NMDA receptors are heteromeric ion channels consisting of four subunits that bind the agonist glutamate and the co-agonists glycine or D-serine (Wolosker, 2006). In the inactivated state, the channel pore is blocked by Mg$^{2+}$ ions. For activation, NMDA receptors require the binding of an agonist, a co-agonist and concomitant postsynaptic depolarization to remove Mg$^{2+}$ from the channel pore (Mori and Mishina, 1995). In this manner, the receptors are uniquely gated by both ligands and voltage. Opening of the receptor channel leads to nonselective influx of cations, mainly Na$^+$ and Ca$^{2+}$, and efflux of K$^+$. Compared to other glutamate receptors, NMDA receptors are the most permeable to calcium, they gate slowly, and desensitize only weakly.
These specific characteristics are important for long-term potentiation and excitotoxicity, which may play a role in several neurological disorders.

1.1.2 Subunit composition

The NMDA receptor complex consists of several subunits and this composition is variable regionally, changes throughout the lifespan, and influences the functional properties of the receptor. All receptors contain two obligatory glycine-binding GluN1 subunits.

(Wollmuth and Sobolevsky, 2004). The NMDA receptor is a heterotetramer consisting of two obligatory GluN1 subunits and a variable composition of GluN2 or GluN3 subunits. The glycine binding site is located on GluN1 subunits, the glutamate site is on GluN2/3 subunits. The channel pore is blocked by a Mg$^{2+}$ ion at rest. Binding of Phencyclidine (PCP) requires opening of the channel pore. Reproduced with permission from Krystanek and Palasz 2019.

Figure 1.1: Scheme of NMDA receptor structure

The NMDA receptor is a heterotetramer consisting of two obligatory GluN1 subunits and a variable composition of GluN2 or GluN3 subunits. The glycine binding site is located on GluN1 subunits, the glutamate site is on GluN2/3 subunits. The channel pore is blocked by a Mg$^{2+}$ ion at rest. Binding of Phencyclidine (PCP) requires opening of the channel pore. Reproduced with permission from Krystanek and Palasz 2019.
Introduction

subunits (Kuryatov et al., 1994) and two variable glutamate-binding GluN2 or GluN3 subunits, according to current nomenclature (Collingridge et al., 2009). Different splice variants for GluN1 messenger ribonucleic acid (mRNA) have been described and they may influence the functional properties of the receptor (Magnusson et al., 2010). Additionally, there is allosteric interaction between glutamate and glycine, the binding of one agonist lowering the affinity for the second (Durham et al., 2020).

Four subtypes of GluN2 subunits, termed GluN2A-D, have been described. Out of these, the GluN2A and GluN2B subunits are most commonly expressed, whereas GluN2C and GluN2D are mainly present during early development (Monyer et al., 1994). GluN2B-containing receptors are predominant during birth and early development, but at the onset of sexual maturity the expression of GluN2B is down-regulated (Bar-Shira et al., 2015). In contrast, GluN2A expression increases during development and adulthood (Monyer et al., 1994). A similar increase of the GluN2A/GluN2B ratio was observed during hippocampal development in humans (Jantzie et al., 2015; Law et al., 2003).

GluN2A and GluN2B subunit-containing receptors differ functionally. GluN1/GluN2A receptors have a higher opening probability and peak open probability in response to glutamate compared to GluN1/GluN2B receptors (N. Chen et al., 1999; Erreger et al., 2005; Gray et al., 2011). In protocols of long-term potentiation (see chapter 1.2.1), GluN2A subunit-containing receptors predominantly responded to tonic stimuli, whereas GluN2B-containing receptors preferentially transferred charges of short low-frequency low-amplitude stimuli (Shipton and Paulsen, 2014). These functional differences may have differential implications for synaptic plasticity and memory. GluN2A knockout mice typically show only minor learning deficits, limited to short-term memory or the rapid acquisition of spatial information (Shipton and Paulsen, 2014). The GluN2B subunit might be relevant for novel-object recognition, spatial reference memory, and fear memory (Magnusson et al., 2010).
The role of GluN3 (subtypes GluN3A and GluN3B) subunits is less well understood. Their expression has been localized to oligodendrocytes (Káradóttir et al., 2005) or excitatory receptors responsive to glycine but not glutamate (Chatterton et al., 2002). The majority of receptors are either diheteromeric, i.e. containing either GluN1/GluN2A or GluN1/GluN2B subunits, or triheteromeric, i.e. containing GluN1/GluN2A/GluN2B. Most research focused on diheteromeric receptors because they can be studied selectively. Although the majority of hippocampal receptors might be triheteromeric (Rauner and Köhr, 2011), most research so far focused on diheteromeric receptors and their role remains largely unclear.

1.1.3 Synaptic and extrasynaptic sites

NMDA receptors may be localized both synaptically and extrasynaptically. Extrasynaptic sites have been implicated in neurodegenerative conditions including Alzheimer’s disease (Bordji et al., 2010). Both receptor populations bind glutamate, but they have different affinities towards co-agonists. Synaptic sites are mainly gated by D-serine and extrasynaptic sites by glycine (Papouin et al., 2012). It is unclear whether specific subunit compositions modulate the localisation of receptors along the synapse. Some authors observed that the organisation of NMDA receptors along synaptic and extrasynaptic sites was mobile and both GluN2A and GluN2B subunits may be located extrasynaptically (Tovar and Westbrook, 2002). Others propose that GluN2B-containing receptors are enriched extrasynaptically (Massey et al., 2004; Papouin et al., 2012).

The site of NMDA receptors may have an influence on their function. Activation of synaptic sites is thought to be neuroprotective, whereas activation of extrasynaptic receptors may promote cell death (Hardingham and Bading, 2010). However, conflicting findings have been reported (Papouin et al., 2012).
1.2 NMDA receptor involvement in neuronal processes

1.2.1 Long-term potentiation and depression

Long-term potentiation (LTP) is a persistent strengthening of synaptic connections based on recent patterns of activity (Cooke and Bliss, 2006a). LTP provides a compelling neuronal model for synaptic plasticity, declarative learning, and memory. In contrast, long-term depression (LTD) is a persistent weakening of synaptic connections. Disturbances of LTP and LTD might play a role in chronic pain, epileptogenesis and dementia (Cooke and Bliss, 2006a).

NMDA receptors are key mediators of synaptic potentiation (LTP) and depression (LTD) that rely on their specific function of coincidence detection. Opening of NMDA receptors requires the simultaneous binding of a presynaptically released agonist, i.e. glutamate, and the depolarization of the postsynaptic membrane to remove the Mg$^{2+}$-block within the channel pore (Nakazawa et al., 2004). The receptor remains inactivated if either one or the other is absent. In this manner, NMDA receptors detect coinciding pre- and postsynaptic activity, a process that is thought to be the molecular basis of declarative or associative learning.

Opening of NMDA receptors leads to an influx of Ca$^{2+}$ ions that trigger a cascade of biochemical events that strengthen the postsynaptic response to glutamate by incorporating AMPA receptors into the postsynaptic membrane (Ehrlich and Malinow, 2004). An indirect mechanism might additionally facilitate presynaptic glutamate release (S. Choi et al., 2003). These processes are Ca$^{2+}$ dependent. Reduction of intracellular Ca$^{2+}$ effectively blocks LTP (S. Williams and Johnston, 1989).

Subunit composition and synaptic localisation may modulate the functional properties of NMDA receptors. GluN2A-containing receptors may primarily subserve LTP, whereas GluN2B-containing receptors trigger LTD (L. Liu et al., 2004). LTP relies on synaptic activation only, whereas LTD involves both synaptic and extrasynaptic sites (Papouin et al., 2012).
Other forms of neuronal plasticity, independent of LTP or LTD, have also been described and NMDA receptors may also play a role (Becker et al., 2014; Vlachos et al., 2013).

1.2.2 Working memory

There is limited knowledge on the neuronal processes involved in working memory, a short-lasting form of memory that is important to transiently hold and manipulate goal-related information and to guide forthcoming actions.

Working memory is stored by the maintained firing of a memory-specific subset of neurons in the prefrontal cortex (Funahashi et al., 1989). Computational modelling suggest that NMDA receptors, due to their slow kinetics, are particularly suited to sustain neuronal activity at low firing rates during working memory (Durstewitz et al., 2000; Lisman et al., 1998; X. J. Wang, 1999). Studies in rodents and non-human primates demonstrated that blocking NMDA receptors abolished persistent activity in prefrontal neurons during a working memory task (Jackson et al., 2004; M. Wang, Yang, C.-J. Wang, Gamn, Jin, Mazer, Morrison, X.-J. Wang and Arnsten, 2013a).

Significant working memory impairments were seen with local or systemic application of NMDA receptor antagonists in rodents (Jackson et al., 2004; Moghaddam and Adams, 1998), non-human primates (B. M. Roberts et al., 2010; M. Wang, Yang, C.-J. Wang, Gamn, Jin, Mazer, Morrison, X.-J. Wang and Arnsten, 2013a), and humans (Driesen et al., 2013; Honey et al., 2004).

Several neurological and psychiatric disorders are associated with both dysfunctional NMDA receptor signalling and working memory deficits. Working memory deficits are a core feature of schizophrenia (Silver et al., 2003) and play an important role in attention-deficit hyperactivity disorder (ADHD) (Martinussen et al., 2005). Several lines of evidence support a hypofunction of NMDA receptors in schizophrenia (Bubeníková-Valešová et al., 2008). Application of NMDAR antagonists is commonly used to model
psychotic and cognitive symptoms in schizophrenia, that include deficits in working memory. Hypofunction of NMDARs has also been described in ADHD (Chang et al., 2014).

Although less typical than impairments in episodic memory, working memory deficits are also commonly observed in both focal epilepsy (Stretton and Thompson, 2012; Stretton et al., 2012) and Alzheimer’s disease (AD) (Stopford et al., 2012). NMDA receptor dysfunction has been demonstrated in these disorders.

1.2.3 Excitotoxicity

Excitotoxicity is the pathological damage to neurons after intense exposure to excitatory neurotransmitters, mainly glutamate (D. W. Choi, 1992; Olney, 1969). Excitotoxicity is predominantly, but not exclusively, mediated by prolonged opening of NMDA receptors, potentially because of their high permeability to Ca\(^{2+}\) and weak desensitization (Rothman and Olney, 1995). Prolonged opening of NMDA receptors leads to excess influx of Ca\(^{2+}\) and consequently trigger a neuronal cell-death cascade (D. W. Choi, 1995; Weiss et al., 1990). Antagonising NMDA receptor activity attenuated glutamate-induced neuronal loss (D. W. Choi et al., 1988; Ferrer-Montiel et al., 1998; S. Liu et al., 1997).

Diverging roles for different NMDA receptor subunit compositions and synaptic localisations in promoting excitotoxic damage were proposed. Activation of receptors containing GluN2B subunits resulted in cell-death, whereas GluN2A containing receptors had both neurotoxic and neuroprotective effects (Engelhardt et al., 2007; Y. Liu et al., 2007). Some authors proposed that synaptic receptors may be neuroprotective whereas extrasynaptic receptors may be neurotoxic (Hardingham and Bading, 2010), whereas others observed that both receptor sites are capable of mediating excitotoxicity (Y. Liu et al., 2007; Sattler et al., 2000; Wroge et al., 2012; Zhou et al., 2013).
Excitotoxicity has been observed in models of cerebral ischemia. Application of NMDA receptor antagonists reduced hypoxic neuronal injury \textit{in vitro} (Rothman, 1984) and \textit{in vivo} (Simon et al., 1984). Excitotoxic injury has also been implicated in models of epilepsy (Meldrum, 1993), Alzheimer’s disease (Olney et al., 1997), Huntington’s disease (DiFiglia, 1990), Parkinson’s disease (Beal, 1998), and other neurodegenerative disorders.

1.2.4 Excitatory and inhibitory roles on neuronal networks

Traditionally, NMDA receptors have been linked to an activating effect on neuronal networks because they bind glutamate, the most prevalent excitatory neurotransmitter in the central nervous system. On the other hand, emerging evidence from basic and clinical science points to the potential of NMDA receptors to exhibit an inhibitory effect on neuronal networks (Fitzgerald, 2012). Although the aspect of network suppression through NMDA receptors has received only little attention, recent evidence in people with genetic forms of epilepsy provides strong support to this concept.

Typically, NMDA receptor antagonism \textit{in vitro} and \textit{in vivo} leads to inhibition of pyramidal neurons (Arvanov and R. Y. Wang, 1997; L. Chen et al., 2003; Hirsch and Crepel, 1991). Paradoxically, NMDA receptor antagonism can, in certain situations, also produce excitatory effects (Grunze et al., 1996; Homayoun and Moghaddam, 2007; Manzoni et al., 1994) and lead to an activation of limbic structures (Höflich et al., 2017; Kraguljac et al., 2017; McMillan et al., 2019). NMDA receptor antagonists may lead to network activation, detected as increased metabolism in the frontal cortex and thalamus and increased blood flow in the anterior cingulate cortex (Lahti et al., 1995; Vollenweider et al., 1997) and on recordings in freely moving rats (Jackson et al., 2004; Suzuki et al., 2002).
There are several potential explanations for the inhibitory effects of NMDA receptors. Network suppression is probably mainly mediated by NMDA receptors located on gamma-aminobutyric-acid (GABA) releasing interneurons that suppress the activity of pyramidal cells (Grunze et al., 1996; Homayoun and Moghaddam, 2007; Manzoni et al., 1994). Additionally, an interaction between NMDA and AMPA receptors may play a role. NMDA receptors can lead to a downregulation of excitatory AMPA receptors (Hall et al., 2007). Conversely, NMDA receptor antagonism increases transmission through AMPA receptors (Moghaddam and Adams, 1998; Moghaddam et al., 1997). A combination of these factors may lead to network level excitation mediated by NMDA receptor hypofunction.

Recent findings in patients with epilepsy, a disease of overt neuronal excitation and insufficient inhibition, underline these concepts. Loss-of-function mutations in GRIN genes, that encode NMDA receptor subunits, can lead to a syndrome with seizures and aphasia (chapter 1.3.3) (Xu and Luo, 2018). NMDA receptor hypofunction in Anti-NMDA-receptor encephalitis (chapter 1.3.5), an autoimmune disorder, also frequently causes seizures (Hughes et al., 2010; Moscato et al., 2014). A therapeutic trial of the highly selective NMDA receptor antagonist D-CPP-ene caused an increase of seizures in a large proportion of cases (Sveinbjornsddottir et al., 1993).

Thus, NMDA receptor activation may lead to either activation or inhibition on a network level (Fitzgerald, 2012). This consideration is important to guide the development of treatments targeting the NMDA receptor. Drugs causing overt hyper- or hypofunction of NMDA receptors were not tolerated well, because they blocked normal synaptic activity and led to intolerable side effects (Le and Lipton, 2001). A balanced tonic activation of NMDA receptors may be necessary for normal function of the brain. In this regard, uncompetitive antagonism is a promising concept. An uncompetitive antagonist is an inhibitor whose activation is contingent on prior activation of the receptor by an agonist (Lipton, 2006). In this manner, an uncompetitive antagonist would block overt hyperactivation, i.e. in the context of
excitotoxicity, but maintain normal function relatively intact to avoid side effects. Memantine is an uncompetitive NMDA receptor antagonist with a rapid off-rate and low affinity (Lipton, 2006). It has been successfully used for treatment of moderate to severe Alzheimer’s disease.

1.3 NMDA receptors in health in disease

1.3.1 Aging

The worldwide population is aging at an unprecedented rate (United Nations Department of Economic and Social Population Affairs, 2019). Aging is associated with cognitive decline and a higher risk of neurodegenerative disorders (Park et al., 2002).

Normal aging leads to a reduced pool of glutamate, particularly in the striatum, as measured in vivo with MR-spectroscopy (Kaiser et al., 2005; Zahr et al., 2013). On the other hand, a reduced glutamate re-uptake and decreased expression of glutamate transporters was observed in older rats (Potier et al., 2010). This could lead to a facilitated activation of glutamatergic receptors, particularly located extrasynaptically, despite a lower overall glutamate pool (Potier et al., 2010).

NMDA receptors may be the most vulnerable type of glutamate ion-channels to the effects of aging (Magnusson and Cotman, 1993; Magnusson et al., 2010). The overall number of NMDA receptors is reduced in older animals (Castorina et al., 1994; Magnusson, 2000; Magnusson and Cotman, 1993; Magnusson et al., 2007; Ontl et al., 2004). Particularly affected are the frontal and parieto-occipital cortex, striatum, and hippocampus.

There is limited knowledge on the effects of aging on NMDA receptors in humans. Some post mortem studies found a decrease of NMDA receptor numbers in older individuals that was linked to an overall loss of neurons (Kornhuber et al., 1988;
Piggott et al., 1992), whereas others did not find a relevant decrease (Law et al., 2003).

The change in overall NMDA receptor number may be counteracted by functional changes. Several, but not all, studies found an age-related increase in sensitivity and responsiveness of the remaining receptors (Billard et al., 1997; Jasek and Griffith, 1998; Kuehl-Kovarik et al., 2000). There is also a well-documented shift of receptor subunit composition from GluN2B towards GluN2A-containing receptors (Brim et al., 2013; Magnusson, 2000; Magnusson et al., 2002; 2006; Zamzow et al., 2013). NMDA receptor heteromers containing GluN2A subunits have a higher opening probability (N. Chen et al., 1999; Erreger et al., 2005; Gray et al., 2011). Additionally, there is a shift from synaptic towards extrasynaptic NMDA receptor sites during aging (Potier et al., 2010). These aspects could contribute to the neuronal hyperexcitability observed in aging (Senatorov et al., 2019), mild cognitive impairment, and Alzheimer’s disease (Fontana et al., 2017; Haberman et al., 2017; Palop et al., 2007; Yassa et al., 2010).

1.3.2 Epilepsy

1.3.2.1 Defining seizures and epilepsy

Epilepsy is one of the most common serious neurological disorders. There are at least 50 million people with epilepsy worldwide (World Health Organization, 2000). Epilepsy has an estimated lifetime prevalence of 5.8 per 1,000 persons in developed countries and 15.4 per 1,000 in developing countries (Ngugi et al., 2010).

Epilepsy has been defined as “a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures, and by the neurobiologic, cognitive, psychological, and social consequences of this condition” (Fisher et al., 2005). A more recent practical approach outlines this predisposition as any of the following (Fisher et al., 2014):

1. “At least two unprovoked (or reflex) seizures occurring >24 h apart;
2. One unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years;
3. Diagnosis of an epilepsy syndrome.”

This practical definition implies that a single remote symptomatic seizure after a relevant insult, e.g. ischemic stroke, qualifies as epilepsy. This is due to the high recurrence rate after stroke of > 70% (Fisher et al., 2014; Hesdorffer et al., 2009).

1.3.2.2 Seizures and the glutamatergic system

Glutamate is directly involved in the generation of epileptic discharges through sequences of paroxysmal depolarization shifts (PDS) (During and Spencer, 1993). An increase in extracellular glutamate can be observed before and during spontaneous seizures in humans (During and Spencer, 1993). Elevated glutamate concentrations in different epilepsy syndromes and aetiologies were demonstrated using magnetic resonance spectroscopy (MRS) (Davis et al., 2015; Helms et al., 2006; Simister et al., 2002; 2007; Simister, McLean, Barker and Duncan, 2003a; 2003b).

PDS are mainly mediated by activation of AMPA receptors (Rogawski, 2011). Blocking of NMDA receptors does not abolish PDS (W. L. Lee and Hablitz, 1989; Neuman et al., 1988). On the other hand, this initial depolarization is a necessary prerequisite for opening of NMDA channels, which consequently sustain and prolong ongoing depolarization during the later stages of epileptic activity (Baldino et al., 1986; Naylor et al., 2013).

NMDA receptors desensitize weakly and are, thus, likely to sustain prolonged seizures and status epilepticus. Blocking NMDA receptors interrupted status epilepticus, reduced refractoriness to benzodiazepines and enhanced survival in animal models (Ormandy et al., 1989; Rice and DeLorenzo, 1999). In humans, several reports
describe successful termination of super-refractory status epilepticus with the NMDA receptor antagonist ketamine (Borris et al., 2000; Prüss and Holtkamp, 2008).

These advances have been translated into antiepileptic treatment with felbamate, an NMDA receptor antagonist and sodium channel modulator (Pellock et al., 2006). Cases of fatal aplastic anaemia and hepatic failure have limited the clinical use of felbamate.

On the other hand, NMDA receptor antagonists may also have proconvulsant effects (Alldredge et al., 1989; Claudet and Maréchal, 2009; Modica et al., 1990; Peltz et al., 2005; Sveinbjörnsdóttir et al., 1993). Treatment with the antagonist D-CPP-ene led to an increase in seizures in a large proportion of epilepsy patients (Sveinbjörnsdóttir et al., 1993).

1.3.2.3  Mechanisms of epileptogenesis

Early epilepsy research in the twentieth century focused mainly on ictogenesis, i.e. the propensity to generate epileptic seizures (Pitkänen and Engel, 2014). Despite considerable progress and the development of over 20 anticonvulsants, approximately one third of people with epilepsy are refractory to medical treatment (Del Felice et al., 2010).

Recently, scientific interest has focused on how a brain develops the enduring predisposition to generate epileptic seizures. This process is called epileptogenesis and has been defined as “the development and extension of tissue capable of generating spontaneous seizures, resulting in a) development of an epileptic condition and/or b) progression of the epilepsy after it is established” (Pitkänen et al., 2013). By increasing our understanding of epileptogenic processes and by developing truly antiepileptogenic treatments, one could prevent and abort the development of epilepsy or modify and eventually cure the already established disease. However, after several unsuccessful antiepileptogenic treatment trials with conventional antiseizure
**Introduction**

### Possible mechanism of epileptogenesis

<table>
<thead>
<tr>
<th>Possible mechanism of epileptogenesis</th>
<th>Selected references</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reorganisation of synaptic circuits</td>
<td></td>
</tr>
</tbody>
</table>
| - Loss of inhibitory interneurons leading to a decrease of GABA-mediated inhibition. | Ribak et al. (1982)  
- Sprouting of mossy fibres, possibly causing increased recurrent excitation. | Sloviter (1987)  
de Lanerolle et al. (1989)  
Kobayashi and Buckmaster (2003)  
Babb et al. (1991)  
Sutula et al. (1989) |
| GABA (γ-Aminobutyric acid)           |                      |
| - Internalisation of GABA<sub>A</sub> receptors. | Goodkin et al. (2005)  
Naylor et al. (2005)  
Brooks-Kayal et al. (1998) |
| - Changes of GABA<sub>A</sub> subunit composition. | Loup et al. (2000)  
Huberfeld et al. (2007) |
| - Disturbances of chloride homeostasis with increase of chloride influx. |                      |
| Growth factors                       |                      |
| - Influence of Brain Derived Neurotrophic Factor (BDNF) on GABA<sub>A</sub> subunit expression. | Roberts et al. (2006)  
Paradiso et al. (2009)  
Chu et al. (2008) |
| - Antiepileptogenic effects of BDNF and erythropoietin injections. |                      |
| Inflammation                         |                      |
| - Inflammatory mediators, reactive astrocytosis, and activated microglia found in resected human epileptic tissue. | Aronica et al. (2007)  
Crespel et al. (2002)  
Amhaoul et al. (2015)  
Bertoglio et al. (2016)  
Kovacs et al. (2006)  
Sayyah et al. (2003)  
Fabene et al. (2008)  
Polascheck et al. (2010) |
| - The degree of microglia activation correlates with neuronal cell loss and spontaneous seizures. |                      |
| - Induction of inflammation with lipopolysaccharide lowered the seizure threshold, anti-inflammatory drugs reduced seizure frequency in animals. |                      |
| mTOR (mammalian target of rapamycin) |                      |
| - mTOR involved in epileptogenesis in tuberous sclerosis complex (TSC). | Zeng et al. (2008)  
Zeng et al. (2009)  
Huang et al. (2010) |
| - mTOR inhibitors supress seizures in TSC and in models of acquired epilepsy. |                      |
| Tau protein                          |                      |
| - Targeting hyperphosphorylation of tau with sodium selenate prevented epileptogenesis in animal models of posttraumatic encephalopathy. | Liu et al. (2016) |

**Table 1.1: Selected mechanisms of epileptogenesis**

Drugs in humans (Trinka and Brigo, 2014), we are still in the beginning of understanding the mechanisms of epileptogenesis.

Epileptogenesis is best studied after a specific insult with a clear onset leading to spontaneous seizures, such as stroke or traumatic brain injury (TBI). Clinical experience
suggests a latent (seizure-free) period of several weeks to years between the initial insult and a first unprovoked seizure (Löscher et al., 2015). However, it is unlikely that epileptogenesis represents a step function of time after injury. Recent data rather indicate that epileptogenesis is a continuous process beginning at the time of brain insult and extending past the first unprovoked seizure (Dudek and Staley, 2012; Kadam et al., 2010; P. A. Williams et al., 2009).

Seizures can develop as a relatively unspecific reaction of the brain to different insults. Hence a wide range of overlapping and parallel pathways might be involved in epileptogenesis. A summary of a few selected mechanisms of epileptogenesis is displayed in Table 1.1.

1.3.2.4 Role of NMDA receptors in epileptogenesis

Several lines of evidence support a progressive involvement of NMDA receptors during the development of epilepsy in animal models (Croucher et al., 1995; Mody and Heinemann, 1987; Vezzani et al., 1988; Yeh et al., 1989). Antagonism of the NMDA receptor prevented epileptogenesis and seizures in the kindling and pilocarpine models of epilepsy (Croucher and Bradford, 1990; Croucher et al., 1988; Gilbert, 1988; Raza et al., 2004; Rice and DeLorenzo, 1998; Stasheff, Anderson, Clark and Wilson, 1989a).

Glutamate released after seizures likely has excitotoxic effects that can cause neuronal damage and could lead to an extension of the epileptic tissue (Tanaka et al., 1997). These excitotoxic effects are mainly mediated through NMDA receptors. Several studies demonstrated that blocking of NMDA receptors during status epilepticus might be neuroprotective (Brandt et al., 2003; Fujikawa et al., 1994; Rice et al., 1998).
1.3.3 Epilepsy-aphasia syndromes

Mutations of the GRIN2A gene, coding the GluN2A subunit of NMDA receptors, have been described in 8% to 20% of focal epileptic encephalopathies of childhood (Carvill et al., 2013; Lemke et al., 2013; Lesca et al., 2013). The majority of cases presented with acquired epileptic aphasia (Landau-Kleffner syndrome) or continuous spike and waves during slow-wave sleep syndrome (CSWSS), characterised by focal motor seizures and regression of language or global cognitive skills. Mutations to other GRIN genes encoding the GluN1 and GluN2B subunits have also been associated with epilepsy (Xu and Luo, 2018).

Functional assessment of the mutated proteins revealed that the majority of these mutations caused a loss of NMDA receptor function, followed by gain-of-function mutations (Xu and Luo, 2018). In mutations affecting the GluN2A subunit, those leading to a receptor gain-of-function were associated with a more severe phenotype (Strehlow et al., 2019).

1.3.4 Brain tumours

Tumour expansion of malignant gliomas inside a rigid skull is facilitated by neuronal damage of peritumoural tissue, which is mediated by glutamate excitotoxicity (Takano et al., 2001). Gliomas release glutamate into the peritumoural tissue that promotes tumour growth (Takano et al., 2001; Ye and Sontheimer, 1999). A potential mechanism is the overexpression of the x-cystine-glutamate antiporter (Buckingham et al., 2011), the increase of extracellular glutamate to toxic levels, and subsequent excitotoxicity mediated by NMDA receptors. NMDA receptor antagonism with MK801 or memantine slowed the growth of glutamate-secreting tumours (Ramaswamy et al., 2014; Takano et al., 2001).

Peritumoural glutamate was associated with a higher risk of seizures in animals (Buckingham et al., 2011) and in humans (Yuen et al., 2012). Blocking of the x-c system
and subsequent reduction of glutamate release, led to reduced frequency of epileptic events (Buckingham et al., 2011). Thus, glutamate lowering agents or inhibitors of glutamate receptors may be a therapeutic option for tumour-related seizures (Campbell et al., 2012). This also suggests that tumour surgery may alleviate seizures by removing the glutamate source.

In a similar manner, D-2-hydroxyglutarate (D2HG), a product of mutant isocitrate dehydrogenase 1 (IDH1mut), is released by tumour cells into the surrounding tissue and may mimic the activity of glutamate on NMDA receptors (H. Chen et al., 2017). IDH1mut gliomas were more likely to cause seizures that could be blocked by NMDA receptor antagonists (H. Chen et al., 2017).

Considerable interest has surrounded the use of perampanel, an AMPA receptor antagonist approved for the treatment of seizures, in patients with gliomas. Perampanel slowed tumour growth and reduced extracellular glutamate levels (Lange et al., 2019; Venkataramani et al., 2019). Perampanel was also used to treat seizures in patients with gliomas (Maschio et al., 2019; 2020). The effects of perampanel may be related to recently described bona fide synapses between neurons and glioma cells that produce AMPA receptor mediated postsynaptic currents and influence neuronal activity dependent brain tumour growth (Venkataramani et al., 2019; Venkatesh et al., 2019).

1.3.5 Anti-NMDA-receptor encephalitis

Antibodies to the GluN1 subunit of NMDA receptors cause a severe but treatable form of immune-mediated encephalitis. Anti-NMDA-receptor encephalitis is typically associated with psychiatric, cognitive, and autonomic dysfunction, seizures, speech abnormalities, movement disorders, and decreased level of consciousness (Dalmau et al., 2007; Graus et al., 2016). The early predominance of psychiatric symptoms, that may mimic schizophrenia, frequently leads to initial admissions on psychiatric units (Al-
Diwani et al., 2019). The psychiatric spectrum is complex and involves mixed mood-psychosis symptoms (Al-Diwani et al., 2019).

The disease most frequently affects young women, 95% of cases being younger than 45 years, and has a female sex predominance of 4:1 (Titulaer et al., 2013). More than half of women aged between 18 and 45 affected by the encephalitis have associated tumours, most commonly ovarian teratomas (Titulaer et al., 2013). Around one quarter of adults older than 45 years have associated tumours, mostly carcinomas, whereas tumours are rare in children (Titulaer et al., 2013). Those with associated tumours are at lower risk of relapses if the tumour can be removed (Titulaer et al., 2013).

Although 80% of cases show favourable outcome after treatment, the overall recovery may often be protracted and up to 25% suffer relapses (Gabilondo et al., 2011; Titulaer et al., 2013). Cognitive deficits may persist for a long time (Finke et al., 2012). Long-term immunotherapy may be necessary to prevent relapses and persistent antibodies have been reported up to 15 years after disease onset (Alexopoulos et al., 2011; Hansen et al., 2013; Mariotto et al., 2017).

The pathomechanism of Anti-NMDA-receptor encephalitis has been studied in vitro and in animal experiments. Anti-GluN1 antibodies first increase the clustering of NMDA receptors in both synaptic and extrasynaptic sites (Ladépêche et al., 2018) and subsequently lead to a cross-linking and internalisation of receptors (Hughes et al., 2010; Moscato et al., 2014; Wright et al., 2015). This results in a decrease of NMDA receptor surface density and NMDA receptor-mediated currents (Hughes et al., 2010). In vivo animal experiments suggest that the magnitude of reduction in NMDA receptor density relates to antibody titres. It may be reversible, because washing out of antibodies improved synaptic receptor density and reduced disease symptoms (Hughes et al., 2010; Moscato et al., 2014). Data in humans is lacking but a reduced NMDA receptor density was reported post mortem in two autopsied patients with anti-NMDA-receptor encephalitis (Dalmau et al., 2007).
1.3.6 Alzheimer’s disease

Alzheimer’s disease (AD) is a neurodegenerative disorder associated with progressive loss of memory and cognitive functions. It is the most common cause of dementia accounting for up to two thirds of cases. The worldwide prevalence of dementia is currently estimated at 44 million, and is expected to double by 2030 and more than triple by 2050. The global costs of dementia were estimated at $604 billion in 2010 and this number is set to rise in the coming years (Prince et al., 2014).

Considerable progress has been made on the pathomechanisms of AD in the past 20 years. However, there is still a significant lack of knowledge on early diagnosis, selection of patients for prophylactic treatment and monitoring of disease progress. Studying activated NMDA receptors in living humans with advanced neuroimaging methods might provide valuable answers to some of these problems.

1.3.6.1 Basic pathomechanisms of Alzheimer’s disease

The most widely accepted model for the pathomechanism of AD is the amyloid hypothesis. This is based on the observation that amyloid beta-peptide (Aβ) is the primary component of the senile plaques observed in brains of AD patients (Masters et al., 1985). This peptide results from cleavage of the amyloid precursor protein (APP), coded on chromosome 21. Mutations of the APP gene can lead to early familial forms of AD (Goate et al., 1991). The main genetic risk factor of AD is a polymorphism in the Apolipoprotein E (APOE) gene, a protein that was observed to bind to Aβ-peptides (Strittmatter et al., 1993). The amyloid hypothesis is also supported by results of cerebrospinal fluid (CSF) and imaging studies. These show that Aβ biomarkers are the first to become abnormal even before cognitive symptoms become obvious (Jack et al., 2010).

However, some concerns with the amyloid hypothesis persist. The most commonly voiced critique is that Aβ levels do not correlate well with cognitive status in affected
individuals (Giannakopoulos et al., 2003). Moreover, even individuals with high Aβ levels can have normal cognition. Some studies observed that Aβ deposition was not associated with relevant neuronal loss in transgenic mice (Irizarry et al., 1997). A considerable amount of controversy remains about the pathomechanism of the neurotoxic effects of Aβ, which is still mostly unknown (Hardy and Selkoe, 2002).

1.3.6.2 Role of NMDA receptors in Alzheimer’s disease

Several lines of evidence link accumulation Aβ plaques with disturbances of NMDA receptors. Hence, NMDA receptors might play a major role in the pathomechanism of AD. This is not surprising, as these receptors are not only involved in learning and memory but also in neurotoxicity. The dual function of NMDA receptors and their complex relationship with Aβ leads to several well-documented interactions, including the (i) overactivation of extrasynaptic NMDA receptors, (ii) overexpression of the GluN2B subunit, (iii) reduction of synaptic NMDA receptor density, and (iv) accumulation of Aβ through NMDA receptor activation.

Aβ has been observed to cause a decreased glutamatergic transmission (Palop et al., 2007; Walsh et al., 2002). A reduced number of synaptic NMDA receptors was found in post mortem hippocampal slices of patients with AD (Jacob et al., 2007; Jansen et al., 1990; Kravitz et al., 2013; Young, 1987). In animals, Aβ caused the internalization of synaptic NMDA receptors through dephosphorylation of the GluN2B subunit (Palop et al., 2007; Snyder et al., 2005). Long-term potentiation was impaired in these animals, which led to memory deficits. This mechanism was thought to explain cognitive decline in AD patients.

However, further research showed that the interaction between Aβ and NMDA receptors may be more complicated. While there was a reduction in synaptic NMDA receptors, those located extrasynaptically may be overactivated. Application of Aβ leads to increased activity of extrasynaptic NMDA receptors (Ferreira et al., 2015; Hsia
et al., 1999; Kamenetz et al., 2003; Shankar et al., 2007; Talantova et al., 2013; J. Zhang et al., 2014). Subsequently, an excitotoxic cascade may cause a rise in intracellular calcium (Ferreira et al., 2015) and lead to synaptic depression and dendritic spine loss (Kamenetz et al., 2003; Shankar et al., 2007). These effects were observed early in the course of AD and may precede the development of amyloid plaques (Hsia et al., 1999).

Blocking of overactivated NMDA receptors in animal models of AD counteracted the intracellular calcium increases (Ferreira et al., 2015), reduced long-term depression (J. Zhang et al., 2014) and prevented synaptic damage (Kamenetz et al., 2003; Shankar et al., 2007; Talantova et al., 2013). Despite the negative impact of NMDA antagonists on long-term potentiation, NMDA receptor antagonists improved the performance of treated animals on spatial memory tests and improved the learning process (J. Zhang et al., 2014).

The uncompetitive NMDA receptor antagonist memantine demonstrated positive effects on cognition, mood, and the ability to perform daily activities in AD and was approved for the treatment of moderately to severely affected patients with AD. Memantine blocks overactivated NMDA receptors while preserving normal glutamatergic activity that may lead to a good tolerability of the drug. Additionally, memantine preferentially blocks extrasynaptic NMDA receptors which are likely to be pathologically up-regulated in AD (Lipton, 2006).

Some studies also found activated NMDA receptors to be the cause of Aβ accumulation (Bordji et al., 2010; Lesné et al., 2005). Such a mechanism could cause a vicious circle with increasing accumulation of Aβ, up-regulation of pathological NMDA receptors and, ultimately, neuronal degeneration. This led some authors to speculate that Aβ may not be directly causative of AD but rather represents a toxic by-product of excessive NMDA receptor activation. These complex processes need to be further elucidated in the context of other possible mechanisms including accumulation of tau protein and neuroinflammation (Hardy and Selkoe, 2002).
1.3.7 Other disorders associated with NMDA receptor dysfunction

Many neurological and psychiatric disorders may be associated with dysfunctional NMDA receptors (Kalia et al., 2008). Hypofunction of NMDA receptors as a model of schizophrenia has received a lot of attention (Olney, Newcomer and Farber, 1999a). Inhibition of NMDA receptors may be a treatment strategy for major depression (Barygin et al., 2017; Murrough et al., 2013). Overactivation of NMDA receptors has been described in levodopa-induced dyskinesias in Parkinson’s disease, that may be treated with amantadine, a noncompetitive NMDA receptor antagonist (Ahmed et al., 2011). Excitotoxic damage, attributed to dysfunctional NMDA receptors, has been proposed in neurodegenerative disorders including Huntington’s disease (Fan and Raymond, 2007) and amyotrophic lateral sclerosis (Shaw and Ince, 1997). Riluzole, a modulator of NMDA receptor mediated transmission, is approved for treatment of amyotrophic lateral sclerosis (Kalia et al., 2008).

On the other hand, clinical trials of NMDA receptor antagonists in stroke and traumatic brain injury failed, possibly because overt blocking of NMDA mediated activity may be detrimental for neuronal survival and plasticity during rehabilitation (Ikonomidou and Turski, 2002).

1.4 Imaging NMDA receptors in vivo

1.4.1 Positron emission tomography of NMDA receptors

Positron emission tomography (PET) allows in vivo imaging of molecular targets in the brain (Galovic and Koepp, 2016) and involves the injection of a positron-emitting radioligand (tracer) and the detection of coincident gamma waves within a scanner. The resulting image represents the spatial distribution of the tracer within the brain (Gunn et al., 2015).
Using PET with a receptor-specific radioligand can provide insights into the molecular functioning of a living human brain. A large number of tracers have been developed but only few demonstrated acceptable brain penetration, low-nonspecific binding, high affinity, and target selectivity to progress into clinical studies (Gunn et al., 2015).

Developing radioligands targeting the NMDA receptor has proven particularly difficult. Until recently, in vivo imaging of NMDA receptors has not been possible due to the lack of a suitable radiotracer (Sobrio et al., 2010). So far, only few tracers were tested in humans (Krämer et al., 2018; McGinnity et al., 2014; van der Aart et al., 2018; 2019; Waterhouse, 2003). Most of these tracers bind to the phencyclidine (PCP) site inside of the NMDA receptor, requiring channel opening for the tracer to bind (McGinnity et al., 2014; Waterhouse, 2003).

One study evaluated eight people with mesial temporal lobe epilepsy (MTLE) with $[^{11}C]$ketamine (Kumlien et al., 1999). There was decreased binding in the ipsilateral temporal lobe, however the authors could not differentiate whether the changes were due to reduced NMDA-receptor density, reduced perfusion, or focal atrophy.

$[^{11}C]$CNS-5161 PET was used to measure binding to the PCP site on NMDA receptors in 18 patients with Parkinson’s disease with (n=8) or without (n=10) levodopa-induced dyskinesias (Ahmed et al., 2011). Both patient groups had similar radioligand binding in the OFF state, i.e. withdrawn from levodopa. Dyskinetic patients had higher tracer uptake in caudate, putamen, and precentral gyrus in the ON state, i.e. after levodopa administration. The results confirm abnormal glutamatergic transmission in motor areas following levodopa administration in dyskinetic patients and provide support for treatment of dyskinesias with NMDA receptor modulators, e.g. amantadine.

A structurally related tracer, $[^{123}I]$CNS-1261, was used in several single photon emission tomography (SPET) studies in patients with schizophrenia. The authors found reduced left hippocampal tracer uptake in medication free, but not in antipsychotic-treated, patients with schizophrenia compared to healthy controls (Pilowsky et al., 2006). The authors also observed global reductions of binding in patients treated with
clozapine (Bressan et al., 2005) and in healthy controls receiving ketamine (Stone et al., 2008).

A limitation of studies using $^{11}$C-labelled tracers is their short half-life of around 20 minutes, restricting their use to facilities with an on-site cyclotron. $^{18}$F-labelled radioligands, with a half-life of around 110 minutes, are more simple to use routinely because they can be more widely distributed and offer the potential for longer acquisitions.

$[^{18}\text{F}]\text{GE-179}$ was developed as an $^{18}$F-labelled structural analogue of $[^{11}\text{C}]\text{CNS-5161}$ (McGinnity et al., 2014; Robins et al., 2010) and was used to study eleven patients with focal epilepsy and frequent interictal epileptiform discharges (McGinnity et al., 2015). A global increase in $[^{18}\text{F}]\text{GE-179}$ uptake was seen in eight epilepsy patients not taking antidepressants, whereas three patients taking antidepressants showed a decreased tracer uptake. Four epilepsy patients showed focal signal alterations compared to controls but the findings were difficult to interpret because of the unclear or multifocal epilepsy localisation in these cases.

In another study reported as an abstract, eight out of ten patients with refractory focal epilepsy had focal areas of increased $[^{18}\text{F}]\text{GE-179}$ uptake (Vibholm et al., 2017). The same authors also observed increased radioligand binding after hippocampal electrical stimulation in pigs (Vibholm, Landau, Alstrup, et al., 2020). A successful blocking experiment with $S$-ketamine was performed in rats electrically stimulated in the amygdala/hippocampus (Vibholm, Landau, Møller, et al., 2020). These findings confirm that $[^{18}\text{F}]\text{GE-179}$ is a use-dependent radioligand of the PCP site within the open NMDA receptor ion channel (Vibholm, Landau, Møller, et al., 2020).

### 1.4.2 $[^{18}\text{F}]\text{GE-179}$

The novel NMDA receptor radioligand $[^{18}\text{F}]\text{GE-179}$ was developed as a structural $^{18}$F-labelled structural analogue of $[^{11}\text{C}]\text{CNS-5161}$ (Robins et al., 2010). It demonstrated
affinity to the PCP site inside the open/active ion channel and is, thus, a potential use-dependent marker of NMDA receptor activation. The radioligand demonstrated high selectivity, moderate lipophilicity, high brain uptake, acceptable between-subject variability, and suitably rapid washout, making it a good candidate for further human studies (McGinnity et al., 2014; Robins et al., 2010).

GE-179 binding was specific to the NMDA receptor PCP site and did not demonstrate significant binding to any of the 60 other receptors, channels, and transporters assessed (McGinnity et al., 2014; Robins et al., 2010). The specificity of $[^{18}F]$GE-179 binding to the PCP site was validated in vivo in electrically stimulated rats (Vibholm, Landau, Møller, et al., 2020). $[^{18}F]$GE-179 PET detected focally activated NMDA receptors following pulsed electrical stimulation in the amygdala/hippocampus that was blocked by administration of S-ketamine, confirming the use-dependent specificity of the radioligand to the open NMDA receptor ion channel.

In comparison, demonstrating binding specificity in anaesthetised animals is challenging because of the low baseline ion channel activity in sedated rodents (McGinnity et al., 2019). Thus, initial blocking experiments in anaesthetised rats and rhesus monkeys were not successful (Schoenberger et al., 2017), possibly due to the effects of anaesthesia. The use-dependent nature of GE-179 binding may require receptor activation/opening to demonstrate allow for blocking experiments and these may not be effective in anaesthetised specimen (McGinnity et al., 2019). In the absence of ketamine or isoflurane anaesthesia, the GE-179 structural analogues CNS-5161 and GMOM showed reduced binding after administration of PCP site antagonists (Biegon et al., 2007; van der Doef et al., 2016).

GE-179 had no effect on any cardiovascular parameters in conscious dogs or on modified expanded acute toxicity in living rats, with a no-observed-adverse-effect-limit (NOAEL) of 316 μg/kg, equivalent to 306-times the expected maximum human clinical dose (Source: GE Healthcare plc, unpublished data, on file). CNS-5161, a structural analogue of GE-179, was administered in doses up to 2 mg to healthy volunteers.
(Walters et al., 2002) and up to 0.5 mg in patients with neuropathic pain (Forst et al., 2007). Most commonly observed side effects were transient increases in blood pressure and heart rate, with mild headaches and mild visual disturbances also reported by some patients. No adverse effects of \[^{18}\text{F}\text{GE-179}\] administered as a radiotracer were observed in a pilot study of healthy volunteers and patients with epilepsy (McGinnity et al., 2014; 2015).
2 Common Methods

2.1 Participants

We included participants from four centres (National Hospital for Neurology and Neurosurgery [NHNN] London, Addenbrooke's Hospital Cambridge, John Radcliffe Hospital Oxford, and St. George's University Hospitals London). The participants were recruited as part of three studies; NMDA receptors in epilepsy, stroke, and traumatic brain injury (UCL study); Imaging NMDA receptor activation following head injury using positron emission tomography (Cambridge study); NMDA receptor binding in patients with frequent inter-ictal epileptiform discharges (McGinnity et al., 2014; 2015) (Hammersmith study). In brief, the studies can be described as follows.

Firstly, most participants for this thesis were recruited as part of the UCL study, a large and ongoing multi-centre project studying NMDA receptor activation using $^{18}$F-GE-179 PET in health and disease. The final study cohort involved 26 subjects with focal epilepsy and five with Anti-NMDA-receptor encephalitis. Additionally, ten healthy volunteers were recruited. The study used a Siemens Biograph mMR combined PET-MR scanner and an image-derived input function (IDIF) with venous blood sampling for quantification.

Secondly, ten healthy volunteers were recruited as part of the ongoing traumatic brain injury (TBI) study at Addenbrooke's Hospital in Cambridge. Eight of these volunteers
were later rescanned. The Cambridge study used a GE Discovery 690 TOF combined PET-CT scanner and an arterial input function for quantification.

Thirdly, nine healthy volunteers were recruited as part of a pilot study using $[^{18}F]$GE-179 PET in Hammersmith (McGinnity et al., 2014; 2015). The study used a Siemens/CTI ECAT EXACT HR+ model 962 PET scanner at Hammersmith Hospital London and an arterial input function for quantification.

2.1.1 Healthy volunteers

We included 29 healthy volunteers (10 UCL study, 10 Cambridge study, 9 Hammersmith study) aged between 25 and 65 years without a history of neurologic or psychiatric illness and not taking regular medication. We rescanned eight healthy volunteers from the Cambridge study, and the remaining two participants were lost to follow-up. Out of these eight rescans, one participant was excluded because of failed metabolite analysis and another because of failure of arterial sampling during the scan, leaving a total of six rescans for analysis. An overview of demographic characteristics is given in Table 2.1.

2.1.2 Patients with epilepsy

We recruited 27 patients with unilateral focal refractory epilepsy aged between 18 and 65 years undergoing presurgical evaluation at NHNN. For each individual the diagnosis, lateralisation, and localisation of epilepsy was determined by a multidisciplinary epilepsy surgery evaluation involving neurologists, neurophysiologists, neurosurgeons, neuropsychologists, and psychiatrists specializing in epilepsy based on clinical history, neurologic examination results, seizure semiology, long-term video-electroencephalography telemetry, MRI, and
neuropsychological and psychiatric assessments. [18F]fluorodeoxyglucose(FDG)-PET was additionally performed in seven cases.

The epileptogenic zone was confirmed using intracranial electrode recordings in four subjects, and in all of these cases [18F]GE-179 PET was performed before electrode implantation.
Excluded were subjects with (i) unclear or undetermined localisation of the epileptogenic zone, (ii) a history of neurologic or psychiatric conditions unrelated to epilepsy, (iii) history of traumatic brain injury leading to intracranial injuries, (iv) regular or recent (<14 days) use of antidepressants, antipsychotics, illicit substances, ketamine or felbamate. One subject was excluded after scanning because of corrupted PET images hindering reconstruction, leaving 26 participants with epilepsy in the final analysis.

All patients with epilepsy were scanned on the Siemens Biograph mMR combined PET-MR scanner and an image-derived input function with venous blood sampling was used for quantification.

### 2.1.3 Patients with Anti-NMDA-receptor encephalitis

We recruited five participants with clinically and laboratory-confirmed Anti-NMDA-receptor encephalitis from John Radcliffe Hospital Oxford (n=3) and St. George’s University Hospitals London (n=2). Included were those who were recently discharged from hospital and able to undergo a 70-minute PET-MR scan. Excluded were subjects with a history of neurologic or psychiatric conditions unrelated to the encephalitis and those with regular or recent (<14 days) use of antidepressants, antipsychotics, illicit substances, ketamine or felbamate.

All patients with encephalitis were scanned on the Siemens Biograph mMR combined PET-MR scanner and an image-derived input function with venous blood sampling was used for quantification.

### 2.2 Regulatory approval

All studies were approved by the local Research Ethics Committee and the local NHS Trust research office. All studies received permission to administer $^{[18F]}$-GE-179 from
the Administration of Radioactive Substances Advisory Committee, U.K. All participants provided written, informed consent before participation.

2.3 Image acquisition and reconstruction

All participants underwent dynamic emission PET scans after intravenous injection of a target dose of 185 MBq of $[^{18}\text{F}]$GE-179.

2.3.1 Image acquisition in the UCL study

The UCL study used a Siemens Biograph mMR combined PET-MR scanner for acquisitions of 70-minute dynamic emission scans with a 25.8mm axial field of view. The rationale for shortening the scan duration from 90 to 70 minutes and for using an image-derived input function was to make the scanning procedure more easily applicable in clinical practice, as requested by the study funder (Medical Research Council). Our group showed that shortening the scan duration to 70 minutes provides images that correlate excellently (Spearman’s rank correlation coefficient 0.99, 95% CI 0.98 - 0.99, p<0.001) with 90 minute scans and the results were robust for all studied subregions (7 distributed regions, Spearman’s rank correlation coefficient ranging from 0.98 to 1.00) (McGinnity et al., 2018). Our group also recently proposed a novel method to estimate the input function from PET images without the need for arterial sampling (Sari et al., 2016). We additionally validated this method (see Project 1 in chapter 3) for use in the current study with data from 10 healthy volunteers scanned in the Cambridge study.

List-mode data were initially processed using an in-house motion detection algorithm (UCL Institute of Nuclear Medicine, in preparation for publication). In brief, an algorithm semi-automatically detected sudden changes in three most relevant principal components of the PET signal. These sudden changes most likely correspond
to sudden head movements. Thus, the frame timing was individually adapted to exclude these typically short (duration between seconds to max. 1 min) signal alterations and reduce the effect of interframe sudden head movement. This resulted in a variable number of 45 to 54 frames. The larger number of short frames during the first two minutes after radioligand injection was important to allow accurate estimation of the peak of an image-derived input function. Data were reconstructed with a 3-dimensional filtered backprojection to voxel sizes of 1.402 x 1.402 x 2.032 mm. A mean resolution of 6.8 mm full width at half maximum (FWHM) was estimated using phantom measurements.

Each subject underwent 3T brain MRI on the Siemens Biograph mMR combined PET-MR scanner (Siemens Healthineers, Erlangen, Germany). The MR protocol included a high-resolution volumetric T1-weighted sequence (MPRAGE) with 2000 ms repetition time, 2.92 ms echo time, 256 x 256 matrix, and 1.1 x 1.1 x 1.1 mm voxels. We also performed a arterial time-of-flight magnetic resonance angiography (TOF-MRA) sequence that included the carotid arteries with 22 ms repetition time, 4.17 ms echo time, 256 x 256 matrix, and 0.625 x 0.625 x 2 mm voxels. A T2-weighted 3D SPACE sequence was acquired with 5000 ms repetition time, 402 ms echo time, 64 x 64 matrix, and 1.1 x 1.1 x 1.1 mm voxels.

Venous samples were obtained 7, 12, 22, 42, and 62 minutes after injection. Samples were analysed for radiolabelled metabolites using high-performance liquid chromatography and for total radioactivity in whole blood and plasma.

2.3.2 Image acquisition in the Cambridge study

The Cambridge study used a GE Discovery 690 TOF combined PET-CT scanner for acquisitions of 90-minute dynamic emission scans with a 15.4 mm axial field of view. Data were reconstructed with a 3-dimensional filtered backprojection to 58 frames.
with voxel sizes of 2.000 x 2.000 x 3.270 mm. A mean resolution of 4.98mm full width at half maximum (FWHM) was previously estimated. (Bettinardi et al., 2011)

Each subject underwent 3T brain MRI on a Siemens Trio or Skyra system (Siemens Healthineers, Erlangen, Germany). The MR protocol included a high-resolution volumetric T1-weighted sequence (MPRAGE), as well as an arterial time-of-flight magnetic resonance angiography (TOF-MRA) sequence that included the carotid arteries.

Arterial blood from the radial artery was continuously sampled for the first 6.5 minutes of the scan with an Allogg ABSS on-line detector (Allogg AB, Mariefred, Sweden), with two discrete samples (30 sec and 4.5 minutes) taken beyond the on-line counter for cross-calibration against the well counter and plasma-to-whole blood ratio determination. Discrete arterial samples were also taken at 10, 15 and 20 minutes post-injection, and at 10 minute intervals thereafter. Venous samples were collected through a cannula placed in the elbow opposite the injection site at 7, 12, 22, 42, and 62 minutes following injection. The radioactivity concentration in whole blood and plasma for all discrete blood samples was determined with a Hidex Triathler well counter (Hidex, Turku, Finland) cross-calibrated to the PET/CT scanner. The fraction of parent tracer in plasma for 6 arterial plasma samples (4.5, 10, 20, 40, 60, and 90 minutes post-injection). Samples were analysed for radiolabelled metabolites using high-performance liquid chromatography and for total radioactivity in whole blood and plasma.

2.3.3 Image acquisition in the Hammersmith study

The Hammersmith study used a Siemens/CTI ECAT EXACT HR+ model 962 PET scanner for acquisitions of 90-minute dynamic emission scans with a 15.5 mm axial field of view. Data were reconstructed with a 2-dimensional filtered back-projection to
34 frames with voxel sizes of 2.092 x 2.092 x 2.420 mm. A mean resolution of 4.75 mm FWHM was previously estimated. (Spinks et al., 2000)

3D Volumetric T1-weighted coronal SPGR MRI sequences were acquired to exclude relevant intracranial structural abnormality and for co-registration with the PET images, using a GE Signa 3T HDx system (General Electric, Waukshua, WI, U.S.A.) with a voxel size of 0.938 mm x 1.100 mm x 0.938 mm. Coronal T2 and FLAIR were also acquired for each participant.

Arterial samples were obtained continuously for the first 7 minutes and at 10 discreet samples afterwards. Venous samples were obtained 7, 12, 22, 42, and 62 minutes after injection in 10 out of 18 scans. Samples were analysed for radiolabelled metabolites using high-performance liquid chromatography and for total radioactivity in whole blood and plasma.

2.4 Fitting of blood data

We used in-house software (UCL Institute of Nuclear Medicine) running in Matlab 9.2 to fit input functions, parent fractions and plasma-over-whole-blood (POB) ratios.

For each participant, the POB ratio was fitted with a function as follow:

\[ f(t) = e^{-x_1 \cdot t} \cdot x_2 + x_3 \]

[Where 0 < x_1, 0 < x_2, 0 < x_3, t is the scan time; x_1 ... x_3 are the model parameters; f POB ratio of [^{18}\text{F}]GE-179 at scan time t].

For each participant, the fraction of plasma radioactivity attributable to the parent [^{18}\text{F}]GE-179 was fitted with a Hill type function (Gunn et al., 1998) as follows:

\[ f(t) = 1 + \frac{t^{x_1} \cdot (x_2 - 1)}{t^{x_1} + x_3} \]
Common Methods

[Where $0 < x_1, 0 \leq x_2 < 1, 0 < x_3$, $t$ is the scan time; $x_1$ ... $x_4$ are the model parameters; $f$ parent fraction of $^{18}\text{F}\text{GE}-179$ at scan time $t$].

The input function (arterial or image-derived) was fitted after correction for parent fraction and POB ratio with Feng’s input function model (Feng et al., 1993), which consists of the sum of a gamma-variate function and two exponentials.

2.5 Estimation of an image-derived input function

2.5.1 Theoretical background and rationale

We aimed to develop and validate a method for the quantification of $^{18}\text{F}\text{GE}-179$ binding that is independent of arterial blood sampling. Arterial sampling is invasive, laborious, uncomfortable, but generally safe (Zanotti-Fregonara, Chen, et al., 2011). Such an invasive approach discourages participation in research studies and hinders the translation of methods into a clinical setting, where arterial sampling usually is not available.

A recent publication from our group evaluated two available options (McGinnity et al., 2018), the calculation of standardized uptake value (SUV) images and the use of a population based input function. SUV images calculated over the interval of 60 to 70 minutes had a Spearman’s correlation coefficient of 0.76 with arterial input function (AIF) images. A population-based input function provided a higher correlation (0.90) with AIF images, but there was a large variability of differences in volume of distribution estimates as demonstrated by Bland-Altman plots. Both proposed methods failed to replicate findings observed in a pilot project involving epilepsy patients (McGinnity et al., 2015). There is no suitable reference region devoid of NMDA receptors.

Thus, we aimed to develop and validate an alternative method using an IDIF, as recently proposed by our group (Sari et al., 2016). IDIFs have been used as a
noninvasive alternative for several years, but practical challenges remain regarding the identification of blood vessels, correction for partial volume effects, and determining the parent fraction of the tracer in plasma (Zanotti-Fregonara, Chen, et al., 2011).

Methods validated on a different tracer or scanner set-up might not be generalizable and need to be re-validated for each specific study (Zanotti-Fregonara, Liow, et al., 2011).

Our method (Sari et al., 2016) uses arterial time-of-flight (TOF) MRI imaging to delineate the location of carotid arteries. However, it does not account for tracer metabolism or tracer binding in plasma. Thus, we modified this method by including data from venous blood samples in the kinetic modelling. We used a robust partial volume correction (PVC) method to correct for spill-out and spill-in effects due to the small size of carotid arteries compared to the scanner resolution (Erlandsson and Hutton, 2014). The single target correction method requires the segmentation of one single volume of interest (i.e. the carotid arteries) and does not need segmentation of background areas, making it less labour-intensive than comparable methods.

PVC is particularly important to correctly detect the radioactivity peak following tracer injection. However, the method is of limited value during steady state with comparable radioactivity concentrations between soft tissues and blood vessels, as it might be susceptible to reinforce noise in images. Thus, PVC was used only for the initial 3.5 minutes after tracer injection to capture the radioactivity peak and uncorrected values were used for the remainder of the acquisition. The 3.5 minute interval was chosen as the time point when intra-carotid and tissue (background) activity started to overlap. We also adjusted the image-derived concentrations in the carotid arteries for a delay occurring when measuring arterial blood drawn from the radial artery, as described previously (Sari et al., 2016).

A previous study by our group showed different tracer metabolism in epilepsy patients versus healthy controls, probably due to intake of antiepileptic drugs in the patient group (McGinnity et al., 2015). Thus, we obtained 5 discrete venous samples as
described above to estimate the parent fraction and to correct for the POB ratio. This also allowed us to calibrate the IDIF with a single venous sample, as has been previously proposed (Zanotti-Fregonara, Chen, et al., 2011). We used the latest venous sample obtained (i.e. 62 minutes after radioligand injection) as the correlation between arterial and venous radioactivity increases with scan duration.

2.5.2 Carotid artery segmentation

We used arterial TOF MRI scans, that provide an excellent separation of arteries from background, for segmentation of carotid arteries. We used a semi-automated region-growing algorithm with intensity constraints implemented in MRcron ([https://people.cas.sc.edu/rorden/mricron/index.html](https://people.cas.sc.edu/rorden/mricron/index.html)). We manually adjusted all segmentations in a slice-by-slice manner to segment the internal carotid artery and visible parts of the common carotid artery only. We did not segment other arteries, e.g. the vertebral arteries, because of their smaller size that increases the potential for partial volume effects. We segmented the internal carotid artery in the cervical, petrous, and cavernous segments. We excluded the carotid siphon and cerebral segment of the internal carotid artery, because of the sigmoid vessel shape and proximity to parts of the temporal lobe, that might make intra-vessel signal estimates less accurate and more prone to spill-in effects from brain tissue.

2.5.3 Coregistration of intra-modal images

We used the linear registration algorithm implemented in Statistical Parametric Mapping 12 (SPM12, Wellcome Centre for Human Neuroimaging) to coregister PET, T1 and TOF images. The simultaneous acquisition of PET and MR images on the combined PET-MR scanner in the UCL study provided an excellent starting point for coregistration between PET and MR modalities. First, we coregistered PET into the space of T1 because of the superior spatial resolution of structural MR imaging. As a
next step, we coregistered T1 to TOF and applied the transformations to the dynamic PET series.

### 2.5.4 Measuring and processing radioactivity concentration in the carotid arteries

We used the single target partial volume correction method with 10 iterations to correct for spill-out and spill-in effects due to the small size of carotid arteries compared to the scanner resolution (Erlandsson and Hutton, 2014). We used PVC for the initial 3.5 minutes after tracer injection to capture the radioactivity peak and obtained uncorrected values for the remainder of the acquisition to reduce the impact of noise introduced by PVC.

Next, we determined a mean delay between radioactivity arriving in the carotid arteries and detected in blood drawn from the radial artery, as described previously (Sari et al., 2016). We shifted each participant’s curve to match the activity obtained from the radial artery and determined a mean delay of 16.4 s ± 4.5 s that was subsequently applied to all participants in a later step.

The availability of venous blood samples allowed us to calibrate each individual’s image-derived measurements with blood data. We correlated late (62min) venous samples with the corresponding arterial radioactivity measurements and modelled the venous to arterial radioactivity conversion using a linear model. We then calculated the estimated arterial radioactivity per subject using this model and scaled the image-derived measurements to match this target value.

Lastly, we fit Feng’s input function model (Feng et al., 1993) including venous parent fraction and POB data to obtain an IDIF.
2.6 Image preprocessing and modelling

2.6.1 Smoothing

PET scans were acquired at three different sites (UCL, Cambridge, and Hammersmith studies) with different scanner equipment. A large proportion of between-scanner differences can be attributed to resolution. We applied a high frequency correction using smoothing, as proposed earlier (Joshi et al., 2009), to correct for these differences and to adjust all data to the same target resolution.

2.6.2 Flipping

Data in people with epilepsy are influenced by the lateralisation of the epileptic focus. In our epilepsy sample, there was an equal proportion of left- and right-lateralised cases. We flipped all data of right-lateralised cases before image spatial preprocessing and used a symmetrical DARTEL normalisation template. To prevent bias introduced through flipping, we also flipped a randomly selected half of all healthy volunteer data. We used flipped volunteer data only for comparisons with epilepsy patients.

2.6.3 Rigid motion correction

Attenuation and scatter-corrected dynamic PET images were corrected for head motion using a post hoc frame-to-frame realignment method, implemented in SPM12. For each subject, an early frame with high signal-to-noise ratio and little evidence of movement was selected as the reference frame and all subsequent frames were rigidly realigned to this reference. The frames within the first 3 minutes after radioligand injection were not realigned due to low signal-to-noise ratio.
2.6.4 Inter-modal coregistration

We combined the motion-corrected dynamic PET images to a summation image that was linearly coregistered to the T1 structural MR image using SPM12. The transformations were then applied to all realigned PET frames.

2.6.5 Structural parcellation

We used an algorithm based on Geodesic Information Flows (GIF) (Cardoso et al., 2015) freely available within the NiftyWeb service tool (University College London Centre for Medical Image Computing; http://niftyweb.cs.ucl.ac.uk/) for parcellation of brain structures on T1 scans. We combined this parcellation with an image segmentation obtained using the Unified Segmentation procedure in SPM12 and added classes of cerebrospinal fluid, soft tissue, skull and air. The parcellation was simplified into 71 structures by combining smaller regions into larger areas. A second atlas was created by combining these areas into cerebral lobes, white matter, cerebellum and brainstem.

We segmented surgical resections using in-house software by comparing post- with presurgical T1 scans and iteratively extracting an empirical prior for an atypical tissue class, i.e. the resection. This procedure is based on an established lesion-segmentation algorithm (Seghier et al., 2008) and has been described in detail previously (Galovic, Baudracco, et al., 2019). All cavity masks were subsequently checked and, if necessary, manually refined by an investigator (MG). Lesions in epilepsy patients were manually segmented by an investigator (MG). Resections and lesions were added as a tissue class to the whole-brain parcellation.
2.6.6 Partial volume correction

The quantification of PET images is affected by the partial volume effect that is related to the limited spatial resolution of usually 5 to 6mm FWHM for modern scanners (Erlandsson et al., 2016). This results in a blurring of the image and to a tissue fraction effect, occurring when a single voxel contains several tissues. These can lead to spill-in or spill-out of activity in neighbouring regions. Particularly affected are small regions in close proximity to cerebrospinal fluid or white matter, e.g. the hippocampus.

Several correction methods have been proposed that utilize structural information from high-resolution MR imaging to compensate for partial volume effects due to low resolution PET. We used the iterative Yang method (Erlandsson et al., 2012) implemented in the PET-PVC toolbox developed in-house (Thomas et al., 2016) for adjusting of whole brain data. The modified GIF parcellation (see above) was used for structural tissue information. As described above, data in carotid arteries for the estimation of an IDIF were corrected using single-target correction.

2.6.7 Modelling

We extracted time activity curves of the parcellated regions from partial volume corrected dynamic PET images. As described previously (McGinnity et al., 2014), we used 2-brain-compartment 4-rate-constant (2c4k) full kinetic models with a variable blood volume component to quantify [$^{18}$F]GE-179 cerebral tissue kinetics. We calculated volume of distribution ($V_T$) estimates for each region.

Additionally we computed $V_T$ for each scan on a voxel level using Logan graphical analysis (Logan et al., 1990). Short frame intervals in the NEST study during the first 3 minutes after tracer injection were necessary to provide accurate estimates of the radioactivity peak in carotid arteries. However, these short frames might introduce additional noise that results in inaccurate $V_T$ estimates. We implemented an additional “temporal smoothing” step that summed short PET frames and effectively reduced
noise. We also applied a median filter to effectively remove noise introduced by inaccurate \( V_T \) estimates in single voxels.

2.6.8 Spatial normalization

We used the Computational anatomy 12 toolbox (CAT12, http://www.neuro.uni-jena.de/cat/) in SPM12 to segment and nonlinearly register all T1 images to a DARTEL template. We applied the same transformations to \( V_T \) images. Lesions were cost-function masked prior to spatial processing to reduce their effect on normalisation (Brett et al., 2001).

Cost-function masked postsurgical images were first nonlinearly coregistered to the participant’s presurgical scan. The normalisation transformations estimated using the presurgical image were then applied to the coregistered postsurgical scan. This procedure ensured a high accuracy despite large resections, as has been described previously (Galovic, Baudracco, et al., 2019).

Normalised grey matter segmentations and \( V_T \) images were masked to grey matter only, also masking any lesions or resections. An 8mm FWHM smoothing kernel was applied to both image modalities.

2.7 Statistical analysis

2.7.1 Numerical data

Categorical variables are presented as N (%), continuous variables as mean ± standard deviation. We used the general linear model implemented in SPSS (version 24.0; IBM Corp) to compute the association of global or regional \( V_T \) values with group allocation (e.g. patient vs. control) or clinical parameters. All models were corrected for age, sex,
and scanner equipment (UCL, Cambridge or Hammersmith scanner). A p-value below 0.05 was considered significant.

2.7.2 Imaging data

Voxelwise data ($V_T$ images and grey matter segmentations) were analysed using full factorial linear models implemented in SPM12. All models were adjusted for age, sex, and scanner equipment (UCL, Cambridge or Hammersmith scanner). Results are reported at a clusterwise threshold of $p<0.05$, family-wise error corrected for multiple comparisons.
3 Project 1: Development and validation of an input function independent of arterial sampling.

3.1 Introduction

PET imaging has been used in the past 30 years to non-invasively image targets in the human brain. An ever-increasing number of radioligands have been developed (Gunn et al., 2015), although only a small fraction of the more than 70 tracers tested in humans has been used routinely. Complicated methodological set-up was, besides tracer availability and costs, one of the factors hindering the translation of research findings into routine clinical scanning.

We recently described the first-in-human use of $[^{18}\text{F}]\text{GE}-179$, a PET radioligand selectively binding to the NMDA receptor complex (McGinnity et al., 2014). NMDA receptors are not only involved in memory and synaptogenesis, but also have a proposed role in excitotoxicity and might contribute to epilepsy, Alzheimer’s and Huntington’s disease, and psychosis (Bordji et al., 2010; Cooke and Bliss, 2006b; Fan and Raymond, 2007; McGinnity et al., 2015; Olney, Newcomer and Farber, 1999a; Rothman and Olney, 1995). NMDA receptor blockers have been used to treat seizures,
Alzheimer’s disease or refractory depression (Lipton, 2006; Murrough et al., 2013; Pellock et al., 2006). We showed increased $[^{18}F]$GE-179 uptake in brains of people with epilepsy, suggesting an increased activation of NMDA receptors (McGinnity et al., 2015).

Several ongoing studies are using $[^{18}F]$GE-179 but a wide utilisation is limited by the need for arterial blood sampling for full quantification of tracer binding. Blood sampling from the radial artery is associated with local pain and bruising and carries the potential, albeit rare, risks of haemorrhage or thrombosis (Zanotti-Fregonara, Chen, et al., 2011). Thus, this invasive and labour-intensive method is not favoured in routine practice. A reference region devoid of NMDA receptors is not available (McGinnity et al., 2014). Standardised uptake value (SUV) images or a population-based input function did not provide accurate quantification (McGinnity et al., 2018).

We have previously proposed a procedure to estimate an image-derived input function (IDIF) for molecular imaging quantification independent of arterial blood sampling (Sari et al., 2016). However, this method cannot distinguish the fraction of the parent compound in plasma from total blood activity and is, thus, of limited use in tracers with relevant metabolism.

Here, we complement this method by including discrete venous samples that allow correction for parent fraction and plasma-over-blood (POB) ratios. We validate the combined procedure for the $[^{18}F]$GE-179 tracer showing high correlation between our approach and arterial input function.

### 3.2 Methods

The methods are described in detail in Chapter 2.

In brief, we studied 10 healthy volunteers at Addenbrooke’s Hospital in Cambridge, UK. Dynamic PET images were acquired on a GE Discovery 690 TOF combined PET-CT scanner after injection of a target 185 MBq of $[^{18}F]$GE-179. We obtained arterial
blood samples continuously from the radial artery for the first 6.5 minutes and at 10 discreet intervals thereafter. Venous samples were collected through a cannula placed in the elbow opposite the injection site 7, 12, 22, 42, and 62 minutes after injection. The same procedures were used for fitting of the arterial and venous parent fraction, POB ratio, and both input functions.

We segmented the internal carotid artery (cervical, petrous, and cavernous segments) on TOF MRI scans. We linearly coregistered the dynamic PET data and T1 MRI data into TOF image space. We used single target PVC (Erlandsson and Hutton, 2014) for the initial 3.5 minutes for estimating the peak of the input function and used uncorrected data for the remainder of the scan to reduce noise. The image-derived radioactivity in the carotid arteries was then shifted by a previously estimated mean delay of 16.4 seconds to match arterial data. We calibrated the image-derived data with the 62-minute venous sample radioactivity. The rationale for this processing is described in chapter 2.5.1.

Imaging data was preprocessed and modelled as described in chapter 2.6. We used a modified GIF-atlas encompassing 11 distinct brain regions. We selected brain regions as representative for different cortical, subcortical, white matter, and infratentorial structures that might be representative for different patterns of brain tracer binding (McGinnity et al., 2014). The data in these regions was modelled using a 2c4k full kinetic model and $V_T$ was estimated for each region.

We calculated the area under the curve (AUC) for the fits of parent fraction, POB ratio, and input function. We interpolated radioactivity measurements in the radial artery to a time of 60 minutes using the fit of the Feng function (Feng et al., 1993) and compared it to venous radioactivity in the sample obtained 62 minutes after injection,
Project 1: Development and validation of an input function independent of arterial sampling.

Figure 3.1: Comparison of arterial and IDIF + venous measurements

Comparison of the areas under the fitted curves (AUC) for arterial and venous parent fraction (panel A) and plasma-to-whole blood ratio (panel B), together with the final input function (panel C). On each plot the dotted line is the linear regression fit, the grey line indicates the line of unity. The comparison of the mean shapes of the arterial and IDIF + venous input functions is displayed in panel D. The light orange/blue areas denote the corresponding 95% confidence intervals.
Project 1: Development and validation of an input function independent of arterial sampling.

assuming a 2 minute delay between arterial and venous data due to tissue diffusion. We compared AUCs, radioactivity counts, and regional $V_T$ estimates between arterial and venous/image-derived data using Pearson’s correlation coefficient ($r$). Additionally, Bland-Altman plots were used to compare $V_T$ estimates. We estimated the regional and global coefficient of variation (CoV) for VT estimates modelled using the arterial (AIF) or image-derived (IDIF) input functions.

Additionally, we evaluated the effect of reducing venous sampling to only the late sample obtained 62 minutes after the injection. This approach required determination of population-based estimates of the $x_1$ and $x_3$ parameters that determine the shape of POB ratio and parent fraction curves (see chapter 2.4). The remaining $x_2$ parameter, determining the amplitude of the curve, was then estimated using the single venous sample. The remaining blood data processing was left unchanged.

3.3 Results

3.3.1 Standard analysis

The demographic characteristics of the studied 10 healthy volunteers are listed in Table 2.1. There was a high correlation between the areas under the curve fits of arterial (mean $31 \pm 10$) and venous (mean $31 \pm 10$) parent fraction measurements ($r = 0.99$, p<0.001, Figure 3.1A). There was a high correlation between AUCs of arterial (mean $111 \pm 9$) and venous (mean $109 \pm 8$) POB measurements ($r = 0.93$, p<0.001, Figure 3.1B).

The mean differences in measured whole blood radioactivity in arterial and venous samples declined over time (Figure 3.2A, 5 min 0.52 kBq/ml [0.25-0.80], 10 min 0.24 [0.15-0.34], 20 min 0.17 [0.11-0.23], 40 min 0.10 [0.06-0.14], 60 min 0.07 [0.04-0.10]). The highest correlation was observed between the arterial 60-minute (1.23 kBq/ml ± 0.29) and venous 62-minute (1.17 kBq/ml ± 0.29) radioactivity concentrations ($r = 0.99$,
Project 1: Development and validation of an input function independent of arterial sampling.

We fitted a linear model to scale 62-minute venous to 60-minute arterial radioactivity concentrations (\( \text{Activity}_{\text{venous}} = \text{Activity}_{\text{arterial}} \times 0.987 + 0.082 \)), that was later applied to calibrate the image-derived data.

There was high correlation of AUCs of fitted AIF (73 ± 16) and IDIF+venous (74 ± 17) corrected for parent fraction and POB ratio (\( r = 0.92, p<0.001 \), Figure 3.1C). A plot of

\( p<0.001, \) Figure 3.2F).

Figure 3.2: Comparison of arterial and venous radioactivity concentrations

The mean difference between arterial and venous radioactivity concentrations at times \( t \) and \( t + 2 \) minutes respectively is displayed in panel A. Vertical bars denote 95% confidence intervals. Scatter plots of arterial vs. venous radioactivity concentration for arterial sampling times of 5, 10, 20, 40, and 60 minutes post-injection are displayed in panels B to F. On each plot the dotted line is the linear regression fit, the grey line indicates the line of unity.
Project 1: Development and validation of an input function independent of arterial sampling.

arterial and image-derived calibrated and delay-corrected radioactivity concentrations is displayed in Figure 3.1D and shows good overlap between the curve shapes.

Regional $V_T$ estimates obtained using arterial or image-derived input functions are presented in Table 3.1. There was a high correlation of an overall 110 (11 regions in 10 subjects) $V_T$ estimates between AIF- and IDIF-modelled data (mean $V_T$ AIF 9.7 ± 2.2 vs. IDIF+venous 9.5 ± 2.2, $r = 0.95$, $p<0.001$). The mean correlations remained high when splitting the data per region (mean $r$ 0.94 ± 0.02, Figure 3.3A) or per subject (mean $r$ 0.94 ± 0.08, Figure 3.3B). A Bland Altman plot comparing $V_T$ estimates obtained using AIF- and IDIF-modelled data is displayed in Figure 3.3C. There was a small between-method mean difference of $V_T$ estimates of -1.7%, with a 95% confidence interval of differences ranging from -15.9% to 12.4%. The regional

---

Table 3.1: Regional $V_T$ estimates obtained with an arterial and venous/image-derived input function.

<table>
<thead>
<tr>
<th>Region</th>
<th>AIF $V_T$ estimate (mean ± SD)</th>
<th>CoV (%)</th>
<th>IDIF – all venous samples $V_T$ estimate (mean ± SD)</th>
<th>CoV (%)</th>
<th>$r$ coefficient</th>
<th>$p$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>WM brain</td>
<td>9.2 ± 2.1</td>
<td>23.2</td>
<td>9.0 ± 2.0</td>
<td>21.8</td>
<td>0.94</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>WM cerebellum</td>
<td>9.3 ± 2.0</td>
<td>21.4</td>
<td>9.2 ± 1.9</td>
<td>20.9</td>
<td>0.94</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>GM cerebellum</td>
<td>8.8 ± 1.9</td>
<td>21.5</td>
<td>8.8 ± 1.9</td>
<td>22.1</td>
<td>0.96</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Brainstem</td>
<td>8.7 ± 1.7</td>
<td>19.1</td>
<td>8.6 ± 1.8</td>
<td>20.4</td>
<td>0.94</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Thalamus</td>
<td>11.9 ± 2.6</td>
<td>21.5</td>
<td>12.0 ± 2.6</td>
<td>21.7</td>
<td>0.95</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Putamen</td>
<td>11.3 ± 2.5</td>
<td>22.3</td>
<td>11.2 ± 2.5</td>
<td>22.5</td>
<td>0.97</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Precentral gyrus</td>
<td>9.2 ± 1.9</td>
<td>21.0</td>
<td>8.8 ± 1.8</td>
<td>20.8</td>
<td>0.89</td>
<td>0.001</td>
</tr>
<tr>
<td>Parahippocampal gyrus</td>
<td>8.6 ± 2.3</td>
<td>27.2</td>
<td>8.4 ± 2.2</td>
<td>26.5</td>
<td>0.93</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Occipital lobe</td>
<td>9.2 ± 1.7</td>
<td>18.2</td>
<td>9.0 ± 1.7</td>
<td>18.6</td>
<td>0.92</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Precuneus</td>
<td>10.0 ± 1.9</td>
<td>19.3</td>
<td>9.7 ± 2.0</td>
<td>20.6</td>
<td>0.92</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Insular cortex</td>
<td>10.1 ± 1.9</td>
<td>19.3</td>
<td>9.9 ± 2.0</td>
<td>20.4</td>
<td>0.94</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Overall</strong></td>
<td><strong>9.7 ± 2.2</strong></td>
<td><strong>21.3 ± 2.5</strong></td>
<td><strong>9.5 ± 2.2</strong></td>
<td><strong>21.5 ± 2.0</strong></td>
<td><strong>0.95</strong></td>
<td><strong>&lt;0.001</strong></td>
</tr>
</tbody>
</table>
Figure 3.3: Comparison of total volume of distribution estimates modelled with arterial or IDIF + venous input functions

Scatter plots of total volume of distribution (VT) estimates obtained with arterial and IDIF + venous input functions are displayed in panel A (split by region) and B (split by patient). The red dotted line is the linear regression fit, the grey line indicates the line of unity. Panel C displays a Bland-Altman plot comparing VT estimates modelled with arterial and IDIF + venous input functions. The thick black line is the mean bias of the VT estimates modelled using an IDIF + venous input function, the dotted black lines denote the 95% confidence intervals.
coefficients of variation between AIF- and IDIF-modelled data were comparable (mean CoV AIF 21.3% ± 2.5% vs. IDIF 21.5% ± 2.0%, t = -0.8, p=0.46).

### 3.3.2 Simplification to one venous sample

We also assessed the performance of the standard venous/IDIF approach described above with a simplified procedure using only a 62-minute venous sample. Using this procedure, there was a lower correlation between the areas under the curve of parent fraction measurements (single venous sample 32 ± 8 vs. arterial 31 ± 10 min, r = 0.96, p<0.001, Figure 3.4A), POB estimates (single venous sample 107 ± 9 vs. arterial 111 ± 9 min, r = 0.91, p<0.001, Figure 3.4B) and input functions (single venous sample 73 ± 13 vs. arterial 73 ± 16 kBq.min/mL, r = 0.81, p=0.005, Figure 3.4C).

Regional $V_T$ estimates obtained using the simplified image-derived input function are presented in Table 3.2. There was a lower correlation between arterial and IDIF + single venous sample modelled data (mean $V_T$: arterial 9.7 ± 2.2 vs. IDIF + single venous sample 10.3 ± 2.3, r = 0.76, p<0.001).
Project 1: Development and validation of an input function independent of arterial sampling.

venous 10.7 ± 2.7, r = 0.71, p<0.001). The mean correlations were also lower when splitting the data per region (mean r 0.64 ± 0.13, Figure 3.5A) or per subject (mean r 0.89 ± 0.08, Figure 3.5B). The Bland Altman plot detected a mean difference of VT estimates of 9.9%, with a 95% confidence interval of differences ranging from -23.9% to 43.7% (Figure 3.5C). The simplified IDIF + single venous sample modelled data had similar coefficients of variation of VT compared to arterial-based data (mean VT CoV: arterial 21.3% ± 2.5% vs. IDIF + single venous 21.5% ± 5.7%, t = 0.2, p=0.87).

<table>
<thead>
<tr>
<th></th>
<th>AIF (mean ± SD)</th>
<th>CoV (%)</th>
<th>IDIF – single venous sample (mean ± SD)</th>
<th>CoV (%)</th>
<th>r coefficient</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>WM brain</td>
<td>9.2 ± 2.1</td>
<td>23.2</td>
<td>9.3 ± 1.7</td>
<td>18.1</td>
<td>0.76</td>
<td>0.01</td>
</tr>
<tr>
<td>WM cerebellum</td>
<td>9.3 ± 2.0</td>
<td>21.4</td>
<td>9.6 ± 1.7</td>
<td>17.8</td>
<td>0.68</td>
<td>0.03</td>
</tr>
<tr>
<td>GM cerebellum</td>
<td>8.8 ± 1.9</td>
<td>21.5</td>
<td>9.4 ± 1.8</td>
<td>19.5</td>
<td>0.69</td>
<td>0.03</td>
</tr>
<tr>
<td>Brainstem</td>
<td>8.7 ± 1.7</td>
<td>19.1</td>
<td>9.0 ± 1.7</td>
<td>18.5</td>
<td>0.63</td>
<td>0.05</td>
</tr>
<tr>
<td>Thalamus</td>
<td>11.9 ± 2.6</td>
<td>21.5</td>
<td>13.8 ± 2.4</td>
<td>17.7</td>
<td>0.71</td>
<td>0.02</td>
</tr>
<tr>
<td>Putamen</td>
<td>11.3 ± 2.5</td>
<td>22.3</td>
<td>12.3 ± 2.5</td>
<td>20.5</td>
<td>0.72</td>
<td>0.02</td>
</tr>
<tr>
<td>Precentral gyrus</td>
<td>9.2 ± 1.9</td>
<td>21.0</td>
<td>10.8 ± 2.3</td>
<td>21.7</td>
<td>0.47</td>
<td>0.17</td>
</tr>
<tr>
<td>Para hippocampal gyrus</td>
<td>8.6 ± 2.3</td>
<td>27.2</td>
<td>9.3 ± 3.5</td>
<td>37.4</td>
<td>0.86</td>
<td>0.002</td>
</tr>
<tr>
<td>Occipital lobe</td>
<td>9.2 ± 1.7</td>
<td>18.2</td>
<td>10.7 ± 1.9</td>
<td>17.6</td>
<td>0.44</td>
<td>0.21</td>
</tr>
<tr>
<td>Precuneus</td>
<td>10.0 ± 1.9</td>
<td>19.3</td>
<td>12.0 ± 2.6</td>
<td>22.0</td>
<td>0.52</td>
<td>0.13</td>
</tr>
<tr>
<td>Insular cortex</td>
<td>10.1 ± 1.9</td>
<td>19.3</td>
<td>11.5 ± 2.4</td>
<td>20.9</td>
<td>0.52</td>
<td>0.12</td>
</tr>
<tr>
<td>Overall</td>
<td>9.7 ± 2.2</td>
<td>21.3 ± 2.5</td>
<td>10.7 ± 2.7</td>
<td>21.1 ± 5.7</td>
<td>0.71</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Table 3.2: Regional VT estimates obtained with an arterial input function or an input function using a single venous and image-derived measurements.
AIF, arterial input function; IDIF, image-derived input function; VT, volume of distribution; CoV, coefficient of variation; r coefficient, Pearson’s correlation coefficient; SD, standard deviation; WM, white matter; GM, grey matter.
Project 1: Development and validation of an input function independent of arterial sampling.

Figure 3.5: Comparison of total volume of distribution estimates modelled with arterial or IDIF + single venous sample input functions

Scatter plots of total volume of distribution (V_t) estimates obtained with arterial and IDIF + single venous sample input functions are displayed in panel A (split by region) and B (split by patient). The red dotted line is the linear regression fit, the grey line indicates the line of unity. Panel C displays a Bland-Altman plot comparing V_t estimates modelled with arterial and IDIF + single venous sample input functions. The thick black line is the mean bias of the V_t estimates modelled with an IDIF + single venous sample input function, the dotted black lines denote the 95% confidence intervals.
3.4 Discussion

We present a novel method for quantification of $^{[18}\text{F}]$GE-179 binding in brain that is independent of arterial sampling and might, thus, support wider use of this radiotracer for the assessment of the NMDA receptor. The input function estimated using a whole blood image-derived input function (IDIF) combined with corrections from venous data (i.e., parent fraction and plasma-to-whole blood ratio) was highly correlated with the gold standard input function determined from arterial sampling. The mean bias in $V_T$ estimates from the IDIF + venous approach was small (< 2%) and between-method differences were within a clinically reasonable range. Furthermore, the IDIF + venous approach did not increase the variability of the $V_T$ estimates. The performance of this procedure was better than that of previously proposed approaches aimed at obviating arterial sampling, namely the use of SUV or population-based input functions (McGinnity et al., 2018). However, simplification of the IDIF + venous method to use a single venous measurement rather than data from five venous samples provided lower correlations and larger differences in $V_T$ estimates.

Previous attempts to simplify $^{[18}\text{F}]$GE-179 quantification using SUV or a population-based input function did not yield convincing results and both methods failed to reproduce differences in grey-matter VT between patients with epilepsy and healthy volunteers ($p>0.05$) that were previously obtained using arterial modelled data on the same dataset (McGinnity et al., 2018). A reference region devoid of NMDA receptors is not available. Thus, an alternative quantification approach is the estimation of an image-derived input function (Sari et al., 2016). However, an IDIF estimates radioactivity in whole blood and cannot determine the parent fraction of the tracer in plasma or the plasma-to-whole blood ratio. Hence, a methodology completely devoid of blood sampling will not provide an accurate input function for kinetic modelling unless radiolabelled metabolites are absent and the plasma-to-whole blood ratio is close to 1. We chose a previously described approach of substituting arterial with...
venous samples and used venous data to determine the tracer parent fraction in plasma, the plasma-to-whole blood ratio and to scale the IDIF.

3.4.1 Comparison of venous and arterial samples

Previous studies found that venous samples taken with a longer delay after tracer injection provided better approximations of radioactivity in arterial blood (Takagi et al., 2004; Zanotti-Fregonara et al., 2012). This points to an increasing equilibrium between venous and arterial blood. Previous studies reported little or no differences between venous and arterial radioactivity concentration more than 40-60 minutes after ligand injection (Meyer et al., 2005; Takagi et al., 2004; Wakita et al., 2000; Zanotti-Fregonara et al., 2012). Similarly, we found decreasing differences and increasing correlations between arterial and venous radioactivity over time. The whole blood radioactivity concentration in a venous sample drawn 62 minutes after tracer injection was highly correlated with the 60-minute arterial sample ($r = 0.99$). There remained a small underestimation of arterial data (mean difference -4% ± 2%) that was corrected using a linear model. Thus, we are confident that late venous whole blood radioactivity concentration provided a good estimate for calibrating the IDIF.

Greuter and colleagues performed an extensive evaluation of venous and arterial data (Greuter et al., 2011), correlating arterial and venous data obtained at 3 to 7 timepoints in studies with 5 different tracers with 254 paired samples overall. They observed differences in correlation coefficients between tracers and measured parameters (radioactivity concentration, parent fraction, POB ratio) concluding that arterial samples cannot be readily substituted with venous measurements but will require validation for each tracer and measured parameter.

We provide evidence that parent fraction, POB ratio, and late radioactivity concentration can be reliably approximated using venous samples in $[^{18}F]$GE-179 PET. The correlations for parent fraction and late radioactivity concentration were high ($r =$
Project 1: Development and validation of an input function independent of arterial sampling.

0.99. The correlation for POB ratio was lower \(r = 0.93\), but still supported the feasibility of venous measurements.

3.4.2 Combination of IDIF with venous data versus an arterial input function

The IDIF determined from the carotid arteries provided a similar shape to the input function determined from data from the radial artery. These data provide support that a previously proposed procedure correctly quantifies the radioactivity concentration in the carotid arteries (Sari et al., 2016). Residual differences between the arterial sampling and IDIF-based input functions can be explained by a higher noise and lower sampling rate in the imaging data for the first 6.5 minutes over which arterial samples were continuously sampled. The slight overestimation of radioactivity between 100 and 300s after the injection could be due to spill-in effects from tracer uptake in brain or other tissue.

The combination of IDIF and venous data provided good estimates of the input function. This translated into high overall, regional, and subject-wise correlations of \(V_T\) estimates, with only minimal mean bias \(-1.7\%\). These correlations were higher than those observed using SUV images or a population-based input function (McGinnity et al., 2018). The range of relative \(V_T\) differences was not negligible but was well within a clinically reasonable 20\% range. This is important and means that clinically relevant effect sizes of 20\% or more are detectable with this technique. Between-method limits of agreement below 20\% are less likely to be clinically relevant. In a population of patients with epilepsy not taking antidepressants scanned with \([^{18}F]GE-179\) PET we previously found a median whole brain \(V_T\) of 8.0 compared to a median \(V_T\) of 6.2 in healthy volunteers (McGinnity et al., 2015). Thus, such a 29\% between-group difference is likely to be detected by our method, providing support for its practical
applicability. There were no relevant outliers and there was no difference in overall data variability, providing further support for the robustness of the proposed method.

3.4.3 Alternative approaches

As expected, reducing the number of venous samples to only one late sample (62-minute) provided less accurate estimates. This approach requires the use of population based curves of parent fraction and POB ratio that were then scaled with the single sample. These estimates were less accurate than those obtained with a full set of venous samples. They translated into inaccuracies in input function and $V_T$ estimates. There was relevant bias in $V_T$ estimates (mean difference 9.9%) and the 95% confidence intervals of $V_T$ differences exceeded the 20% range, making this approach not reliably applicable for clinically use.

Another potential approach for estimating an input function from imaging data is simultaneous estimation (SIME), that estimates the input function by fitting multiple tissue activity curves from different brain regions (Sari et al., 2018). However, SIME involves the estimation of a large number of parameters, might lack precision and may need scaling with one or several discrete blood samples (Feng et al., 1997). The application of SIME to $[^{18}F]$GE-179 PET will be the focus of future studies.

3.4.4 Limitations

This study has limitations. We studied a small number of subjects acquired at a single centre due to the limited use of this radiotracer so far. We did not include people with neuropsychiatric disorders but the large variability of tracer binding ($V_T$) in the included healthy subjects makes us confident that the IDIF + venous approach may be generalisable to people with brain disorders taking medication. Our procedure requires venous sampling that is invasive and labour intensive. Puncture of the cubital...
vein is, nevertheless, less invasive and safer than placement of a cannula in the radial artery, and does not require such highly trained personnel. Estimation of the IDIF requires manual editing of the segmentation of the carotid arteries but this process could be automated in future (Jodas et al., 2016).

3.4.5 Conclusions

We validated a reliable method to quantify $^{18}$FGE-179 binding that does not require arterial sampling. In addition, we present evidence for reliable estimation of parent fraction, POB ratio and late whole blood radioactivity concentration for this tracer using venous sampling. These approaches might widen the use of this tracer and the method could also be applied to other radiotracers, but this will require separate validation. A simplification of the method to use a single venous sample provided less accurate estimates and should not be used, unless full venous sampling is not available or not feasible.
4 Project 2: NMDA receptor activation in aging.

4.1 Introduction

A global increase in longevity has led to an unprecedented ageing of the world’s population. In 2018, for the first time in human history, persons aged above 65 years outnumbered children below five years of age (United Nations Department of Economic and Social Population Affairs, 2019). The proportion of above 80-year-olds will double by 2045 and quadruple by 2095 (United Nations Department of Economic and Social Population Affairs, 2019). Ageing is associated with a decline in cognitive abilities, particularly affecting processing speed, declarative, and working memory (Park et al., 2002). The risk of neurodegenerative disorders, e.g. Alzheimer’s or Parkinson’s disease, increases with age.

N-methyl-D-aspartate (NMDA) receptors are ionotropic receptors that bind glutamate, the main excitatory neurotransmitter of the nervous system. NMDA receptors are heterotetramers assembling two GluN1 subunits with two variable units, typically GluN2A or GluN2B and less frequently GluN3. NMDA receptors are key mediators of long-term synaptic potentiation (LTP) and depression (LTD) that are believed to represent the cellular correlates of declarative learning and memory, thus gaining
considerable interest (Cooke and Bliss, 2006b; Nakazawa et al., 2004). They also subserve persistent neuronal firing during working memory retention (Lisman et al., 1998; M. Wang, Yang, C.-J. Wang, Gamo, Jin, Mazer, Morrison, X.-J. Wang and Arnsten, 2013b).

Activation of NMDA receptors located extrasynaptically can be neurotoxic and has been implicated in Alzheimer’s disease and excitotoxicity (Hardingham and Bading, 2010; Y. Zhang et al., 2016). Accumulation of amyloid-beta in Alzheimer’s disease redistributes NMDA receptors from synaptic towards extrasynaptic sites (Snyder et al., 2005). In turn, extrasynaptic NMDA receptor activation raises amyloid-beta production (Hoey et al., 2009), overexpresses tau proteins (Sun et al., 2016), and might inhibit long-term potentiation underlying memory consolidation (Li et al., 2011). Suppression of overactivated, primarily extrasynaptic, receptors with the uncompetitive antagonist memantine is a routine treatment for Alzheimer’s disease (Lipton, 2006).

NMDA receptors are more vulnerable to aging than other glutamate ion-channels (Magnusson and Cotman, 1993; Magnusson et al., 2010). Lower overall expression of NMDA receptors was observed in older animals, particularly in the frontal and parieto-occipital cortex, striatum, and hippocampus (Castorina et al., 1994; Magnusson, 2000; Magnusson and Cotman, 1993; Magnusson et al., 2007; Ontl et al., 2004). Despite the loss of overall receptor numbers, several, but not all, studies described an age-related increase in sensitivity and responsiveness of the remaining receptors (Billard et al., 1997; Jasek and Griffith, 1998; Kuehl-Kovarik et al., 2000). This might be explained by a selective decline of GluN2B subunits and shift towards a larger proportion of GluN2A-containing receptors (Brim et al., 2013; Magnusson, 2000; Magnusson et al., 2002; 2006; Zamzow et al., 2013) that have a higher opening probability (N. Chen et al., 1999; Erreger et al., 2005; Gray et al., 2011). In addition, aging caused a shift of receptors from the synapse to extrasynaptic sites (Potier et al., 2010). A decreased expression of glutamate transporters with deficient glutamate re-uptake was observed in aged rats, leading to facilitated activation of extrasynaptic NMDA receptors (Potier
et al., 2010). A relationship between NMDA receptor abnormalities during senescence and cognitive decline has been proposed (Kumar, 2015).

Little knowledge exists on the effects of aging on NMDA receptors in humans. Several (Kornhuber et al., 1988; Piggott et al., 1992), but not all (Law et al., 2003), studies found a decrease in NMDA receptor numbers in post mortem brains of older individuals, potentially linked to an overall loss of neurons. Functional aspects are, however, difficult to evaluate in post mortem tissue and can only be reliably assessed in vivo.

Here, we measured the in vivo opening probability of NMDA receptors across different age-ranges in three independent cohorts of healthy adults. We used positron emission tomography (PET) with $[^{18}F]$GE-179, a recently developed radiotracer that selectively binds inside the open, i.e. activated, NMDA receptor complex (McGinnity et al., 2014).

### 4.2 Methods

Recruitment, data acquisition and imaging preprocessing were performed as described above (see Common Methods in chapter 2). In brief, we recruited 29 healthy volunteers scanned using $[^{18}F]$GE-179 at three sites (UCL, Cambridge, Hammersmith). No volunteers took regular medication or had a history of neuropsychiatric conditions.

We extracted $V_T$ estimates in grey matter, white matter and non-brain tissue (combination of soft tissue and skull). We calculated the association of regional $V_T$ estimates with age using the general linear model, adjusting for the effects of sex and scanner equipment. P-values below 0.05 adjusted for multiple comparisons using Bonferroni correction were considered significant. Scatter plots of age to $V_T$ estimates are displayed for values adjusted for the effects of sex and scanner equipment.
To address the subregional distribution of findings in grey matter, we also performed a voxel-wise analysis of parametric $V_T$ images. We calculated the association of voxelwise $V_T$ estimates with age using a full factorial general linear model, adjusting for the effects of sex and scanner equipment. We report p-values at a threshold of $p<0.05$ on a cluster-level family-wise error corrected for multiple comparisons.

To address the contribution of age-related neurodegeneration, i.e. reductions in grey matter volume, to our findings, we performed voxel-based morphometry (VBM) using segmented and modulated parametric grey matter volume images obtained using the CAT12 toolbox on 3T T1 MRI scans. We determined the association of global $[^{18}F]$GE-179 $V_T$ uptake with grey matter volume reduction and display the overlap of $V_T$ and VBM voxelwise findings.

Lastly, we performed sensitivity analyses of age-related $[^{18}F]$GE-179 $V_T$ changes in grey matter in each cohort separately. In cohorts without significant voxelwise results, we also reported exploratory findings at an uncorrected threshold of $p<0.05$ with a minimum cluster size of 100 contiguous voxels.

4.3 Results

4.3.1 Overall results

We included 29 healthy volunteers with a mean age $41 \pm 13$ years (range 25 to 63 years, Table 2.1). There were no between-cohort differences in distributions of age ($\text{Hammersmith}$ mean $42 \pm 16$ years, $\text{Cambridge}$ $40 \pm 10$, $\text{UCL}$ $41 \pm 13$, $p = 0.94$) or sex ($\text{Hammersmith}$ 3/9 female, $\text{Cambridge}$ 1/10 female, $\text{UCL}$ 4/10 female, $p = 0.32$).

We found a significant association of $V_T$ in grey matter with age ($F = 7.2$, $p = 0.04$, Figure 4.1A), with an estimated $V_T$ increase of 0.6 per 10 years ($95\% \text{ CI} 0.1$ to $1.1$; corresponding to a 7% increase compared to mean $V_T$, $95\% \text{ CI} 1-12\%$). The linear
Project 2: NMDA receptor activation in aging.

A  Global GE-179 uptake in grey matter, association with age

B  Subregional GE-179 uptake, association with age

Figure 4.1: Association of GE-179 uptake in grey matter with age in healthy volunteers

The association of grey matter GE-179 $V_T$ with age in healthy volunteers (n=29) is displayed in panel A. Grey matter $V_T$ and age are displayed as mean centred values that were adjusted for the effects sex and scanner equipment. The regression line fit and its 95% confidence interval for the overall cohort is displayed on the left, the fits for each individual cohort are displayed on the right. The subregional distribution of grey matter $V_T$ associated with age is shown in panel B (p<0.05 FWE corrected).
regression line fits of age over grey matter $V_T$ were highly similar between all cohorts (Figure 4.1A right). On a subregional level (Figure 4.1B), we observed significant age-related increases in $V_T$ in bilateral parieto-occipital junctions and posterior temporal lobes (right, $T = 6.0, 4167$ voxels, $p < 0.001$; left, $T = 5.1, 5295$ voxels, $p < 0.001$), bilateral striata and hippocampal heads (right, $T = 5.9, 5427$ voxels, $p < 0.001$; left, $T = 6.0, 5566$ voxels, $p < 0.001$), and bilateral superior and middle frontal gyri (right, $T = 5.8, 4854$ voxels, $p < 0.001$; left, $T = 5.7, 5267$ voxels, $p < 0.001$).

There was no association of grey matter $V_T$ with sex ($F = 1.1, p = 0.93$) or scanner equipment ($F = 1.2, p = 0.95$). There was no association of age with $V_T$ in white matter ($F = 1.3, p = 0.78$, $V_T$ increase by 0.2 per 10 years, 95% CI -0.2 to 0.7, Figure 4.2A) or non-brain tissue ($F = 1.7, p = 0.63$, $V_T$ decrease by 0.1 per 10 years, 95% CI -0.3 to 0.1, Figure 4.2B).

There was a negative association of age with grey matter volume ($F = 8.4, p = 0.008$, volume decrease by 19 ml per 10 years, 95% CI 5 to 32 ml, Figure 4.3A). On a voxel-wise level (Figure 4.3B), higher age correlated with lower grey matter volume in bilateral medial superior frontal gyri ($T = 8.7, 7880$ voxels, $p < 0.001$), bilateral fusiform and lingual gyri (right, $F = 6.7, 1685$ voxels, $p = 0.001$; left, $F = 7.1, 2752$ voxels, $p < 0.001$), bilateral mesial temporal lobes and insular cortices (right, $F = 5.8, 5295$ voxels, $p < 0.001$; left, $F = 6.9, 8007$ voxels, $p < 0.001$), right parietooccipital junction ($F = 6.3, 781$ voxels, $p = 0.03$), bilateral thalami ($F = 5.9, 1062$ voxels, $p = 0.007$), and bilateral posterior cingulate gyri ($F = 4.8, 652$ voxels, $p = 0.05$). Figure 4.3B shows that the majority of areas with age-related increases in $[^{18}F]GE-179$ uptake were different from areas that showed significantly reduced grey matter volume with age. Grey matter $V_T$ was not associated with grey matter volume ($F = 0.2, p = 0.69$).
A White matter GE-179 uptake, association with age

Figure 4.2: Association of GE-179 uptake in white matter and nonbrain tissue with age in healthy volunteers

Association of GE-179 $V_T$ in white matter (panel A) and nonbrain tissue (panel B) with age in healthy volunteers ($n=29$). Grey matter $V_T$ and age are displayed as mean centred values that were adjusted for the effects sex and scanner equipment. The regression line fit and its 95% confidence interval for the overall cohort is displayed on the left, the fits for each individual cohort are displayed on the right.
4.3.2 Sensitivity analyses

We performed sensitivity analyses in each cohort separately. The lowest coefficient of variation was observed in the Hammersmith cohort (13.2%) compared to the Cambridge (16.4%) or UCL (25.3%) cohorts. There was a significant association of $V_T$ in grey matter with age in the Hammersmith cohort ($F = 29.6, p = 0.002, V_T$ increase by 0.6 per 10 years, 95% CI 0.3 to 0.9, Figure 4.4A). The slope of the linear regression fit was similar but the association was non-significant in the Cambridge ($F = 1.7, p = 0.24, V_T$ increase by 0.6 per 10 years, 95% CI -0.5 to 1.7, Figure 4.4B) and UCL ($F = 1.2, p = 0.30, V_T$ increase by 0.8 per 10 years, 95% CI -0.9 to 2.4, Figure 4.4C) cohorts.

On a voxelwise level, there was a significant association of age with increased $V_T$ in bilateral superior frontal gyri (right, $T = 5.5, 2270$ voxels, $p = 0.005$; left, $T = 5.3, 1579$ voxels, $p = 0.02$) left striatum, caudate nucleus, and hippocampus ($T = 5.1, 2261$ voxels, $p = 0.005$), and left posterior temporal lobe and temporo-occipital junction ($T = 4.8, 1908$ voxels, $p = 0.01$) in the Hammersmith cohort (Figure 4.4A). There were no significant clusters in the Cambridge or UCL cohorts. An exploratory analysis found non-significant ($p<0.05$ uncorrected) clusters in bilateral parieto-temporo-occipital junctions, inferior and superior frontal lobes, striata and entorhinal cortices in the Cambridge cohort (Figure 4.4B) and in bilateral superior and medial frontal gyri, striata, and occipital lobes in the UCL cohort (Figure 4.4C).

4.3.3 Epilepsy cohort

Similarly, age-related increases in $[^{18}F]GE-179$ $V_T$ were observed in a group of 26 people with focal refractory epilepsy ($F = 9.9, p = 0.006, V_T$ increase by 1.4 per 10 years, 95% CI 0.5 to 2.4; corresponding to a 14% increase per 10 years compared to mean $V_T$, 95% CI 5-24%) after correction for sex, duration of epilepsy, seizure frequency, number of AEDs and intake of Lamotrigine, Lacosamide, and Perampanel.
Figure 4.3: Association of grey matter volume with age in healthy volunteers

The association of grey matter volume with age in healthy volunteers (n=29) is displayed in panel A. Grey matter volume and age are displayed as mean centred values that were adjusted for the effects sex and scanner equipment. The regression line fit and its 95% confidence interval for the overall cohort is displayed on the left, the fits for each individual cohort are displayed on the right. The subregional distribution of grey matter volume (blue colours) and GE-179 Vr (yellow/red colours) associated with age is shown in panel B (p<0.05 FWE corrected).
The effects were most pronounced in the striatum and thalamus contralateral to the epileptic focus. For details please refer to chapter 5.3.2 and Figure 5.2A.

4.4 Discussion

We measured aging-related changes to the in vivo opening probability of NMDA receptors in humans by pooling data acquired with the novel $[^{18}\text{F}]$GE-179 PET radioligand. We found increased NMDA receptor opening probability in grey matter of older healthy adults and older people with focal epilepsy. These changes were specific to grey matter and were not observed in white matter or non-brain tissue. They were spatially and statistically not related to grey matter volume loss, a surrogate marker of neurodegeneration. The effects were most pronounced in bilateral superior frontal lobes, striata, temporo-parieto-occipital junctions, and, to a lesser extent, medial temporal lobes.

4.4.1 Age-related increase of NMDA receptor opening probability

There are several potential explanations for an age-related increase of NMDA receptor opening probability in humans. Firstly, it is unlikely that it reflects an increase in overall NMDA receptor availability. Most animal studies described a decrease of NMDA receptor numbers with higher age (Castorina et al., 1994; Magnusson, 2000; Magnusson and Cotman, 1993; Magnusson et al., 2007; Ontl et al., 2004). Similarly, several (Kornhuber et al., 1988; Piggott et al., 1992), but not all (Law et al., 2003), post mortem studies in humans found reduced overall NMDA receptor binding. It is unclear to what extent the reduction of NMDA receptor numbers relates to loss of neurons. The effects were, however, more pronounced for NMDA receptors compared to other glutamate ion channels (Magnusson and Cotman, 1993; Magnusson et al., 2010), suggesting a higher vulnerability of NMDA receptors to aging. Thus, the higher $[^{18}\text{F}]$GE-179 binding observed in the current study likely relates
to a functional modification of NMDA channel opening probability, despite a probable decrease in receptor numbers. This is corroborated by several studies that found an age-related increase in sensitivity and responsiveness of the remaining receptors (Billard et al., 1997; Jasek and Griffith, 1998; Kuehl-Kovarik et al., 2000). It has been suggested that these adaptations could reflect functional compensation to maintain cognitive function during aging despite neuronal or ion-channel loss (Billard et al., 1997; Serra et al., 1994).

Secondly, an aging-related shift in NMDA receptor subunit composition and synaptic localisation could contribute to an increased opening probability. GluN2B subunits are more susceptible to aging compared to GluN2A subunits, leading to an age-related increase in the GluN2A/GluN2B ratio (Brim et al., 2013; Magnusson, 2000; Magnusson et al., 2002; 2006; Zamzow et al., 2013). GluN2A containing NMDA receptors have a higher opening probability and peak open probability in response to glutamate (N. Chen et al., 1999; Erreger et al., 2005; Gray et al., 2011). Additionally, aging also causes a facilitated activation of extrasynaptic compared to synaptic NMDA receptor sites (Potier et al., 2010). Extrasynaptic NMDA receptors are also more likely to be activated in neurodegenerative disorders, particularly by amyloid-beta in Alzheimer’s disease (Sepulcre et al., 2016; Talantova et al., 2013). In turn, overactivated extrasynaptic NMDA receptors are more likely to induce cell death (Hardingham and Bading, 2010) and accumulation of neurofibrillary tau tangles (Chohan and Iqbal, 2006).

Thirdly, alterations of glutamate homeostasis during aging could contribute to an increased NMDA receptor opening probability. Evidence in rodents points to a decreased expression of glutamate transporters and consequently a reduced glutamate reuptake in aged animals (Brothers et al., 2013; Farrand et al., 2015; Nickell et al., 2007; Potier et al., 2010; Vatassery et al., 1998). This can lead to glutamate spillover to the extrasynaptic space and to activation of extrasynaptic NMDA receptors that might cause excitotoxicity (Farrand et al., 2015; Potier et al., 2010). Treating aged
Figure 4.4: Association of GE-179 uptake in grey matter with age in individual cohorts

The association of grey matter GE-179 V̂T with age in healthy volunteers is displayed in the Hammersmith (n=9, panel A), Cambridge (n=10, panel B), and UCL (n=10, panel C) cohorts. The subregional distribution of grey matter V̂T associated with age is shown on the left (p<0.05 FWE corrected for Hammersmith, and p<0.05 uncorrected for Cambridge and UCL). Scatter plots with the regression line and 95% confidence intervals are shown on the right. Grey matter V̂T and age are displayed as mean centred values that were adjusted for the effects sex and scanner equipment.
rodents with riluzole, a glutamate modulator, increased glutamatergic reuptake and prevented age-related cognitive deficits (Brothers et al., 2013; Pereira et al., 2014). The findings observed in healthy aging were replicated in people with focal refractory epilepsy. Interestingly, the aging-related increase of tracer binding in people with epilepsy was more than double that of normal aging (V increase 1.4 in epilepsy vs. 0.6 in healthy volunteers per 10 years). We speculate that epilepsy and aging may have additive effects on NMDA receptor alterations. This could be due to additional release of glutamate during seizures and possible excitotoxicity (During and Spencer, 1993), oxidative stress, metabolic disturbances, and inflammation in epilepsy (Sutula et al., 2003; Vezzani et al., 2011). Similarly, we previously observed that the rate of ongoing neurodegeneration in epilepsy, measured with cortical thinning, was more than double that of normal aging (Galovic, van Dooren, et al., 2019). Because the rate of cortical thinning was particularly accelerated in people with epilepsy aged above 55 years, we hypothesized that the brains of people with epilepsy are more vulnerable to aging-related disturbances (Galovic, van Dooren, et al., 2019).

4.4.2 Spatial distribution of age-related changes to NMDA receptors

We showed that aging-related alterations of NMDA receptors were not uniform throughout the human brain but preferentially affected specific cortical and subcortical areas. Most of these regions have been suggested to play a role in cognitive processes. The superior anterior frontal cortex (D’Esposito et al., 1995), the striatum (Provost et al., 2015), and the temporo-parieto-occipital junction (Salmon et al., 1996) play a role in working memory (Owen et al., 2005). The medial temporal lobe subserves episodic memory (Nyberg et al., 1996). In addition, several, but not all, of the areas with increased NMDA receptor opening probability overlap with regions of the default mode network (DMN), a brain system preferentially active when individuals
are left to think to themselves. Aging leads to increases in DMN activity that reflect a deficit in cognitive control associated with worse working memory performance (Sambataro et al., 2010). Lastly, the spatial distribution of NMDA receptor alteration in our study resembles the cortical distribution of tau and amyloid-beta deposits in cognitively normal elderly individuals (Sepulcre et al., 2016) and in Alzheimer’s disease (Jack et al., 2013; Okamura et al., 2014). Early Alzheimer’s disease and mild cognitive impairment are associated with network hyperexcitability (Fontana et al., 2017; Haberman et al., 2017; Palop et al., 2007; Yassa et al., 2010) that can also be observed during normal aging (Senatorov et al., 2019). Taken together, the areas of greater NMDA receptor disturbances might be part of cognitive brain system that is vulnerable to aging and neurodegenerative diseases. Such functional changes may precede grey matter atrophy in these areas.

The spatial distribution of age-related effects on NMDA receptors in people with epilepsy was restricted to subcortical structures contralateral to the seizure focus. This is a more restricted pattern compared to healthy volunteers, probably because of an inverse effect of epilepsy duration on cortical structures (longer duration of epilepsy leads to lower NMDA receptor opening probability).

There is also a large overlap between the areas with age-related NMDA receptor alterations in humans and in rodents. Similarly to the current study in humans, the frontal cortex (Castorina et al., 1994; Magnusson, 2000; Magnusson and Cotman, 1993; Ontl et al., 2004), striatum (Castorina et al., 1994; Magnusson and Cotman, 1993), parieto-occipital cortex (Magnusson, 2000; Magnusson and Cotman, 1993), and hippocampus (Castorina et al., 1994; Magnusson, 2000) previously showed NMDA receptor abnormalities in older animals. This supports the notion that age-related abnormalities follow a specific spatial pattern and that some brain areas are more vulnerable than others.
4.4.3 Methodical considerations

Several methodical considerations should be noted. Firstly, \( ^{18}\text{F}\)GE-179 is a novel radioligand that showed specific and selective binding \textit{in vitro} and \textit{in vivo} to the phencyclidine site inside the open NMDA channel (McGinnity et al., 2014; Vibholm, Landau, Møller, et al., 2020). Demonstrating specific binding \textit{in vivo} can be challenging for use dependent tracers (McGinnity et al., 2019). Recently, administration of the NMDA receptor antagonist S-ketamine successfully blocked \( ^{18}\text{F}\)GE-179 binding in a use dependent manner \textit{in vivo} during pulsed electrical stimulation (Vibholm, Landau, Møller, et al., 2020), confirming the specificity for the phencyclidine site. Likewise, GE-179’s antecedent, CNS 5161, was successfully blocked by phencyclidine site antagonists \textit{in vivo} (Biegon et al., 2007). It should be noted that the phencyclidine site is expressed on all NMDA receptors. Thus, \( ^{18}\text{F}\)GE-179 imaging cannot distinguish between the subunit composition or synaptic/extrasynaptic localisation of receptors.

Secondly, it has been suggested that NMDA receptor abnormalities might be the consequence of neuronal loss (Billard et al., 1997; Serra et al., 1994). In our study, the spatial distribution of increased NMDA receptor opening probability in the brain differed from the pattern of progressive structural neurodegeneration measured with grey matter volume, suggesting that these are distinct processes. In addition, to reduce the influence of grey matter atrophy on our results we corrected the PET findings for partial volume effects, but the observed effects were comparable when using non-corrected data.

Thirdly, aging might result in differences in radioligand metabolism or cerebral blood perfusion. It is unlikely that this would influence our findings because \( V_T \) estimates are corrected for tracer metabolism and cerebral perfusion.

Fourthly, although the slope of regression fits and the subregional distribution of findings was similar between cohorts, the results were not significant in the Cambridge
and UCL cohorts. One explanation is the small sample size of cohorts. In addition, both the Cambridge and UCL cohorts showed higher PET data variability, owing to a lower PET scanner resolution and the use of image-derived input function estimates in the UCL cohort. This would reduce the signal-to-noise ratio and make it less likely to observe significant effects despite comparable trends. Thus, pooling of multicentre data was necessary to increase the statistical power of our study. Scanning equipment did not significantly influence the results and we adjusted all statistical models for site allocation to further minimise any residual between-cohort effects.

Lastly, we were restricted to studying a limited age range of 25 to 65 years for healthy volunteers and 18 to 65 years for people with epilepsy due to ethical considerations. Younger participants are more likely to be adversely affected by radiation and older subjects are less likely to tolerate a 70 to 90 minute scan and have a higher risk of concomitant or subclinical neurodegenerative disorders. We included few women of childbearing age due to the potential effects of radiation.

4.4.4 Conclusions

We observed in vivo increased NMDA receptor opening probability in older healthy adults and people with epilepsy. These functional changes were not uniform throughout the brain but particularly affected areas that may play a role in cognitive processes and preceded grey matter atrophy of these regions. The exact pathophysiology is not clear with several potential explanations for this finding. Future studies should determine the age-related expression of NMDA receptor subunits and glutamate transporters. They should examine whether increased NMDA receptor activation relates to cognitive decline or neurodegenerative disorders and whether it might be a marker of the risk to develop Alzheimer’s dementia. Lastly, our findings provide support for exploratory human trials of memantine and riluzole to reduce NMDA receptor opening probability and cognitive decline in elderly individuals.
5 Project 3: NMDA receptor activation in focal epilepsy.

5.1 Introduction

Epilepsy, a disease characteristically manifesting with neuronal hyperexcitability, has been linked to dysfunction of NMDA ion-channels that bind glutamate, the main excitatory neurotransmitter in the central nervous system. Alterations of NMDA receptors played a role in animal models of epileptogenesis, the process underlying the development of epilepsy (Ghasemi and Schachter, 2011). Blocking of NMDA receptors prevented epileptogenesis and was neuroprotective (Brandt et al., 2003; Raza et al., 2004; Stasheff, Anderson, Clark and Wilson, 1989b).

In humans, the available evidence on the role of over- or underactivated NMDA receptors in epilepsy is conflicting. Firstly, immunohistochemistry studies of postsurgical temporal lobe specimen in people with refractory epilepsy found decreased (Bayer et al., 1995; Blumcke et al., 1996; Geddes et al., 1990; Hosford et al., 1991; Spreafico et al., 1998) or increased (Brines et al., 1997; Geddes et al., 1990; Mathern et al., 1997; McDonald et al., 1991) NMDA receptor density. Binding inside the open, i.e. activated, NMDA receptor channel was described (Hosford et al., 1991; McDonald et al., 1991). A higher proportion of GluN2B subunits has also been observed (Mathern et al., 1998).
Secondly, mutations in GRIN genes coding GluN1, GluN2A, and GluN2B subunits cause a neurodevelopmental disorder with seizures. More mutations were functionally characterised as loss- than gain-of-function, but both alterations led to seizures (Xu and Luo, 2018). In mutations affecting the GluN2A subunit, those leading to a receptor gain-of-function were associated with a more severe phenotype (Strehlow et al., 2019).

Thirdly, NMDA receptor antagonists have been used to treat seizures (Felbamate Study Group in Lennox-Gastaut Syndrome, 1993; Pellock, 1999) and status epilepticus (Borris et al., 2000; Prüss and Holtkamp, 2008) but proconvulsant effects have also been reported (Alldredge et al., 1989; Claudet and Maréchal, 2009; Modica et al., 1990; Peltz et al., 2005; Sveinbjörsdóttir et al., 1993).

Lastly, only two studies thus far analysed NMDA receptors in people with epilepsy in vivo using PET, but they produced contradictory results. [$^{11}$C]ketamine binding was reduced in the ipsilateral temporal lobe in eight people with mesial temporal lobe epilepsy (MTLE), which could either point to a reduced NMDA receptor density, reduced tissue perfusion or focal atrophy (Kumlien et al., 1999). We performed a pilot study with [$^{18}$F]GE-179, measuring the opening probability of NMDA receptors in eleven people with focal epilepsy and frequent interictal epileptic discharges (McGinnity et al., 2015). We observed globally increased binding in eight patients not taking antidepressants and decreased binding in three patients on antidepressants. Focal NMDA receptor binding alterations were detected in a subset of patients but were difficult to interpret because of the undetermined localisation of epilepsy in these cases.

Here, we measured in vivo NMDA receptor activation using [$^{18}$F]GE-179 PET in people with well-localised refractory focal epilepsy undergoing presurgical evaluation and matched healthy volunteers. We associated NMDA receptor binding with clinical characteristics and epilepsy localisation, and compared postsurgical with presurgical uptake.
Project 3: NMDA receptor activation in focal epilepsy.

5.2 Methods

We followed the methods as described in detail in chapter 2. We included 26 people (mean age 38 ± 13 years, 11 [42%] female) with unilateral focal refractory epilepsy arising from the temporal (n=17) and frontal lobes (n=5) or other localisation (n=4) undergoing presurgical evaluation at NHNN and scanned at the UCL site. Seven

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean ± SD or N (%)</th>
<th>F</th>
<th>Beta (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years, unadjusted)</td>
<td>38 ± 13</td>
<td>0.1</td>
<td>0.02 (-0.09, 0.13)</td>
<td>0.71</td>
</tr>
<tr>
<td>Female Sex (unadjusted)</td>
<td>15 (58%)</td>
<td>0.4</td>
<td>-0.8 (-3.6, 1.9)</td>
<td>0.53</td>
</tr>
<tr>
<td>Non-European Ethnicity</td>
<td>5 (20%)</td>
<td>0.03</td>
<td>-0.3 (-4.0, 3.4)</td>
<td>0.87</td>
</tr>
<tr>
<td>Smoking</td>
<td>3 (12%)</td>
<td>2.7</td>
<td>-3.3 (-7.6, 0.9)</td>
<td>0.12</td>
</tr>
<tr>
<td>Beck’s Depression Inventory score</td>
<td>13 ± 9</td>
<td>0.003</td>
<td>0.004 (-0.15, 0.16)</td>
<td>0.95</td>
</tr>
<tr>
<td>Duration of epilepsy (years)</td>
<td>19 ± 12</td>
<td>4.9</td>
<td>-0.13 (-0.26, -0.01)</td>
<td>0.04</td>
</tr>
<tr>
<td>Focal lesion on MRI</td>
<td>17 (65%)</td>
<td>1.1</td>
<td>-1.5 (-4.4, 1.4)</td>
<td>0.31</td>
</tr>
<tr>
<td>Epilepsy localisation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mesial temporal</td>
<td>7 (27%)</td>
<td>0.1</td>
<td>-0.6 (-3.8, 2.7)</td>
<td>0.72</td>
</tr>
<tr>
<td>Temporal</td>
<td>18 (69%)</td>
<td>1.2</td>
<td>-1.7 (-4.9, 1.5)</td>
<td>0.28</td>
</tr>
<tr>
<td>Frontal</td>
<td>5 (19%)</td>
<td>0.7</td>
<td>1.5 (-2.4, 5.5)</td>
<td>0.43</td>
</tr>
<tr>
<td>Other</td>
<td>3 (12%)</td>
<td>0.3</td>
<td>1.2 (-3.2, 5.6)</td>
<td>0.57</td>
</tr>
<tr>
<td>Seizure frequency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall seizure frequency (per month)</td>
<td>34 ± 40</td>
<td>0.7</td>
<td>0.02 (-0.02, 0.05)</td>
<td>0.40</td>
</tr>
<tr>
<td>SPS frequency (per month)</td>
<td>14 ± 27</td>
<td>1.5</td>
<td>0.03 (-0.02, 0.09)</td>
<td>0.24</td>
</tr>
<tr>
<td>CPS frequency (per month)</td>
<td>19 ± 31</td>
<td>0.03</td>
<td>0.004 (-0.04, 0.05)</td>
<td>0.87</td>
</tr>
<tr>
<td>SGS frequency (per month)</td>
<td>1 ± 3</td>
<td>0.9</td>
<td>-0.3 (-0.8, 0.3)</td>
<td>0.36</td>
</tr>
<tr>
<td>Last seizure (days before scan)</td>
<td>25 ± 107</td>
<td>0.1</td>
<td>-0.002 (-0.02, 0.01)</td>
<td>0.73</td>
</tr>
<tr>
<td>Antiepileptic drugs at scan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of antiepileptic drugs</td>
<td>2 ± 1</td>
<td>4.3</td>
<td>1.3 (0.003, 2.5)</td>
<td>0.05</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>10 (39%)</td>
<td>1.5</td>
<td>1.7 (-1.2, 4.5)</td>
<td>0.24</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>10 (39%)</td>
<td>2.1</td>
<td>2.1 (-0.9, 5.0)</td>
<td>0.16</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>7 (27%)</td>
<td>5.7</td>
<td>-3.3 (-6.2, -0.4)</td>
<td>0.03</td>
</tr>
<tr>
<td>Zonisamide</td>
<td>7 (27%)</td>
<td>0.1</td>
<td>-0.6 (-3.8, 2.7)</td>
<td>0.73</td>
</tr>
<tr>
<td>Lacosamide</td>
<td>5 (19%)</td>
<td>6.5</td>
<td>3.9 (-0.7, 7.1)</td>
<td>0.02</td>
</tr>
<tr>
<td>Clobazam</td>
<td>5 (19%)</td>
<td>0.03</td>
<td>-0.3 (-4.0, 3.3)</td>
<td>0.86</td>
</tr>
<tr>
<td>Perampanel</td>
<td>3 (12%)</td>
<td>4.2</td>
<td>4.1 (-0.07, 8.2)</td>
<td>0.05</td>
</tr>
</tbody>
</table>

**Table 5.1:** Clinical characteristics and their association with $[^{18}F]GE-179$ uptake in epilepsy patients.

SD, standard deviation; SPS, simple partial seizure; CPS, complex partial seizure; SGS, secondarily generalized seizure.
patients had mesial temporal lobe epilepsy with hippocampal sclerosis and half (n=13) of all patients had epilepsy lateralised to the left hemisphere. Six patients were rescanned after anterior temporal lobe resection. Twenty-nine healthy volunteers (mean age 41 ± 13 years, 8 [28%] female) were recruited and scanned at three sites (UCL [n=10], Cambridge [n=10], Hammersmith [n=9]).

The Cambridge and Hammersmith sites used PET-CT scanners with an arterial input function, whereas the UCL site used a PET-MR scanner with a venous/image-derived input function (see chapter 3 for method validation). Only one venous sample was obtained in 6 patients in the UCL study and we applied the simplified one-sample approach to these cases (chapter 3.3.2). Venous sampling failed in 4 scans and we used population-based parent-fraction and plasma-over-blood ratio curves in these scans (McGinnity et al., 2018). Prior to preprocessing, imaging data in epilepsy patients and an equivalent proportion of randomly selected healthy volunteers were flipped to display the hemisphere ipsilateral to the epileptic focus on the left.

As a first step, we extracted $V_T$ estimates in grey matter and calculated their association with clinical characteristics in patients with epilepsy using the general linear model adjusting for age and sex. We chose significant variables from the first set of analyses and included them in a multivariable model, additionally correcting for seizure frequency as a proxy for disease severity. To address the subregional distribution of the findings, we replicated the same multivariable general linear model on voxelwise $V_T$ estimates in grey matter.

We determined test-retest reliability of $[^{18}F]GE-179$ PET scans using data from 5 healthy volunteers scanned at least 1 year apart in the Cambridge study using scatter plots, correlation coefficients, and Bland Altman plots. In addition to absolute $V_T$, we also compared relative $V_T$, i.e. the ratio between lobar and global grey matter $V_T$ in a scan.

Next, we compared the overall grey matter $V_T$ in healthy volunteers with epilepsy patients using the general linear model adjusting for sex, age, and cohort allocation.
We split patients into subgroups with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE+HS), temporal lobe epilepsy (TLE, including both neocortical or mesial localisations), and frontal lobe epilepsy (FLE). We also analysed subregional differences in voxelwise V_t estimates with a full factorial general linear model corrected for sex, age, and cohort allocation taking global V_t into account via an analysis of covariance (ANCOVA) by group (McGinnity et al., 2015). To address the contribution of epilepsy-related grey matter atrophy to our findings, we performed voxel-based morphometry (VBM) using segmented and modulated...
parametric grey matter volume images obtained using the CAT12 toolbox on 3T T1 MRI scans. We displayed the overlap of $V_T$ and VBM voxelwise findings.

Lastly, we analysed changes in relative regional $V_T$ after anterior temporal lobe resection in six patients using paired t-tests. We used relative instead of absolute $V_T$ measurements due to their improved reproducibility (chapter 5.3.1). We compared post- with presurgical voxelwise $V_T$ using a paired t-test and a small volume correction to regions found to be significant in the regional analysis (contralateral basal ganglia and temporal lobe).

We report voxelwise p-values at a threshold of $p<0.05$ on a cluster-level family-wise error corrected for multiple comparisons.

5.3 Results

5.3.1 Test-retest measurements of [$^{18}$F]GE-179 uptake

Five healthy volunteers from the Cambridge cohort were rescanned at least one year apart. Absolute grey matter $V_T$ in cerebral lobes and subcortical structures (basal ganglia, thalamus) correlated moderately between measurements ($r = 0.48$, $p = 0.002$, Figure 5.1A). Bland Altman plots (Figure 5.1B) showed positive bias of the mean (4.4%) and large variability (95% CI -25.7 to 34.4%) of $V_T$ differences between scans.

In contrast, relative grey matter $V_T$ was highly correlated between measurements ($r = 0.91$, $p < 0.001$, Figure 5.1C). There was small bias of the mean (0.4%) and small variability (95% CI -4.8 to 5.7%) of relative $V_T$ differences between scans (Figure 5.1D).

5.3.2 [$^{18}$F]GE-179 uptake and demographics in epilepsy patients

Detailed clinical characteristics of the included 26 patients with epilepsy and their association with global $V_T$ in grey matter are displayed in Table 5.1. We included all
Project 3: NMDA receptor activation in focal epilepsy.

We found a significant positive association of $V_T$ in grey matter with age ($F = 9.9, p = 0.006$, Figure 5.2A), observing an estimated $V_T$ increase of 1.4 (95% CI 0.5 to 2.4) per 10 years. On a subregional level (Figure 5.2A), we observed significant age-related increases in $V_T$ in a large cluster ($T = 5.1, 13465$ voxels, $p=0.002$) involving the bilateral striata, ipsilateral orbitofrontal cortex, contralateral thalamus, and contralateral hippocampus.

We also found a significant negative association with duration of epilepsy ($F = 10.9, p = 0.004$, Figure 5.2B), with an estimated $V_T$ decrease of 1.6 (95% CI 0.6 to 2.7) per 10 years. In the voxelwise analysis, duration of epilepsy was negatively associated with $V_T$ (i.e. the longer the duration of epilepsy the lower the $V_T$) in the ipsilateral striatum, thalamus, temporo-frontal junction (piriform cortex, amygdala, orbitofrontal cortex), anterior temporal neocortex ($T = 4.9, 7052$ voxels, $p = 0.03$), and in the contralateral striatum, thalamus, and orbitofrontal cortex ($T = 4.6, 6223$ voxels, $p = 0.04$).

<table>
<thead>
<tr>
<th>Variable</th>
<th>$F$</th>
<th>Beta (95% CI)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (per 10 years)</td>
<td>9.9</td>
<td>1.4 (0.5, 2.4)</td>
<td>0.006</td>
</tr>
<tr>
<td>Duration of epilepsy (per 10 years)</td>
<td>10.9</td>
<td>-1.6 (-2.7, -0.6)</td>
<td>0.004</td>
</tr>
<tr>
<td>Lacosamide intake at scan</td>
<td>9.8</td>
<td>4.5 (1.5, 7.6)</td>
<td>0.006</td>
</tr>
<tr>
<td>Female Sex</td>
<td>1.0</td>
<td>-1.0 (-3.2, 1.1)</td>
<td>0.34</td>
</tr>
<tr>
<td>Overall seizure frequency (per month)</td>
<td>0.01</td>
<td>0.001 (-0.03, 0.03)</td>
<td>0.91</td>
</tr>
<tr>
<td>Number of antiepileptic drugs</td>
<td>0.7</td>
<td>0.2 (-1.0, 1.5)</td>
<td>0.68</td>
</tr>
<tr>
<td>Lamotrigine intake at scan</td>
<td>1.5</td>
<td>-1.4 (-3.8, 1.0)</td>
<td>0.24</td>
</tr>
<tr>
<td>Perampanel intake at scans</td>
<td>1.2</td>
<td>1.9 (-1.7, 5.4)</td>
<td>0.28</td>
</tr>
</tbody>
</table>

Table 5.2: Multivariable model of $[^{18}F]$GE-179 uptake in epilepsy patients.
Project 3: NMDA receptor activation in focal epilepsy.

Figure 5.2: Association of GE-179 uptake with age, disease duration, and lacosamide intake in patients with epilepsy.

The figure shows the association of GE-179 uptake with age (panel A), disease duration (panel B), and lacosamide intake (panel C) in patients with epilepsy (n=26). The voxelwise distribution of results is shown on brain surfaces and slices on the left (p<0.05 FWE corrected; blue colours indicate increased uptake, red colour indicate decreased uptake), the global grey matter findings are shown in plots on the right. Global grey matter uptake and clinical variables are displayed as mean centred values adjusted for co-variates.
Grey matter $V_t$ was increased in patients taking lacosamide at time of scan ($F = 9.8$, Beta $4.5$, 95% CI $1.5$ to $7.6$, $p = 0.006$). These increases were localised to the ipsilateral temporal neocortex and temporo-parieto-occipital junction ($T = 5.8$, $12357$ voxels, $p = 0.003$, Figure 5.2C). Lamotrigine intake was associated with a nonsignificant decrease in $V_t$ ($F = 1.5$, Beta $-1.4$, 95% CI $-3.8$ to $1.0$, $p = 0.24$) and perampanel intake with a nonsignificant increase in $V_t$ ($F = 1.2$, Beta $1.9$, 95% CI $-1.7$ to $5.4$, $p = 0.28$). On voxelwise analyses, we did not detect any areas with significant changes in $V_t$ related to lamotrigine or perampanel intake.

5.3.3 $[^{18}F]$GE-179 uptake in epilepsy patients compared to healthy volunteers

People with epilepsy and healthy volunteers did not significantly differ in age ($F=0.4$, $p=0.52$) and sex ($F=0.1$, $p=0.76$). Global $[^{18}F]$GE-179 $V_t$ in grey matter did not differ between healthy volunteers ($n = 29$, mean $V_t 9.2$, 95% CI $8.5$ to $10.0$) compared with patients with mesial temporal lobe epilepsy and hippocampal sclerosis (MTLE+HS, $n = 7$, mean $V_t 9.1$, 95% CI $7.5$ to $10.8$, $F = 0.01$, $p = 0.93$), patients with temporal lobe epilepsy (TLE, $n = 18$, mean $V_t 9.5$, 95% CI $8.0$ to $10.9$, $F = 0.2$, $p = 0.67$), or patients with frontal lobe epilepsy (FLE, $n = 5$, mean $V_t 10.4$, 95% CI $7.8$ to $13.0$, $F = 0.8$, $p = 0.38$).

On voxelwise analysis, patients with MTLE+HS (Figure 5.3A) had focal relative decreases of $V_t$ in bilateral precunei and cuneus ($T = 8.0$, $2063$ voxels, $p < 0.001$), ipsilateral mesial temporal lobe ($T = 6.4$, $2166$ voxels, $p < 0.001$), contralateral superior and middle temporal gyri ($T = 6.4$, $2060$ voxels, $p < 0.001$), contralateral inferior temporal gyrus ($T = 5.9$, $778$ voxels, $p = 0.002$), and bilateral opercula (ipsilateral, $T= 5.3$, $545$ voxels, $p = 0.01$; contralateral, $T = 6.0$, $1828$ voxels, $p < 0.001$).
Figure 5.3: Abnormal GE-179 uptake and epilepsy localisation.

The figure shows abnormal GE-179 V\(T\) in patients with mesial temporal lobe epilepsy with hippocampal sclerosis (n=7, panel A), temporal lobe epilepsy (n=18, panel B), and frontal lobe epilepsy (n=5, panel C) compared with healthy volunteers (n=29). The voxelwise distribution of GE-179 PET results is shown on brain surfaces and slices on the left (p<0.05 FWE corrected; blue colours indicate increased uptake, red colour indicate decreased uptake). Grey matter atrophy assessed with voxel-based morphometry is overlaid in purple (p<0.05 FWE corrected). Comparisons of estimated marginal means of global grey matter GE-179 V\(T\) between patients and healthy volunteers are shown in plots on the right.
Patients with TLE (Figure 5.3B) had focal relative decreases of $V_T$ in bilateral precunei ($T = 6.6$, 4277 voxels, $p < 0.001$), bilateral opercula (ipsilateral, $T = 4.8$, 546 voxels, $p = 0.02$; contralateral, $T = 6.1$, 2830 voxels, $p < 0.001$), contralateral superior and middle temporal gyri ($T = 5.9$, 1965 voxels, $p < 0.001$), contralateral inferior temporal gyrus ($T = 5.7$, 1401 voxels, $p < 0.001$), ipsilateral mesial temporal lobe ($T = 5.4$, 796 voxels, $p = 0.002$), and ipsilateral middle and inferior temporal gyri ($T = 5.0$, 487 voxels, $p = 0.03$).

Patients with FLE (Figure 5.3C) had focal relative decreases of $V_T$ in bilateral orbitofrontal cortices (ipsilateral, $T = 4.5$, 650 voxels, $p = 0.003$; contralateral, $T = 4.5$, 369 voxels, $p = 0.04$), ipsilateral posterior superior temporal gyrus ($T = 6.0$, 2589 voxels, $p < 0.001$), ipsilateral angular gyrus ($T = 5.3$, 648 voxels, $p = 0.003$), and ipsilateral fusiform gyrus ($T = 4.7$, 363 voxels, $p = 0.04$).

We found significant grey matter atrophy measured with VBM in patients with MTLE+HS (Figure 5.3A) in the ipsilateral hippocampus ($T = 7.6$, 1724 voxels, $p = 0.001$). VBM did not detect significant grey matter atrophy in the overall group of patients with TLE (Figure 5.3B) or FLE (Figure 5.3C).

### 5.3.4 $[^{18}F]$GE-179 uptake before and after temporal lobe surgery

Due to improved reproducibility (chapter 5.3.1), we determined relative $V_T$ ratios in cerebral lobes and subcortical structures (basal ganglia, thalamus) in six patients with temporal lobe epilepsy scanned before and after anterior temporal lobe resection. After surgery, there was a significant increase in relative $V_T$ (Figure 5.4A) in the contralateral temporal lobe (mean relative $V_T$ presurgical 1.00 vs. postsurgical 1.04, $T = 3.2$, $p = 0.02$) and basal ganglia (mean relative $V_T$ presurgical 1.11 vs. postsurgical 1.15, $T = 5.5$, $p = 0.003$). In comparison, mean relative $V_T$ in healthy volunteers was 1.05 (95% CI 0.93 to 1.17) in the temporal lobe and 1.15 (95% CI 0.97 to 1.33) in the basal ganglia. Other regions did not show significant differences. There were no
Project 3: NMDA receptor activation in focal epilepsy.

A  Regional pre-postsurgical changes

- **Panel A** shows relative changes of GE-179 Vᵢ in the contralateral temporal lobe and basal ganglia of patients with temporal lobe epilepsy before and after anterior temporal lobe resection.

- **Panel B** shows the voxelwise distribution of post-vs. presurgical relative GE-179 Vᵢ in these patients (p<0.05 FWE corrected; blue colours indicate increased relative uptake after surgery, red colours indicate decreased relative uptake after surgery).

**Figure 5.4:** Relative changes in GE-179 uptake after epilepsy surgery.

**Panel A** shows relative changes of GE-179 Vᵢ in the contralateral temporal lobe and basal ganglia of patients with temporal lobe epilepsy before and after anterior temporal lobe resection. **Panel B** shows the voxelwise distribution of post-vs. presurgical relative GE-179 Vᵢ in these patients (p<0.05 FWE corrected; blue colours indicate increased relative uptake after surgery, red colours indicate decreased relative uptake after surgery).
differences in postsurgical relative $V_T$ changes between patients who became seizure-free and those with ongoing seizures. On voxelwise analysis (Figure 5.4B), we confirmed postsurgical increases of relative $V_T$ in the contralateral middle and inferior temporal gyri ($T = 9.4$, 546 voxels, $p = 0.01$).

5.4 Discussion

We report in vivo alterations of NMDA receptor activation in the largest cohort of patients with epilepsy studied with NMDA receptor PET to date. We found decreased interictal tracer uptake in patients with longer duration of epilepsy, whereas uptake was increased in older individuals. We observed focal reductions of tracer uptake in patients with epilepsy compared with healthy volunteers and these reductions were bilateral and spread beyond the epileptic focus. The spatial distribution of decreased uptake was related to the localisation of the epileptic focus and differed between patients with temporal or frontal lobe epilepsy. After anterior temporal lobe resection, we found relative increases in tracer binding in the contralateral temporal lobe and, less consistently, in the contralateral basal ganglia.

5.4.1 NMDA receptor hypofunction and neuronal hyperexcitability

Traditionally, activation of NMDA receptors that bind glutamate, an excitatory neurotransmitter, was thought to lead to activation of neuronal circuits. Emerging evidence from animal and human studies points to both activating and suppressing effects of NMDA receptors on neuronal networks (Fitzgerald, 2012). Network suppression could be mediated by activation of NMDA receptors on GABAergic interneurons that may in turn inhibit excitatory pyramidal cells (Grunze et al., 1996; Homayoun and Moghaddam, 2007; Manzoni et al., 1994). Another potential mechanism is the downregulation of excitatory AMPA receptors through NMDA receptors (Hall et al., 2007). Conversely, NMDA receptor antagonism increases
glutamatergic transmission through AMPA receptors (Moghaddam and Adams, 1998; Moghaddam et al., 1997). A recurrent finding is the activation of limbic structures after blocking of NMDA receptors with ketamine (Höflich et al., 2017; Kraguljac et al., 2017; McMillan et al., 2019). Thus, NMDA receptor hypofunction may lead to hippocampal activation and subsequently to increased likelihood of seizures.

In patients with epilepsy, reduced binding inside the open, i.e. activated, NMDA ion channel and a higher proportion of GluN2B subunits, that have a lower opening probability (N. Chen et al., 1999; Erreger et al., 2005; Gray et al., 2011), have been observed in temporal lobe specimen (Hosford et al., 1991; Mathern et al., 1998; McDonald et al., 1991). Both gain- and loss-of-function mutations in GRIN genes encoding NMDA receptor subunits led to seizures (Xu and Luo, 2018). Seizures are frequent in anti-NMDA receptor encephalitis, an autoimmune disorder associated with internalisation and hypofunction of NMDA receptors (Hughes et al., 2010; Moscato et al., 2014). An increase of seizures was observed in a large proportion of patients in a trial of the competitive highly selective NMDA receptor antagonist D-CPP-ene (Sveinbjørnsdottir et al., 1993).

These observations allow for several interpretations of our findings. We demonstrated lower tracer uptake in epilepsy patients with longer disease duration (Figure 5.2B) and spatially distinct reductions in patients compared to controls (Figure 5.3). Lower $[^{18}F]$GE-179 uptake points to a reduced opening probability of NMDA receptors (McGinnity et al., 2014) that could reflect a reduction in the surface expression or change of the functional properties of NMDA receptors. Our results are in line with the notion that increased NMDA receptor activation is relevant during epileptogenesis and the early stages of epilepsy whereas longer disease duration leads to progressive hypoactivation of NMDA receptors (McNamara et al., 1988).

NMDA receptor hypofunction, as observed in our chronic refractory epilepsy cohort, could lead to reduced activation of inhibitory interneurons (Grunze et al., 1996; Homayoun and Moghaddam, 2007; Manzoni et al., 1994) and increased glutamatergic
activation of AMPA receptors (Hall et al., 2007; Moghaddam and Adams, 1998; Moghaddam et al., 1997), that was recently observed in patients with epilepsy (Miyazaki et al., 2020). This may subsequently cause limbic hyperexcitability (Höflich et al., 2017; Kraguljac et al., 2017; McMillan et al., 2019) and could contribute to seizures. Alternatively, NMDA receptor hypofunction could reflect a compensatory mechanism due to increased release of glutamate during seizures (During and Spencer, 1993). Glutamatergic stimulation may reduce the transcription of the obligatory GluN1 subunit, thus leading to a reduced NMDA receptor density (Gascón et al., 2005). Overall, this is a less likely explanation because NMDA receptors tend to be stably expressed and are less likely to be regulated by neuronal activity than other glutamatergic ion channels (Lissin et al., 1998).

Our results are in accordance with several, but not all, previous PET and immunohistochemistry studies in human epilepsy (Bayer et al., 1995; Blumcke et al., 1996; Geddes et al., 1990; Hosford et al., 1991; McDonald et al., 1991; Sprefico et al., 1998). A study using [11C]ketamine found reduced binding in the ipsilateral temporal lobe of patients with MTLE (Kumlien et al., 1999). We previously observed increased [18F]GE-179 binding in eight epilepsy patients not taking antidepressants and decreased binding in three patients on antidepressants (McGinnity et al., 2015). Increased binding in this previous study could reflect the selective inclusion of patients with frequent interictal epileptic discharges. Epileptic discharges during the scan could lead to glutamate release (During and Spencer, 1993) and activation of NMDA receptors. Because subjects included in the current study were less likely to have interictal epileptic discharges they may have been less prone to abnormal glutamate release during the scan.
5.4.2 Focal changes of NMDA receptor activation in epilepsy

Focally decreased NMDA receptor activation was spatially distinct between epilepsy subtypes (Figure 5.3). The ipsilateral mesial temporal lobe was more likely to show abnormal tracer uptake in MTLE+HS, whereas the ipsilateral temporal neocortex showed abnormal uptake in the overall TLE group. In contrast, patients with FLE had abnormal tracer uptake mainly in the orbitofrontal cortex and the parietal lobe. In all subgroups, reductions in NMDA receptor activation were widespread, affecting areas beyond the epileptic focus and spreading to the contralateral hemisphere. We did not observe any focal increases in NMDA receptor activation. This reinforces the concept of epilepsy as a network disorder. A similar distribution has been found in studies examining structural MRI abnormalities in epilepsy (Galovic, van Dooren, et al., 2019; Whelan et al., 2018). These regions may be particularly vulnerable because of their high interconnection with the epileptic focus. There is a high overlap between the areas affected in MTLE+HS (Figure 5.3A) and the regions structurally connected with the hippocampus (Figure 5.5, reproduced with permission from (Galovic, van Dooren, et al., 2019).

Although we observed a different spatial distribution of NMDA receptor alterations between TLE and FLE (Figures 5.3B and 5.3C), the value of [$^{18}$F]GE-179 PET for presurgical evaluation may be limited because the abnormalities were bilateral and widespread. In contrast, FDG-PET shows in many cases a large area of reduced uptake that includes the epileptogenic zone and was shown to be helpful in localisation and lateralisation of the epileptic focus (Willmann et al., 2007). FDG-PET was performed in 6 of our epilepsy patients and showed focal hypometabolism in the presumed epileptogenic zone in five cases and bilateral hypometabolism in one case. Further studies may be needed to directly evaluate the lateralising and localising value of [$^{18}$F]GE-179 PET in individual patients with epilepsy.

We found relative postsurgical increases of tracer uptake in the contralateral temporal lobe (on voxelwise and regional analysis) and basal ganglia (on regional analysis only).
after anterior temporal lobe resections (Figure 5.4). These areas showed reduced tracer uptake in TLE before surgery (Figure 5.3B). Thus, postsurgically increased uptake could reflect normalisation of NMDA receptor activation in the contralateral hemisphere after removal of the ipsilateral epileptogenic zone. This is supported by the observation that postoperative relative $V_T$ in these areas was comparable to that observed in healthy volunteers. Alternatively, it could point to neuronal compensation through increased NMDA receptor activation in the contralateral temporal cortex after removal of ipsilateral temporal lobe.

5.4.3 Effects of antiepileptic drugs

We observed increased NMDA receptor activation, particularly in the ipsilateral temporal lobe and parieto-occipital junction, in patients taking lacosamide (Figure 5.2C). Lacosamide’s primary mechanism of action is thought to be the blocking of voltage-gated sodium channels. However, lacosamide is an analogue of the endogenous amino acid and NMDA-receptor modulator D-serine (European Medicines Agency Evaluation of Medicines …, 2008). *In vitro* models did not find
direct binding of lacosamide to NMDA receptors, nor did lacosamide modulate NMDA receptor currents (Errington et al., 2006). On the other hand, lacosamide efficiently prevented NMDA-induced convulsions and reduced mortality in rodents (Stöhr et al., 2007). Thus, lacosamide might modulate NMDA receptor function through a yet unrecognised mechanism that warrants further evaluation.

Patients taking lamotrigine showed a trend for decreased tracer binding, whereas those taking perampanel had a trend for increased tracer binding, but they were not significant in the multivariable model (Table 5.2). Lamotrigine acts as a glutamatergic modulator and attenuates cortical glutamate release and could, in accordance with our observations, cause nonsignificant reductions of NMDA receptor activation (Anand et al., 2000; Farber et al., 2002; C.-Y. Lee et al., 2008; Ramadan et al., 2012; S. J. Wang et al., 1996). Lamotrigine effectively reduced glutamatergic excitotoxicity (Eisen et al., 1993; Tekin et al., 1998). Perampanel does not directly affect NMDA receptor currents. It might, however, lead to increased availability of unbound extracellular glutamate through AMPA receptor antagonism that could indirectly and nonsignificantly activate NMDA receptors (C.-Y. Chen et al., 2014).

5.4.4 Effects of age

We confirmed in this cohort of patients with focal epilepsy that aging is associated with an increased opening probability of NMDA receptors (Figure 5.2A), as previously demonstrated in healthy individuals (detailed discussion in chapter 0). The rate of receptor overactivation per decade in epilepsy patients was more than double that of healthy volunteers, pointing to a higher vulnerability of the epileptic brain to aging. This observation supports previous findings of progressive neurodegeneration on structural neuroimaging (Galovic, van Dooren, et al., 2019). The subcortical areas affected by aging in epilepsy patients (Figure 5.2A) were largely similar to those in healthy volunteers (Figure 4.1). Cortical areas were less likely to show an aging-related
increase in tracer uptake in patients with epilepsy compared to healthy individuals because epilepsy leads to decreased uptake in several cortical areas (Figure 5.3).

### 5.4.5 Methodical considerations

Several methodical considerations should be noted. Firstly, \[^{18}\text{F}]\text{GE-179}\) has demonstrated specificity for the open NMDA ion channel \textit{in vitro} and during recent activation/blocking studies \textit{in vivo} (discussed in more detail in chapter 0). Tracer binding is, however, not selective for any NMDA receptor subunit and, thus, cannot distinguish between heteromeric compositions or synaptic localisations of receptors. Tracer binding reflects receptor opening probability, a compound measure of receptor availability and activation.

Secondly, our findings of reduced tracer uptake in epilepsy patients are unlikely to be explained by grey matter atrophy because the PET signal changes far exceeded reductions of grey matter volume on VBM (Figure 5.3). Additionally, we corrected the PET results for partial volume effects, thus adjusting the PET signal for potential effects of brain atrophy. It is also unlikely that our findings relate to tissue hypoperfusion, because hypoperfusion is usually unilateral and restricted to the epileptogenic zone whereas our findings were bilateral and widespread (Boscolo Galazzo et al., 2015). In addition, \(V_T\) estimates obtained using kinetic modelling applied to the PET signal are not dependent on tissue blood perfusion.

Thirdly, we showed large variability of test-retest \(^{18}\text{F}]\text{GE-179}\) measurements. Thus, PET studies might be more robust to detect relative focal differences rather than absolute global changes. This might explain why relative focal differences were consistently demonstrated in all epilepsy subgroups (Figure 5.3) and postsurgically (Figure 5.4), but global changes could not be detected compared to healthy volunteers. Additional signal variability might have been introduced by the usage of a venous/image-derived input function in the UCL cohort. Thus, analysing PET studies
with high signal variability requires large cohorts for group comparisons and may make comparisons on an individual level difficult and restricted to relative focal rather than absolute global changes. To increase statistical power, we pooled data from three available healthy control cohorts. Scanning equipment did not significantly influence the results (see cohort comparison in chapter 4.3.1) and we adjusted all statistical models for site allocation to further minimise any residual between-cohort effects.

Lastly, a limitation inherent to most epilepsy studies is the possible influence of AED intake in patients compared with controls. However, even when correcting for number of type of AED taken in epilepsy patients we found reduced tracer uptake in cases with longer duration of epilepsy (Figure 5.2), adding support for the finding of reduced tracer uptake in epilepsy patients compared to healthy volunteers.

### 5.4.6 Conclusions

We observed reduced interictal NMDA receptor activation in patients with chronic refractory focal epilepsy, particularly in those with longer disease duration. These results challenge traditional concepts of NMDA receptor overactivation in chronic epilepsy. In view of this and previous studies, achieving a balanced NMDA receptor activation might be necessary for normal neuronal function, because both increased and reduced activation of NMDA receptors can cause seizures. Such knowledge will have an impact on the development of new antiepileptic drugs targeting NMDA receptors. Further research should address the value of $^{18}\text{F}\text{GE-179 PET}$ as a molecular surrogate marker for monitoring epileptic activity.
6 Project 4: NMDA receptor activation in Anti-NMDA-receptor encephalitis

6.1 Introduction

Anti-NMDA-receptor encephalitis is a recently described autoimmune disorder leading to a syndrome with psychiatric, cognitive, and autonomic dysfunction, seizures, speech abnormalities, movement disorders, and decreased level of consciousness (Dalmau et al., 2007; Graus et al., 2016). Around 80% of cases have a favourable outcome following immunotherapy but relapses may occur in up to a quarter of cases (Gabilondo et al., 2011; Titulaer et al., 2013). The majority of recovered cases report persistent cognitive deficits of variable severity affecting executive functions and memory (Finke et al., 2012).

The disease is mediated by autoantibodies to the GluN1 subunit of the NMDA receptor that cause a crosslinking and internalisation of the receptors (Hughes et al., 2010; Ladépêche et al., 2018; Moscato et al., 2014). In vitro and animal experiments showed that the magnitude of reduction in NMDA receptor density is related to antibody titres and the effects are reversible when the antibody titre is reduced (Hughes et al., 2010; Moscato et al., 2014). Similarly, a reduction of NMDA receptor
density was reported post mortem in two autopsied patients with anti-NMDA-receptor encephalitis (Dalmau et al., 2007).

It is controversial whether antibody titres in serum and cerebrospinal fluid (CSF) correlate with clinical outcome, as persistently elevated titres were observed in some but not all patients who did not improve clinically (Dalmau et al., 2008; Gresa-Arribas et al., 2014). It remains unknown how to guide the intensity and duration of immunotherapy. In particular, reliable biomarkers for the risk of relapses or long-term outcome after an initial episode of Anti-NMDA-receptor encephalitis are not available and it is unclear how to monitor disease activity in the longer term.

Neuroimaging studies described several abnormalities in patients with Anti-NMDA-receptor encephalitis. Around half of cases show T2 or FLAIR hyperintensities in the hippocampi, cerebellar or cerebral cortex (Dalmau et al., 2007). Volumetry may detect hippocampal atrophy that correlates with disease severity and memory performance (Finke et al., 2016). Patients also show widespread white matter changes, particularly affecting the cingulum, and a reduced connectivity of both hippocampi with the default mode network (Finke et al., 2013). FDG-PET shows a typical pattern of occipital hypometabolism that may be more sensitive than structural MRI (Leyboldt et al., 2012; Probasco et al., 2018). Nevertheless, none of the imaging methods studied so far enabled the direct measurement of NMDA receptor activity in vivo in patients with Anti-NMDA-receptor encephalitis.

Here, we used PET with the novel radioligand [18F]GE-179 that binds inside the open, i.e. activated, NMDA ion channel to study five females after discharge from hospital following confirmed Anti-NMDA-receptor encephalitis. We aimed to determine, whether disturbances in NMDA receptor function persist even after improvement of most symptoms and whether they correlate with antibody titres in serum.
6.2 Methods

We followed the methods as described in detail in chapter 2. We screened consecutive patients with Anti-NMDA-receptor encephalitis that were hospitalised or under regular follow-up in two tertiary referral centres in the UK (John Radcliffe University Hospital Oxford and St. George’s University Hospital London). We included patients with confirmed disease according to established diagnostic criteria (Graus et al., 2016) who were (i) between 18 and 65 years old, (ii) had minimal or no symptoms and could thus tolerate a 70-minute PET-MR scan, and (iii) did not take any medication that could interfere with NMDA receptors, in particular antipsychotics or antidepressants, permitting immunotherapy and anticonvulsants. The included participants in the “active” group (cases #1-4) had detectable Anti-GluN1 antibodies in serum on day of scanning. We also included one “inactive” participant (case #5) with nondetectable antibodies in serum for comparison.

All patients were scanned at the UCL site. Clinical data were retrospectively extracted from medical records according to previously described procedures (Al-Diwani et al., 2019). We calculated the CASE score, a measure of autoimmune encephalitis severity, at discharge (Lim et al., 2019). Cognitive testing with Addenbrooke’s Cognitive Examination III (ACE-III) and assessment with Beck’s Depression Inventory (BDI) were performed shortly before the scan.

The live cell-based assays for serum Anti-GluN1 titre measurements were done as follows. HEK293T cells were cultured at 37°C in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with foetal calf serum and antibacterial/antimycotic solution for 30 hours on glass cover slips, then transfected with plasmid DNA containing GluN1 subunit for 15 hours. Following incubation for a further 24 hours in 1.4 μL/ml ketamine supplemented culture medium sera were tested. Serum, previously thawed to room temperature, was diluted 1:20 with DMEM supplemented with 1% bovine serum albumin and 200mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). 250μL diluted samples were testing alongside positive and negative controls. Samples
<table>
<thead>
<tr>
<th>Variable</th>
<th>Case #1</th>
<th>Case #2</th>
<th>Case #3</th>
<th>Case #4</th>
<th>Case #5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, Sex, Ethnicity</strong></td>
<td>22, F, Asian</td>
<td>36, F, Caribbean</td>
<td>25, F, Caribbean</td>
<td>30, F, European</td>
<td>28, F, European</td>
</tr>
<tr>
<td><strong>Data at scan</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GE-179 uptake in GM</td>
<td>7.3</td>
<td>6.6</td>
<td>6.0</td>
<td>4.6</td>
<td>9.7</td>
</tr>
<tr>
<td>Serum GluN1-IgG</td>
<td>1:320</td>
<td>1:320</td>
<td>1:160</td>
<td>1:320</td>
<td>Not detectable</td>
</tr>
<tr>
<td>Current episode</td>
<td>Relapse</td>
<td>Relapse</td>
<td>First</td>
<td>First</td>
<td>First</td>
</tr>
<tr>
<td><strong>Overall number of episodes</strong></td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>ACE-III</strong></td>
<td>96</td>
<td>95</td>
<td>86</td>
<td>96</td>
<td>96</td>
</tr>
<tr>
<td><strong>BDI</strong></td>
<td>16</td>
<td>3</td>
<td>8</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td><strong>Timing</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time from discharge to scan (months)</td>
<td>2</td>
<td>8</td>
<td>6</td>
<td>8</td>
<td>16</td>
</tr>
<tr>
<td>Duration of hospitalization (months)</td>
<td>1.5</td>
<td>1.3</td>
<td>10</td>
<td>2.5</td>
<td>2</td>
</tr>
<tr>
<td>Time from symptom onset to scan (months)</td>
<td>4</td>
<td>12</td>
<td>18</td>
<td>11</td>
<td>19</td>
</tr>
<tr>
<td>Time from symptom onset to admission (days)</td>
<td>14</td>
<td>21</td>
<td>64</td>
<td>12</td>
<td>25</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current medication</td>
<td>CP, Prednisone, Lorazepam, TMP/SMX, Omeprazole</td>
<td>Levitiracetam, Clonazepam, Ferrous fumarate</td>
<td>Prednisone, Lansoprazole</td>
<td>Levitiracetam</td>
<td>Oral contraceptive</td>
</tr>
<tr>
<td>Immunotherapy during hospitalisation</td>
<td>Steroids, PLEX, CP</td>
<td>Steroids, PLEX, CP</td>
<td>Steroids, PLEX, IVIG</td>
<td>Steroids, PLEX</td>
<td>Steroids, PLEX, IVIG, CP</td>
</tr>
<tr>
<td>Other treatments during hospitalisation</td>
<td>Antipsychotic, Benzodiazepine</td>
<td>Antipsychotic, Antiepileptic, Benzodiazepine</td>
<td>Antipsychotic, Antiepileptic, Benzodiazepine</td>
<td>Antiepileptic</td>
<td>Antipsychotic, Antiepileptic, Benzodiazepine</td>
</tr>
<tr>
<td><strong>Clinical features during hospitalisation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CASE score at discharge</td>
<td>5</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>Prodrome</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Cognitive</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Speech dysfunction</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Seizures</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Movement disorder</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Reduced consciousness</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>Autonomic</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Central hypoventilation</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Ovarian teratoma</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>Post-HSV encephalitis</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td><strong>Para-clinical features during hospitalisation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI abnormal</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>EEG abnormal</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>?</td>
</tr>
<tr>
<td>CSF pleocytosis</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>CSF lymphocytosis</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>CSF elevated protein</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
</tr>
</tbody>
</table>

**Table 6.1: Characteristics of patients with Anti-NMDA-receptor encephalitis**

Y, Yes/Present; N, No/Absent; ?, unknown; F, female; CM, Grey matter; ACE-III, Addenbrooke’s Cognitive Examination III; BDI, Beck’s Depression Inventory; CP, Cyclophosphamide, TMP/SMX, Trimethoprim/sulfamethoxazole; PLEX, Plasma exchange; IVIG, Intravenous immunoglobulins; HSV, Herpes simplex virus; MRI, Magnetic resonance imaging; EEG, Electroencephalography; CSF, Cerebrospinal fluid examination.
were incubated with transfected cells for 1 hour at room temperature. The diluted samples were then aspirated, each well was washed 3 times with DMEM-HEPES, each cover slip was then fixed with 4% formaldehyde for 5 minutes and then washed three times with DMEM-HEPES. The cells were then incubated with secondary antibody (Alexa Fluor 594-conjugated donkey anti-human IgG Fc-gamma; Jackson 709-585-098) in the dark for 45 minutes. This was aspirated, and each well was washed twice in DMEM-HEPES then twice in PBS. Each coverslip was individually mounted in 4′,6-diamidino-2-phenylindole (DAPI)-supplemented mounting medium on a glass slide. Following review of positive and negative control cover slips test samples were read at 40x zoom on a Leica DM2000 fluorescence microscope. Positivity was determined by the presence of a characteristic coronal cell surface deposition of fluorescent reporter antibody on multiple cells. All positive samples were repeated on an independent assay and serially diluted to establish an end-point dilution, the dilution at which the positive signal was still unambiguously present.

We compared these subjects with twenty-nine healthy volunteers from three cohorts (UCL [n=10], Cambridge [n=10], Hammersmith [n=9]). The Cambridge and Hammersmith sites used PET-CT scanners with an arterial input function, whereas the UCL site used a PET-MR set-up with a venous/image-derived input function (see chapter 3 for method validation). All participants gave written informed consent according to the Declaration of Helsinki.

We calculated $[^{18}F]$GE-179 volume of distribution ($V_T$) estimates in global grey and white matter and in lobar regions of interest. We compared $V_T$ estimates between patients with encephalitis and healthy volunteers using the general linear model adjusting for age, sex, and cohort allocation (i.e. scanning equipment). We report $V_T$ means as estimated marginal means that were adjusted for the effects of age, sex, and cohort allocation. To analyse the subregional distribution of the findings, we fitted the same general linear model on voxelwise $V_T$ estimates. To address the contribution of grey matter atrophy to our findings, we performed voxel-based morphometry (VBM).
Figure 6.1: GE-179 uptake in “active” or “nonactive” Anti-NMDA-receptor encephalitis and healthy volunteers.

The figure shows the spatial distribution of $[^{18}F]$GE-179 V$_T$ on brain slices and surface projections. Panel A displays individual ligand uptake in “active” Anti-NMDA-receptor encephalitis cases (n=4) that were scanned 2-8 months after discharge and had elevated serum Anti-GluN1 antibodies (1:160 – 1:320). The mean brain uptake in these cases is shown below. Panel B displays one “nonactive” Anti-NMDA-receptor encephalitis case scanned 16 months after discharge with undetectable Angi-GluN1 antibodies on day of scanning. Panel C shows mean uptake in healthy volunteers (n=29).
using segmented and modulated parametric grey matter volume images obtained using the CAT12 toolbox on 3T T1-weighted MRI scans. We report voxelwise p-values at a threshold of p<0.05 on a cluster-level family-wise error corrected for multiple comparisons.

6.3 Results

We included four “active” patients (cases #1-4, mean age 28 ± 6 years, all female) with Anti-NMDA-receptor encephalitis, mild or minimal symptoms, and persisting Anti-GluN1 antibodies in serum (titre range 1:160 to 1:320) that were scanned two to eight months after discharge from hospital. For comparison, we included one “inactive” patient (case #5, age 28, female) with undetectable antibodies in serum who was scanned 16 months after discharge from hospital and 29 healthy volunteers (mean age 41 ± 13 years, 8 [28%] female). Patient characteristics are displayed in Table 6.1.

Active cases #1-4 had lower [$^{18}$F]GE-179 brain uptake compared to the inactive case #5 and to healthy volunteers (Figure 6.1). Active cases had lower [$^{18}$F]GE-179 $V_T$ in grey matter (estimated marginal mean 6.2 [95% CI 4.4 – 8.0]) compared to healthy volunteers (8.8 [95%CI 8.1 – 9.4], $F$=6.5, $p$=0.02) but not in white matter (4.3 [95% CI 2.6 – 6.0] vs. 5.6 [95% CI 5.0 – 6.2], $F$=2.0, $p$=0.17), as shown in Figure 6.2A. All female healthy volunteers younger than 40 years had $V_T$ estimates in grey matter above 8 (mean 9.3 [95% CI 6.3-12.3]). Inactive case #5 had similar $V_T$ estimates in grey (9.7) and white (5.8) matter compared to healthy volunteers (Figure 6.1).

The relationship between serum Anti-GluN1 IgG titres and time from discharge from hospital with grey matter $V_T$ is displayed in Figures 6.3A-B. There was little variability in cognitive testing results at time of scanning (ACE-III, range 86 to 96, Figure 6.3C) and symptom severity at discharge (CASE score at discharge, range 4 to 8, Figure 6.3D) because all cases were only minimally affected.
Project 4: NMDA receptor activation in Anti-NMDA-receptor encephalitis

A Global and regional GE-179 uptake

![Boxplot](image)

- **Panel A**: Comparison of GE-179 uptake in antibody-positive Anti-NMDA-receptor encephalitis cases and healthy volunteers.

  Panel A shows boxplots of GE-179 $V_T$ in global grey matter in antibody-positive “active” cases with Anti-NMDA-receptor encephalitis (ENC, n=4) and healthy volunteers (CTRL, n=29, split by cohort). Panel B shows voxelwise differences in GE-179 $V_T$ between encephalitis cases and healthy volunteers ($p<0.05$ FWE corrected, red colours indicate decreased uptake in encephalitis cases). Panel C displays voxelwise differences in grey matter volume between encephalitis cases and healthy volunteers ($p<0.05$ FWE corrected, blue colours indicate atrophy in encephalitis cases).

**Figure 6.2:** Comparison of GE-179 uptake in antibody-positive Anti-NMDA-receptor encephalitis cases and healthy volunteers.
On voxelwise analysis (Figure 6.2B), active cases had significantly reduced $[^{18}F]GE$-179 uptake in bilateral anterior temporal lobes (left, $T = 4.5, 1937$ voxels, $p = 0.02$; right, $T = 4.9, 1416$ voxels, $p=0.05$) and a large cluster involving bilateral superior parietal lobes, paracentral lobules, left posterior cingulate gyrus, and left precuneus ($T = 5.8, 6593$ voxels, $p < 0.001$). Reduced uptake in active cases compared to healthy volunteers was confirmed in the temporal (cases $5.7 \ [95\% \ CI \ 3.9 \ – \ 7.6]$ vs. controls $8.6 \ [95\% \ CI \ 8.0 \ – \ 9.2], F=8.3, p=0.008$) and parietal ($6.2 \ [95\% \ CI \ 4.3 \ – \ 8.2]$ vs. $9.1 \ [95\% \ CI \ 8.4 \ – \ 9.8], F=7.3, p=0.01\) lobes using regional $V_T$ estimates (Figure 6.2A). Reduced grey matter volume on VBM (Figure 6.2C) was observed in both cerebellar hemispheres (left, $T = 4.6, 2189$ voxels, $p = 0.001$; right, $T = 4.3, 1337$ voxels, $p = 0.008$) and did not overlap with the PET findings.

6.4 Discussion

We report the first use of $[^{18}F]GE$-179 to measure in vivo the activation of NMDA receptors in patients with Anti-NMDA-receptor encephalitis. We demonstrated a reduced opening probability of NMDA receptors, most prominently in the anterior temporal and superior parietal cortices, in a series of patients with detectable Anti-GluN1 antibodies in serum, despite them having only mild or minimal symptoms and being discharged from hospital several months before the scan. In contrast, a clinically recovered patient without detectable Anti-GluN1 antibodies in serum had normal NMDA receptor opening probability.

6.4.1 NMDA receptor hypofunction as a disease mechanism in Anti-NMDA-receptor encephalitis

These results confirm the proposed mechanism of Anti-GluN1 antibodies that was observed in vitro, in animal studies and in post mortem specimen. The crosslinking
**Figure 6.3**: Association of GE-179 uptake in Anti-NMDA-receptor encephalitis cases with clinical variables.

Scatter plots show the association of GE-179 Vr in Anti-NMDA-receptor encephalitis cases (n=5, “active” and “nonactive” cases) with serum Anti-GluN1 IgG (panel A), time from discharge to scan (panel B), cognitive testing with ACE-III (panel C), and symptom severity at discharge measured with the CASE score (panel D).
and internalization of NMDA receptors mediated by these antibodies (Hughes et al., 2010; Ladépêche et al., 2018; Moscato et al., 2014) is in accord with the reduced receptor opening probability observed in our study. The degree of this reduction (mean 30% reduction in “active” patients compared to healthy volunteers) is striking, considering the mild or minimal symptoms in the studied patients and that scanning was performed two to eight months after discharge from hospital. Our results indicate that impaired function of NMDA receptors may persist for months after discharge from hospital despite only minimal symptoms. The human brain may largely compensate for a 30% reduction of NMDA receptor opening probability at rest, thus leading only to mild symptoms.

Persistent Anti-GluN1 antibodies in CSF and serum have been previously observed up to 15 years after disease onset (Alexopoulos et al., 2011; Hansen et al., 2013; Mariotto et al., 2017). It remains controversial whether persistent antibodies have pathogenic effects on the brain. It has been suggested that antibody synthesis might not reflect disease activity (Hansen et al., 2013; Mariotto et al., 2017). Our results may argue against this notion, because we observed a mean 30% reduction of NMDA receptor opening probability in cases with elevated antibody titres in contrast to normal NMDA receptor activation in a case without antibodies in serum. Our results suggest that persistent antibodies may disturb NMDA receptor function in the brain that can be compensated, leading only to minimal symptoms. It has to be noted that two out of four of the patients with antibodies in serum had relapses and three out of four were reducing their anti-inflammatory medication. Thus, it is unclear whether the studied series is representative of the typical population of Anti-NMDA-receptor encephalitis patients. Further studies with $[^{18}F]GE$-179 will need to assess larger groups of patients at several time points and correlate the PET findings with clinical recovery and antibody titres in CSF and serum.

We could only scan patients who tolerated a 70 minute PET scan and were not taking antipsychotics or antidepressants to prevent confounding our results with movement
Project 4: NMDA receptor activation in Anti-NMDA-receptor encephalitis

artefacts or the effects of medication on NMDA receptors. We did not include cases with severe symptoms or anesthetised patients, because anaesthetics might reduce the baseline activity of NMDA receptors and could bias the results. Nevertheless, we expect that the opening probability of NMDA receptors at the peak of clinical symptoms would be substantially lower compared to the mildly affected cases studied here. Thus, future studies with $[^{18}\text{F}]\text{GE-179}$ should assess more severely affected cases. However, such studies would run into the risk of biasing the findings through the action of antipsychotic medication or anaesthetic agents.

6.4.2 NMDA receptor hypofunction and clinical correlates

NMDA receptor hypofunction observed in our study may explain several of the symptoms in Anti-NMDA-receptor encephalitis. NMDA receptors subserve long-term potentiation (Cooke and Bliss, 2006b), a process relevant for memory consolidation. Sustained activation of NMDA receptors is also relevant for persistent neuronal activity that is the basis for storage of working memory (Lisman et al., 1998; M. Wang, Yang, C.-J. Wang, Gamo, Jin, Mazer, Morrison, X.-J. Wang and Arnsten, 2013b; X. J. Wang, 1999). Altered NMDA receptor function would, thus, explain episodic and working memory deficits. Anti-NMDA-receptor encephalitis patients typically show psychiatric features with mixed mood-psychosis symptoms, that may be initially misdiagnosed as a first episode of schizophrenia (Al-Diwani et al., 2019). The administration the NMDA receptor antagonists ketamine and phencyclidine can lead to psychotic symptoms including hallucinations and dissociative experiences (Krystal et al., 1994). They may also induce orofacial and limb dyskinesia, autonomic instability, and seizures (Alldredge et al., 1989; Modica et al., 1990; Weiner et al., 2000). These observations have led to the NMDA receptor hypofunction hypothesis in schizophrenia (Olney, Newcomer and Farber, 1999b) and warrant future PET studies using $[^{18}\text{F}]\text{GE-179}$ in patients with psychosis.
Although we observed a global reduction of NMDA receptor activation in patients with Anti-NMDA-receptor encephalitis (Figure 6.1 and 6.2A), the effects were most pronounced in the anterior temporal, superior parietal, and posterior cingulate cortices (Figure 6.2B). The anterior temporal lobe is important for episodic memory (T. M. C. Lee et al., 2002). Both parietal and posterior cingulate cortices were found to be involved in psychosis (Northoff et al., 2005; Yildiz et al., 2011). Electrical stimulation of the superior parietal lobule evoked visual and sensory hallucinations (Balestrini et al., 2015). Thus, altered NMDA receptor function in these areas may correspond to the spectrum of symptoms observed in Anti-NMDA-receptor encephalitis.

Our findings cannot be explained by differences in grey matter volume, because VBM did not detect relevant atrophy outside of the cerebellum and the PET results were corrected for partial volume effects. The findings are also independent of brain perfusion, because Vr estimates are corrected for local and global blood perfusion effects.

It is unclear how to interpret the variability of tracer uptake in “active” cases (Figure 6.1A). This variability could reflect disease activity. Although antibody titres in serum were similar in “active” cases (range 1:160 to 1:320, Figure 6.3A), intrathecal titres might be a better marker of disease activity. However, we could not obtain CSF samples on the day of scanning because of ethical considerations. The degree of cognitive deficits at time of scan (Figure 6.3C), disease severity at discharge (Figure 6.3D) and other clinical parameters (Table 1) were not related to tracer uptake. ACE-III might not be sufficiently sensitive to detect mild deficits that were reported by the patients at time of scanning. Another explanation for the variability observed between “active” patients is the 21.3% coefficient of variation for [18F]GE-179 PET.
6.4.3 Limitations

This study has limitations. Firstly, the sample size in this pilot study was small. However, despite including only four active patients, we found marked and significant reductions of tracer binding compared to healthy volunteers.

Secondly, the age and sex distribution of healthy volunteers differed from patients. The healthy control group was obtained by pooling the majority of data obtained with \([^{18}F]GE-179\) PET worldwide in order to maximise statistical power. These healthy volunteers were acquired for studies of patients with epilepsy and traumatic brain injury and they infrequently included young female individuals to reduce the potential effects of radiation. Future studies of Anti-NMDA-receptor encephalitis cases will require a dedicated control group. Nevertheless, no healthy females below age 40 in our study had tracer uptake in grey matter below 8, thus making it unlikely that our results can be explained by difference in age or gender alone. Additionally, all analyses were statistically corrected for age, gender, and cohort effects to reduce confounding to a minimum.

Thirdly, data of healthy controls was acquired in several cohorts with different scanner equipment and data acquisition protocols. Small between-cohort differences remained (i.e. lower signal across all regions in the Cambridge cohort, Figure 6.2A) and we statistically corrected for these factors in all models. Additionally, Figure 6.2A indicates a lower grey matter \(V_T\) in patients vs. controls at the UCL site, making it unlikely that the results can be explained by between-cohort differences alone.

Lastly, we could not completely eliminate the effect of medication on scanning but, because substances with potential effects on NMDA receptors were not permitted, the effects are likely to be minor.
6.4.4 Conclusions

To conclude, we observed in vivo the reduced activation of NMDA receptors in a series of patients with Anti-NMDA-receptor encephalitis using a novel and minimally invasive imaging approach. If validated in larger and longitudinal studies, this method might be used to track disease activity and response to treatment in Anti-NMDA receptor encephalitis and might generate novel insights into disease mechanisms.
Conclusions and outlook

7 Conclusions and outlook

In this thesis, I describe the use of $^{18}$FGE-179 PET to characterize NMDA receptor activation in aging, focal epilepsy, and Anti-NMDA-receptor encephalitis.

NMDA receptors are involved in several physiological neuronal processes and in the disease mechanisms of several neurological and psychiatric disorders (Bordji et al., 2010; Cooke and Bliss, 2006b; Fan and Raymond, 2007; McGinnity et al., 2015; Olney, Newcomer and Farber, 1999a; Rothman and Olney, 1995). The recent development of $^{18}$FGE-179, a radioligand specific to the open, i.e. activated, NMDA receptor is an important step towards understanding of their role in physiological and pathological processes in the human brain. So far, a small number of studies have been reported with this tracer (McGinnity et al., 2014; 2015; Vibholm et al., 2017; Vibholm, Landau, Alstrup, et al., 2020).

I present data from the largest cohort assessed with $^{18}$FGE-179 PET so far. We developed and validated a methodology for kinetic modelling independent of arterial sampling, that may allow a more widespread adoption of this radioligand. We found increased opening probability of NMDA receptors during aging in healthy volunteers and patients with focal epilepsy. Conversely, we observed a reduced NMDA receptor opening probability in adults with focal epilepsy and women with Anti-NMDA-receptor encephalitis. These findings increase our understanding of NMDA receptor function in health and disease and may guide the development of future treatment strategies.
7.1 Methodological considerations

\[^{18}\text{F}]\text{GE-179}\text{ binds specifically to the phencyclidine site inside the NMDA receptor channel (McGinnity et al., 2014). Tracer binding requires the opening of the receptor channel complex. NMDA receptor opening is a complicated process that usually involves binding of an agonist and co-agonist as well as the removal of the Mg\(^{2+}\) ion blocking the channel pore (Mori and Mishina, 1995). This typically occurs during simultaneous pre- and postsynaptic activation. In other words, there may far less opening of NMDA receptors at rest than during activation, e.g. during a memory task. NMDA receptor opening may also be subject to the modulatory effects of co-agonists and other receptor types.}

Successful blocking experiments were performed \textit{in vivo} for GE-179 in rats following activation of NMDA receptors using electrical stimulation (Vibholm, Landau, Møller, et al., 2020) and for the structural analogues CNS-5161 and GMOM in non-anaesthetised rodents (Biegon et al., 2007; van der Doef et al., 2016), confirming the specificity of the tracer to the phencyclidine site within the open NMDA receptor ion channel.

Because anaesthesia is expected to reduce the baseline opening probability of NMDA receptors, blocking experiments in anaesthetized rodents were not successful (Schoenberger et al., 2017). We found reduced \[^{18}\text{F}]\text{GE-179}\ uptake in our study of people with Anti-NMDA-receptor antibodies (Project 4). This supports the current hypothesis of receptor internalisation caused by Anti-NMDA-receptor antibodies, as described in animal studies (Hughes et al., 2010; Moscatò et al., 2014; Wright et al., 2015), and provides further \textit{in vivo} evidence that GE-179 binding reflects the number of activated NMDA receptors.

These observations are important for the interpretation of \[^{18}\text{F}]\text{GE-179}\ binding. Firstly, tracer binding does not reflect the number or overall density of NMDA receptors. It is a use-dependent measure of receptor opening probability, i.e. the number of
activated NMDA receptors. This reflects a compound measure of receptor availability on the cell surface and their opening/activation. Secondly, the phencyclidine site is present on all types of NMDA receptors. Thus, tracer binding is not specific to any receptor subunit composition. The tracer cannot distinguish between synaptic and extrasynaptic receptor localisation. Thirdly, our findings were obtained in subjects while resting inside the scanner and reflect the baseline opening probability of NMDA receptors at rest. Future studies may explore task-specific binding, e.g. during a memory task or during electrographic seizures. NMDA receptor opening probability in these conditions may differ from activation observed during rest.

The adoption of $[^{18}\text{F}]$GE-179 PET in a larger number of studies and in clinical routine depends not only on tracer availability but also on the methodological set up. We simplified kinetic modelling of $[^{18}\text{F}]$GE-179 PET by validating an approach independent of arterial sampling. The method still requires the acquisition and analysis of serial venous samples. Future refinement might involve the use of a simultaneous estimation (SIME) approach that may determine the parent fraction of tracer bound in plasma without the need for blood data (Sari et al., 2018). Widespread clinical use will also require the development of an automated pipeline that does not require manual input, which is currently not feasible due to the requirement to analyse blood data.

Although $[^{18}\text{F}]$GE-179 has relevant shortcomings, particularly considering the high test-retest variability of absolute binding (whereas relative binding had a favourable test-retest performance), there are few viable alternatives. An evaluation of $[^{18}\text{F}]$PK-209, a radioligand for the ion channel binding site of NMDA receptors, did not demonstrate sufficient reliability or specificity (van der Aart et al., 2018). $[^{11}\text{C}]$HACH242 has been evaluated as a radioligand for the GluN2B subunit of NMDA receptor in non-human primates but an evaluation in humans has not yet been performed (van der Aart et al., 2019).
7.2 NMDA receptor activation in aging

We found a higher opening probability of NMDA receptors in grey matter of older individuals. This effect was demonstrated both in a multicentre cohort of healthy volunteers and in a single-centre cohort of patients with refractory focal epilepsy. The annualised rate of increased NMDA receptor activation in people with epilepsy ($V_T$ increase by 1.4 per 10 years) was almost double that of healthy volunteers ($V_T$ increase by 0.8 per 10 years), suggesting that epilepsy may lead to accelerated brain aging (Galovic, van Dooren, et al., 2019). Aging-related NMDA receptor alterations particularly affected areas that may be involved in cognitive processes (Sambataro et al., 2010) and those that are susceptible to tau and amyloid-beta deposits in elderly individuals (Sepulcre et al., 2016).

There are several potential explanations for an increased activation of NMDA receptors in older individuals. It could be related to an altered NMDA receptor subunit composition (Brim et al., 2013; Magnusson, 2000; Magnusson et al., 2002; 2006; Zamzow et al., 2013) or disturbed glutamate homeostasis (Brothers et al., 2013; Farrand et al., 2015; Nickell et al., 2007; Potier et al., 2010; Vatassery et al., 1998). Alternatively, it may reflect functional compensation to maintain cognitive function during aging despite neuronal or ion-channel loss (Billard et al., 1997; Serra et al., 1994).

Further experiments will be required to distinguish between these potential explanations. Gene expression patterns of NMDA receptor subunits and glutamate transporters during aging could address their differential contribution to altered NMDA receptor function. Alternatively, immunohistochemistry in surgical specimen from people with epilepsy or post mortem brain samples could be used to address the expression of NMDA receptor subunits and glutamate transporters. However, these methods cannot directly assess functional alterations of receptors in vivo.
A further step in understanding the functional relevance of NMDA receptor alterations is to assess their impact on cognition by acquiring $[^{18}\text{F}]$GE-179 PET data in healthy aging and in neurodegenerative disorders together with cognitive testing. Alzheimer’s disease (Bordji et al., 2010) and other neurodegenerative conditions may be related to NMDA receptor dysfunction. Studying people with dementia using $[^{18}\text{F}]$GE-179 PET before and after the administration of memantine, an uncompetitive NMDA receptor antagonist, will be of interest in future.

Lastly, our studies were so far restricted to tracer uptake at rest. Activity of NMDA receptors may, however, be highly susceptible to stimulation during specific tasks. We performed a pilot study of 5 healthy volunteers using a working memory task with simultaneous $[^{18}\text{F}]$GE-179 PET and functional MRI. The results of this project are currently being analysed.

### 7.3 NMDA receptor activation in epilepsy

We found a lower interictal NMDA receptor opening probability in patients with longer duration of epilepsy. The spatial distribution of decreased tracer uptake formed distinct patterns and differed between temporal and frontal lobe epilepsy. Surgical removal of the epileptic focus in the ipsilateral temporal lobe caused a relative increase in postsurgical tracer uptake in the contralateral temporal lobe and basal ganglia. We also found effects of certain AEDs, lacosamide in particular, on NMDA receptors that merit further study.

Our results argue against traditional models that postulate an increased activation of NMDA receptors in people with epilepsy. Our findings rather support more recent models that suggest that both an increase or decrease in NMDA receptor function may lead to network hyperexcitability. Thus, AEDs should restore the balance of NMDA receptor activity. Use-dependent or uncompetitive antagonists may be particularly promising in this regard. Excessive blocking of NMDA receptors may in
Conclusions and outlook

turn exacerbate seizures and cause a number of neuropsychiatric side effects (Sveinbjornsdottir et al., 1993). These observations will be relevant for the development of treatment strategies for epileptic seizures.

In contrast, a previous study from our group in patients with epilepsy and frequent epileptic discharges on EEG showed an increase of tracer binding in a subset of patients. This may relate to an increased release of glutamate during epileptic discharges that may, in turn, activate NMDA receptors.

Future research should focus on the process of epileptogenesis which has been related to NMDA receptor abnormalities in animal studies (McNamara et al., 1988). We will study people at risk of developing epilepsy after ischemic stroke or traumatic brain injury as part of this ongoing project. They will receive a \([^{18}\text{F}]\text{GE-179 PET scan}\) shortly after the insult and a follow up scan after two years. These ongoing studies may be a first step to develop biomarkers of epileptogenesis and may inform the investigation of antiepileptogenic or disease-modifying treatments.

We also found previously unrecognised effects of certain AEDs on NMDA receptor function. These findings provide support for future Pharmaco-PET studies, that could measure NMDA receptor activation before and after treatment with specific AEDs. Such studies could reveal direct or indirect effects in vivo that may be difficult to assess in vitro.

The increase of contralateral tracer uptake after unilateral removal of the epileptic focus in the temporal lobe should be studied in a larger cohort. This effect could relate either to compensation, restitution of normal contralateral function, or both. In our small cohort, we did not see a clear effect of post-surgical outcome on tracer binding. A larger study should determine whether postsurgical \([^{18}\text{F}]\text{GE-179 PET}\) is a predictor of surgical outcome. In this regard, it also remains to be determined whether \([^{18}\text{F}]\text{GE-179 PET}\) may qualify as a biomarker of ongoing epileptogenesis or ictogenesis. This would require a properly powered longitudinal study that may be difficult to perform. Nevertheless, such a biomarker would be helpful for treatment
decisions, i.e. starting people on AEDs after a first seizure or withdrawal of AEDs after successful surgery.

7.4 NMDA receptor activation in Anti-NMDA-receptor encephalitis

We found a reduced opening probability of NMDA receptors in patients with detectable Anti-GluN1 antibodies after hospitalisation for Anti-NMDA-receptor encephalitis. The findings were most prominent in anatomical areas associated with cognitive processes and psychosis. One recovered case without detectable antibodies in serum had normal brain tracer uptake.

Our results provide a first in vivo human confirmation of the proposed receptor phenomena induced by Anti-GluN1 antibodies. We also observed that a mean 30% reduction of NMDA receptor activation at rest can persist for months after discharge from hospital and may be well compensated, causing only minimal symptoms.

Future studies will need to expand on these findings in larger cohorts of patients with Anti-NMDA-receptor encephalitis by including serum and CSF antibody titres and detailed cognitive testing. Longitudinal scanning may also be helpful to characterise receptor phenomena during the course of the disease and to relate them with response to treatment and the risk of relapses.

It will be of interest to scan patients during their peak clinical symptoms. However, this may prove difficult because more severely affected patients are unlikely to tolerate a long PET scan and the results may be confounded by concomitant medication, e.g. antipsychotics or anaesthetics.
7.5 Overall conclusion

\(^{18}\text{F}\)GE-179 PET provides unprecedented insights into in vivo functional alterations of NMDA receptors. It may increase our knowledge on receptor phenomena in health and disease and may generate novel hypothesis for the development of treatment strategies. It could also be used to assess direct or indirect effects of medication on NMDA receptors or to non-invasively monitor disease activity.

Several questions were raised in this thesis that merit further evaluation. The development of entirely computational fully automated and non-invasive methods for the quantification of radioligand binding will be helpful to adopt novel tracers in clinical routine. It should be determined whether the effects of aging on NMDA receptors relate to cognitive decline or promote neurodegeneration and whether they can be mitigated by pharmaceuticals targeting of glutamate transporters or NMDA receptors. The bi-directional role of NMDA receptors in epilepsy may need to be re-evaluated and could lead to novel therapeutic strategies. Lastly, the development of uncompetitive agonists could represent a well-tolerated treatment for a number of disorders with disturbed NMDA receptor function.


References


References


References

Fitzgerald PJ. The NMDA receptor may participate in widespread suppression of circuit level neural activity, in addition to a similarly prominent role in circuit level activation. Behav. Brain Res. 2012; 230: 291–298.


References


References


Jackson ME, Homayoun H, Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 2004; 101: 8467–8472.


Lee TMC, Yip JTH, Jones-Gotman M. Memory deficits after resection from left or right anterior temporal lobe in humans: a meta-analytic review. Epilepsia 2002; 43: 283–291.


Magnusson KR, Scruggs B, Zhao X, Hammersmark R. Age-related declines in a two-day reference memory task are associated with changes in NMDA receptor subunits in mice. BMC Neurosci 2007; 8: 43.
Magnusson KR. Declines in mRNA expression of different subunits may account for differential effects of aging on agonist and antagonist binding to the NMDA receptor. J. Neurosci. 2000; 20: 1666–1674.


References


Neuman R, Cherubini E, Ben-Ari Y. Epileptiform bursts elicited in CA3 hippocampal neurons by a variety of convulsants are not blocked by N-methyl-D-aspartate antagonists. Brain Res. 1988; 459: 265–274.


Simon RP, Swan JH, Griffiths T, Meldrum BS. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. 1984; 226: 850–852.

References


Vatassery GT, Lai JC, Smith WE, Quach HT. Aging is associated with a decrease in synaptosomal glutamate uptake and an increase in the susceptibility of synaptosomal vitamin E to oxidative stress. Neurochem Res 1998; 23: 121–125.


References


